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1CHAPTER I
INTRODUCTION
Antimicrobial peptides (AMPs) are found in virtually every living being as a part
of the innate immune system. In vertebrates, there are two major families of AMPs,
namely defensins and cathelicidins. They kill a broad range of pathogens ingested by
phagocytes and also help fight off pathogens trying to enter through mucosal surfaces and
skin. The antibacterial action of AMPs is mediated primarily through binding and
disruption of microbial membranes.
In addition to the antimicrobial activity, they exert various modulatory effects on
the innate and adaptive immune system. Many AMPs are directly chemotactic for
neutrophils, monocytes, and lymphocytes. They are capable of inducing the production of
an array of proinflamatory cytokines and chemokines from immune and epithelial cells.
They also play a role in differentiation and maturation of dendritic cells, which are
professional antigen-presenting cells of the immune system. Paradoxically, some AMPs
also have anti-inflammatory effects by preventing the release of tumor necrosis factor-
from the immune cells induced by lipopolysaccharide (LPS), a major cell wall
component of Gram-negative bacteria. Due to their pleotropic effects on the immune
system, AMPs are also being called host defense peptides (HDPs).
2Recently, there is a sharp rise in the incidence of antibiotic-resistant infections
with some bacteria even showing resistance to multiple antibiotics. Due to their potent
antimicrobial and immunomodulatory effects, AMPs are being actively explored as
potential antibacterial drugs especially against antibiotic-resistant bacteria. It is extremely
difficult for bacteria to gain resistance to these peptides as opposed to traditional
antibiotics. Several of such peptides are in clinical trials to treat both topical and systemic
infections.
In this report, we present the latest advances on defensins and cathelicidins
pertaining to their pleotropic activities and potential as antibacterial drugs (Chapter II).
We have discovered the complete repertoire of the - and -defensin gene families in
various mammalian species including the human, rat, mouse, chimpanzee and dog
through a comprehensive bioinformatics approach (Chapter III & IV). Furthermore, we
characterized in vitro antibacterial properties of rattusin, a novel -defensin-related
peptide in rat (Chapter V). Overall findings are summarized and future prospect are also
discussed (Chapter VI).
3CHAPTER II
REVIEW OF LITERATURE
Discovery of penicillin and a host of other antibiotics in the middle of last century
led to a decrease in infectious disease mortality by 20-fold from year 1900 to 1980 (170).
Since then, widespread and sometimes misuse of antibiotics in clinical practice and in the
food animals has caused bacteria to quickly acquire resistance to antibiotics (31, 41, 79,
167). These days, >70% hospital-acquired bacterial infections show resistance to at least
one antibiotic (www.niaid.nih.gov/factsheets/antimicro.htm). For example, resistant
strains have been found with Streptococcus pneumoniae, Staphylococcus aureus,
Enterococci, Neisseria gonorrhoeae, Salmonella enterica serovar Typhi
(http://www.cdc.gov/drugresistance/diseases.htm), and certain bacteria have become
resistant to multiple antibiotics (125).
Furthermore, antibiotic resistance increases the cost of treatment through longer
duration of hospitalization and use of expensive drugs to treat infection. The estimated
cost of treating antibiotic-resistant infections in the US is $30 billion (101). This cost
keeps on rising as the number of bacterial strains resistant to antibiotics are increasing
and the pharmaceutical industry is unable to bring novel antibiotics to treat resistant
infections (174). Therefore, discovery of novel antimicrobial drugs with a very low risk
of resistance development are urgently required. Cationic host defense peptides (HDPs)
4constitute a potential novel class of antimicrobials by virtue of their bactericidal as well
as immunomodulatory properties (32, 87, 88).
These HDPs are small (12 to 50 amino acids), cationic (+ 2 to + 10 charge due to
the presence of multiple arginine and lysine residues), and amphipathic. They are capable
of killing Gram-positive and Gram-negative bacteria and fungi and inhibiting the
replication of enveloped viruses like influenza A virus, human papilloma virus, vesicular
stomatitis virus and human immunodeficiency virus (58, 63). Antibacterial activity of
HDPs is exerted by physical disruption of bacterial membranes mainly (15). Due to this
physical mechanism of action, cationic HDPs kill a broad range of bacteria including
antibiotic-resistant strains with a low risk of developing resistance. This property
combined with their modulatory effects on innate and adaptive immune system, have
made them very attractive candidates for antibacterial drug development, particularly
against antibiotic-resistant strains (43, 44, 87, 197). This review will focus on the
antibacterial and immunomodulatory properties of vertebrate HDPs.
CLASSIFICATION OF HOST DEFENSE PEPTIDES
Vertebrates mainly produce two major families of HDPs called defensins and
cathelicidins (36, 72, 140, 162, 194, 195). Based on the structure difference, HDPs can be
classified into distinct classes such as -helical, -sheet, cyclic and extended peptides
(87). Defensins are amphipathic molecules characterized by the presence of six conserved
cysteine residues, and a number of hydrophobic and cationic residues. Defensins are
5further divided into three different subclasses, namely -, - and -defensins (36, 72,
140). This classification is based on the spacing of cysteine residues and the pattern of
disulfide bonds. -defensins consist of three disulfide bonds between Cys1-Cys6, Cys2-
Cys4 and Cys3-Cys5, whereas in -defensins, cysteines are connected between Cys1-
Cys5, Cys2-Cys4 and Cys3-Cys6. -defensins are mainly produced by leukocytes and
Paneth cells of small intestine, whereas -defensins are expressed mainly by mucosal
epithelial cells and skin (36, 72, 140). In humans, there are four neutrophil -defensins
[human neutrophil peptide (HNP)-1 to 4] and two enteric -defensins [human defensin
(HD)-5 and 6] (113, 124, 127). In rhesus monkey, myeloid as well as intestinal -
defensins have been identified (154, 155). While multiple enteric -defensins are present
in mice, neutrophil -defensins are absent (30, 114). Rat neutrophils express three -
defensins, and mRNA for six additional -defensins have been identified in small
intestine (120). Over 35 -defensins have been identified in humans and rodents (121,
123).
Tertiary structures of several - and -defensins are available (4, 48, 51, 52, 59,
69, 86, 119, 135, 137, 145, 204). All defensins possess triple stranded antiparallel -sheet
with a hairpin conformation stabilized by three disulfide bonds. In the case of human -
defensin (HBD)-1 to 3, mouse -defensin (MBD)-7, and 8 and penguin sphenecin, there
is an additional N-terminal -helical segment involving the first cysteine (4, 51, 52, 69).
However, such a segment is absent in bovine neutrophil -defensin (BNBD)-12 (204). -
defensins also lack the N-terminal helical segment. Cryptdin-4, which is a potent mouse
Paneth cell -defensin, has a different orientation of -hairpin and lower -sheet content
6than other defensins. These unique structural features with its high cationicity have been
suggested to be responsible for high antibacterial potency of cryptdin-4 (59). All - and
-defensins possess a conserved GXC motif involving cysteine 4, which forms a bulge
essential for correct folding of defensins (182, 191).
-defensins are cyclic peptides expressed by leukocytes of old world primates
(156) and possess activity against a wide spectrum of bacteria, fungi, and viruses (156,
172, 190). They are produced by ligation of two different -defensin-like peptides with
premature termination of the open reading frame between the third and fourth conserved
cysteine (156). Each peptide thus contributes three cysteines and cyclizes in a head-to-tail
manner with formation of three disulfide bonds (156). NMR structure of rhesus -
defensin (RTD)-1 shows the presence of two flexible -strands connected by a hairpin at
both ends (165). Unlike other classes of host defense peptides, RTD-1 is not amphipathic
(165). In humans and chimpanzee, -defensin genes are pseudogenes with a stop codon in
the signal sequence leading to early termination of translation (100, 121).
Cathelicidins constitute another major family of HDPs in vertebrates and are
characterized by the presence of an N-terminal conserved pro-sequence called cathelin
(162, 194, 196). This cathelin pro-sequence is connected to a 20-80-residue, diversified
cationic segment at the C-terminus (162, 194, 196). Both cathelin and C-terminal mature
peptide play a role in host defense (195). Cathelicidins are stored in the granules of
neutrophils. In addition, they are also expressed by skin and various mucosal epithelial
surfaces. To date, cathelicidins have been found in a number of vertebrate species
7including primates, glire, canine, porcine, bovine, ovine, caprine, equine, chicken and
fish (21, 22, 162, 180). In cattle, sheep, and pigs, multiple cathelicidins are present,
whereas in primates and glire only one member is present in each species (162, 200).
Even though all cathelicidins are amphipathic and cationic, they adopt either -
helical, -sheet, or extended structures. Examples of -helical peptides include human
LL-37, mouse CRAMP, sheep SMAP-29, and chicken fowlicidins (110, 149, 151, 180,
192). Guinea pig CAP-11 possesses a single cysteine towards the C-terminus and exists
in the dimeric form due to the formation of an intermolecular disulfide bond (98). Some
cathelicidins are rich in certain amino acids, which render them extended structures.
Extended peptides include bovine indolicidin (Trp and Pro rich), porcine PR-39 (Pro and
Arg rich), and porcine prophenin (Pro and Phe rich) (18, 45, 68). Porcine protegrins and
bovine and ovine dodecapeptides are looped -sheet peptides due to the presence of
intramolecular disulfide bonds (66, 177). Protegrins consist of four cysteines forming two
intramolecular disulfide bonds, whereas bovine and ovine dodecapeptides have two
cysteines each forming one disulfide bond.
PLEOTROPIC EFFECTS OF HOST DEFENSE PEPTIDES
Defensins and cathelicidins are either produced constitutively or induced in
response to infection or injury (194, 195). All these released HDPs exert a host defense
role by directly killing a broad spectrum of bacteria. Recent evidence also shows a novel
way of antibacterial action, in which macrophages acquire granules of apoptotic
8neutrophils, thereby acquiring HDPs to kill intracellular Mycobacterium tuberculososis
(152).
Studies involving knock-out and transgenic mice have provided convincing
evidence showing an indispensable role of HDPs in protection against infections. Mice
deficient in matrix metalloproteinase 7 (MMP-7), which is responsible for conversion of
inactive precursors of enteric -defensins into active forms, become more susceptible to a
lethal S. typhimurium infection (175). Similarly, mice deficient in -defensin-1 (Defb1)
show decreased clearance of Staphylococci in the bladder (91) and exhibit enhanced
colonization of H. influenzae in the lung (92). Role of cathelicidin (mouse CRAMP) in
protecting skin infection from Group A Streptococci is evident by the presence of large
and persistent skin lesions in mice lacking mCRAMP (105). Conversely, transgenic mice
possessing porcine cathelicidin PR-39 display increased resistance to skin infections by
Group A Streptococci (71). Transgenic mice expressing human -defensin HD-5 are
resistant to a lethal challenge of S. typhimurium infection (132).
Different models have been proposed to explain the mechanism of antibacterial
action of HDPs (15). Initial interaction of cationic peptide occurs with negatively charged
molecules on bacteria such as lipopolysacharide (LPS) of Gram-negative bacteria and
lipoteichoic acid of Gram-positive bacteria, followed by formation of either transient or
stable pores across membranes. Rabbit neutrophil defensins form short-lived pores,
whereas human neutrophil defensins form stable channels (60, 77, 176). The formation of
stable channels correlates with oligomerization of human neutrophil defensins in contrast
9to the monomeric form adopted by rabbit neutrophil defensins. Mouse cryptdin-4
interacts with phospholipid head groups through charge-charge interactions between the
cationic peptide and negatively charged membrane lipids and disrupts bilayer head
groups (133, 134). Rhesus -defensin-1 (RTD-1), which lacks an amphipathic structure,
has been shown to induce membrane thinning and formation of pores across membranes
(17, 173). Additionally, defensins can also interfere with intracellular processes. Human
neutrophil peptides 1-3 (HNP 1-3) completely inhibit the synthesis of DNA, RNA and
protein at sub-lethal concentrations (73). Killing of bacteria by defensins can also occur
through activation of cell-wall lytic enzymes (131).
In the case of cathelicidins, the mechanism of action on model membranes is
studied in more detail than that for defensins. Human LL-37 disrupts model membranes
through formation of transmembrane torroidal pores lined by polar lipid head groups and
peptides (47). Porcine protegrin-1, a -sheet cathelicidin, also permeabilizes model
membranes through formation of torroidal pores (82, 83, 183). Ovispirin, a peptide
derived from ovine cathelicidin SMAP-29, permeabilize bacterial membranes through the
“carpet” mechanism by binding to lipid bilayer in parallel, leading to the formation of
micelles when reaching the threshold concentrations (184). Cathelicidins also kill
bacteria by interfering with intracellular processes. Porcine PR-39 kills bacteria by
inhibition of bacterial DNA and protein synthesis (8). PR-26, an N-terminal version of
PR-39, causes filamentation of S. typhimurium, suggesting the inhibition of cell division
(142). Bovine indolicidin also inhibits DNA synthesis resulting in filamentation of
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Escherichia coli (150). Indolicidin has been shown to directly bind HIV-1 DNA through
covalent cross-linking, resulting in inhibition of integrase activity (84).
In addition to direct bacterial killing, HDPs exert important modulatory activities
on the innate and adaptive immune system. Defensins and cathelicidins possess
chemotactic activities on various immune cells. HNPs are chemotactic for monocytes, T
cells, and immature dendritic cells (24, 158, 185). The identities of receptors used by
HNPs are not clear. HBD-2 is chemotactic for immature dendritic cells, memory T cells,
TNF--treated neutrophils, and mast cells through interactions with CCR-6 chemokine
receptor (102, 186). HBD-3 and HBD-4 are chemotactic for monocytes (37, 38).
Similarly, murine -defensins are also capable of attracting immature dendritic cells and
help induce antitumor immunity (6). LL-37 is chemotactic for neutrophils, monocytes, T
cells and mast cells (29, 103). PR-39 is a chemoattractant for neutrophils (55). Bovine-
bactenecin derived peptide, Bac2A, is a chemoattractant for monocytes (12). Mouse
CRAMP is a chemoattractant for neutrophils and monocytes (67). Cathelicidins induce
chemotaxis by binding to formyl peptide receptor. Recruitment of immune cells to the
site of infection leads to elicitation of cell-mediated and humoral immune responses to
fight off infection.
HDPs are also able to induce the release of cytokines and chemokines from
immune cells and epithelial cells. Human neutrophil defensins up-regulate chemokine IL-
8 production by human airway epithelial cells (168). Cryptdin-3, but not cryptdin-4,
induces secretion of IL-8 from human intestinal cells (76). In peripheral blood
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mononuclear cells (PBMCs), HBD-2 induces IL-8, IL-6, IL-10, MCP-1, MIP-1,
RANTES, IL-1, ENA-78, GRO, IGFBP-3 and EGF, whereas HBD-1 induces IL-8, IL-
10, IL-6 and MIP1, and HBD-3 stimulates IL-8, MCP-1 and IGFBP-3 production (9).
HBD-2, 3 and 4, but not HBD-1, induces expression of IL-6, IP-10, IL-10, RANTES,
MCP-1, MIP-3 at both mRNA and protein levels in skin keratinocytes (104). LL-37
induces secretion of IL-8, IL-6, IL-1, and TNF- in human corneal endothelial cells (56)
and IL-1, IL-6, IL-8, TNF-, and GM-CSF in keratinocytes (13). LL-37 also enhances
IL-8 release from human airway smooth muscle cells (205). Thus, chemokines and
proinflammatory cytokines released by different cell types under influence of HDPs
might help recruit immune cells and modulate the microenvironment, ultimately leading
to robust immune responses.
Given the immunostimulatory activities exhibited by HDPs, one would expect
that they have adjuvant-like effects on the immune system. Indeed, both defensins and
cathelicidins potentiate immune responses to particularly non-immunogenic antigen.
HNPs administered together with an antigen induce antigen-specific IgG response in
mice (75). HNPs help induce tumor-specific IgG and T cell responses, thereby increasing
resistance of mice to a tumor challenge (157). HBD-1 also induces antigen-specific IgG
response in mice (16). A DNA vaccine encoding a fusion protein of non-immunogenic
lymphoma antigen with mouse -defensin-2 and 3 generates tumor-specific protective
humoral and cell-mediated immunity (6). Similarly, LL-37, when fused with a tumor
antigen and administered as a DNA vaccine, generates humoral and cellular immune
responses and increases survival against a tumor challenge (3). However, the mechanism
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by which these HDPs exert adjuvant-like effects remains elusive (10). It is likely that
defensin and cathelicidins act as a carrier and target the fusion partner to antigen-
presenting cells by binding to chemokine receptors. It is also possible that these HDPs
alter the micro-environment by inducing cytokines and chemokines, thereby influencing
differentiation and maturation of dendritic cells indirectly. The third scenario is that
HDPs directly interact with dendritic cells and modulate their differentiation.
Nevertheless, further research is needed to study the immunomodulatory effect of HDPs
to facilitate the development of HDPs as adjuvants for vaccine use (5).
Conversely, some HDPs are also able to suppress the production of
proinflammatory cytokines such as TNF- and IL-1 in response to LPS stimulation.
Cathelicidins, including human LL-37, bovine indolicidin, rabbit CAP18, and chicken
fowlicidins, are thought to neutralize the effects of LPS through direct binding to and
competing with LPS for its receptor, CD14 (128, 180). However, recent evidence
indicates that LL-37 and bovine BMAP-27 suppress LPS-induced responses by inhibiting
the transcription of proinflammatory genes (89, 90). Both peptides reduce LPS-induced
translocation of NF-B subunits, p65 and p50, into nucleus. Thus, overall neutralization
of LPS effects seems to occur through multiple mechanisms (89). Protection against LPS-
induced sepsis by cathelicidins has been demonstrated in animal models (26, 33, 39, 40).
In contrast, only one human -defensin, DEFB-123, has been found to prevent LPS-
induced TNF- secretion in vitro and protect mice against LPS-induced septic shock (93).
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In addition to endotoxins, several defensins were recently shown to be able to
neutralize several types of exotoxins. HNPs neutralize anthrax lethal toxin and protect
mice against lethal effects of the toxin (61). HNP-1 inhibits lethal toxin by inhibiting the
cleavage of mitogen-activated protein kinase kinase by toxin. HNPs neutralize diphtheria
toxin and Pseudomonas exotoxin A by competitively inhibiting toxin-mediated ADP-
ribosylation of eukaryotic elongation factor 2 (62). -defensins also neutralize anthrax
lethal toxin, in addition to killing bacilli and germinating spores of Bacillus anthracis
(171).
HDPs also play a role in the resolution of inflammation and wound healing. HNPs
stimulate proliferation of epithelial and fibroblast cells (1, 96) and enhance wound
closure of the airway (2). HBD-2, -3 and -4 promote wound healing by promoting
keratinoycte migration and proliferation through binding to epidermal growth factor
receptor (EGFR) (104). Cathelicidin LL-37 promotes angiogenesis and neo-
vacularization of endothelial cells (65) and is involved in re-epithelization of skin wounds
(46). LL-37 induces keratinocyte migration through transactivation of EGFR (161). LL-
37 also stimulates airway epithelial cell proliferation and wound closure through EGFR
(141). Rat CRAMP promotes healing of gastric ulcers by inducing epithelial cell
proliferation through TGF--dependant transactivation of EGFR (189). Porcine PR-39
facilitates the formation of new functional blood vessels in a mouse model through
inhibition of proteasome-mediated degradation of hypoxia induced factor 1- protein
(74). PR-39 also helps in wound healing through induction of syndecan-1 and 4, which
14
are important in regulating cell proliferation and migration in response to heparin binding
growth factors (35).
STRUCTURE-ACTIVITY RELATIONSHIPS
Structural and physicochemical properties such as disulfide bond, charge, length,
helicity, hydrphobicity and amphipathicity play a critical role in antibacterial,
immunomodulatory, and cytotoxic activities of HDPs. It is possible to design peptides
with improved antibacterial and immunomodulatory activities and reduced cytotoxicity
for therapeutic application by varying one or more of the above properties.
In the case of defensins, conserved disulfide bonds are dispensable for the
antibacterial activity. Defensin variants lacking disulfide bonds or having a varying
number of disulfide bonds display similar antibacterial activities to the parent peptide
(53, 64, 80, 81, 178). Absence of disulfide bonds also does not affect the cytotoxicity of
defensins (64). However, the disulfide motif is required for in vivo stability of defensins.
Absence of disulfide bonds renders cryptdin-4 susceptible to MMP-7, a protease which
converts cryptdin-4 precursors into active forms (80, 143). Another function of disulfide
bonds in defensins is to maintain the chemotactic activity as observed for HBD-3 (178).
Furthermore, even with intact disulfide bonds, mutations in N-terminal helix containing
primarily hydrophobic residues of HBD-1 result in a significant reduction of its binding
to the CCR-6 receptor, underscoring the importance of these residues in chemotaxis
(122). A conserved salt bridge in HNP-2, which is dispensable for the antibacterial
15
activity, is necessary to maintain its stability against protease degradation (179). The
same conserved salt bridge in cryptdin-4 is not required for the antibacterial activity or
proteolytic stability (129).
Antibacterial activity of defensins is mainly dictated by net positive charges. In
the case of cryptdin-4, charge reversal from cationic arginines to anionic aspartic acids
abolishes the antibacterial activity, irrespective of the location of arginine (153). There is
a direct positive correlation between the number of charged residues and antibacterial
activity as seen with HBD-1 (122). A combination of strong cationicity and moderate
hydrophobicity is necessary for the antibacterial activity of HBD-3, whereas high
hydrophobicity results in an increase in cytotoxicity to mammalian cells (64). Arginine
residues in defensins also have a role in modulating in vivo functions. ADP ribosylation
of arginines of HNP-1 in the respiratory tract results in a decreased cytotoxicity and
antibacterial activity without altering the chemotactic and IL-8-inducing ability (116).
In the case of -helical peptides, an appropriate balance of the net positive charge,
-helical content and amphipathicity dictate the antibacterial activity (28, 163). Recently,
this was demonstrated with a group of de novo synthesized peptides based on the
template obtained by comparing naturally occurring -helical peptides (198, 199, 201).
These synthetic peptides show reduced potency when the net positive charge is decreased
to +3 or below. Increasing the charge above +6 fails to enhance the antibacterial potency.
Additionally, peptides that are both -helical and amphipathic have broad-spectrum
antibacterial activity. However, peptides with a rigid -helix possess a strong hemolytic
16
activity and a poor antibacterial activity. An increase in the flexibility of -helix by
introducing a glycine or proline is generally associated with a decrease in cytotoxicity.
Peptides also display a decreased cytotoxicity with moderate hydrophobicity, and a
further decrease in hydrphobicity reduces the antibacterial activity.
Most of the above described principles are also true for naturally occurring -
helical cathelicidins. In the case of ovispirin, which is the N-terminal -helical segment
of SMAP-29 with strong hemolytic and cytotoxic activities (136), a replacement of either
isoleucine 10 with glycine or isoleucine 7 with threonine enhances the flexibility and
substantially reduces hemolytic and cytotoxic activities (136). In contrast, despite being a
rigid helical peptide, CAP-18 shows a low hemolytic activity. Antibacterial activity of
CAP-18-derived peptides with moderate to high helicity correlates well with the net
positive charge than helicity (23, 166). CAP-18-derived peptides with very low helicity
exhibit reduced antibacterial activity, despite introductions of additional positively
charged residues (164). Some peptides contain a hinge around the center of -helix
consisting of PXXP or PXXXP motif. This hinge divides the peptide into the N- and C-
terminal helices. When the N-terminal helix binds to membrane, the hinge bends and
allows the insertion of the C-terminal helix into lipid bilayer (187). In the case of highly
hydrophobic BMAP-27 and 28, maintenance of the N-terminal amphipathic -helix while
reducing hydrphobicity diminishes the cytotoxicity without changing the antibacterial
activity (146). Removal of the four N-terminal hydrophobic residues of LL-37 gives rise
to a less cytotoxic derivative without affecting membrane permeabilization or the
antibacterial activity (110).
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Successful attempts have been made to identify short fragments of naturally
occurring -helical peptides with improved antibacterial and immunomodulatory
activities and less cytotoxicity. LL-37-derived peptides with N-terminal hydrophobic
amino acids removed, display similar antibacterial, LPS-neutralizing, and chemotactic
activities as LL-37, but with significantly reduced cytotoxicity (25, 99, 144). Recently, a
large panel of LL-37-derived short fragments were compared for their antibacterial and
immunostimulatory activities (13). Two LL-37 fragments, namely RK-31 and KS-30,
possess a dramatically improved antibacterial activity with little capacity to stimulate the
release of IL-8 from keratinocytes. These two fragments also display slightly reduced
toxicity. Interestingly, both fragments have been reported to be present in human sweat,
suggesting this gain of function demonstrated in vitro has in vivo implications (95).
For guinea pig CAP-11 peptide, the antibacterial activity of the N-terminal
fragment of 18 residues can be further improved by increasing amphipathicity (109).
Interestingly, the C-terminal -helix of chicken fowlicidin-1 is the major region for
antibacterial, cytotoxic and LPS-neutralizing activities with three hydrophobic residues
just before N-terminal -helix also sharing cytotoxic and LPS-binding activities.
Removal of these three hydrophobic residues results in an almost 10-fold reduction in
cytotoxicity and 60-fold reduction in hemolysis without significantly affecting LPS-
neutralizing and antibacterial activities (181). Angiogenic and NF-B-inhibiting activities
of PR-39 have been attributed to the N-terminal 11 residues with three arginines being
essential for both activities (34). Furthermore, the N-terminal arginines of PR-39 are
critical for the antibacterial activity, induction of syndecans and interaction with the SH3
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domain (20), whereas the C-terminal part of PR-39 is important only for antibacterial
activity but not for interactions with the SH3 domain in mammalian cells (20).
STRATEGIES FOR PEPTIDE DESIGN AND SYNTHESIS
Although HDPs have broad-spectrum antibacterial activities, the issues related to
antibacterial potency, stability, toxicity, cost and salt sensitivity need to be addressed in
order to develop them into therapeutic drugs. A number of strategies for peptide design
and synthesis are evolving. Besides structure-based rational design as depicted in the
previous section, other strategies include amidation, acylation, cyclization, dimerization,
D-enatiomerization, development of peptide mimetics, and high throughput synthesis and
screening of synthetic peptides.
Various types of modifications of peptide termini, backbone or amino acid
residues are being tried to improve the antibacterial activity and stability of peptides.
Amidation of the C-terminus has been shown to increase the antibacterial activity of
porcine cathelicidin, tritrpticin (138, 188). N-terminal acylation or C-terminal amidation
also protects peptide from being cleaved by exopeptidases. Such de novo designed
peptides with both termini modified retain the antibacterial activity (99). Peptide
backbone can be modified by introducing carbamate bonds or reduced amide bonds (70,
107). Reduced amide bond increases the net positive charge and antibacterial activity.
Introduction of carbamate bonds reduces helicity and the hemolytic activity. Another
modification of backbone is the inclusion of peptoid residues, which are helix-disrupting
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amino acids. Such modifications can decrease the cytotoxicity of HDPs with increased
activity towards bacteria (147, 203). Backbone modification also increases half lives of
peptides in serum as they become less susceptible to proteolysis (107). Incorporation of
unnatural amino acids into synthetic antibacterial peptides has been tried successfully to
increase the resistance of peptides to serum proteases without affecting the antibacterial
activity (108).
Incorporation of D-amino acids into HDPs is another promising approach to
achieve desirable biological properties. Diastereomeric synthetic peptides containing D-
amino acids tend to be less hemolytic and cytotoxic while retaining the antibacterial
activity (115, 117, 148, 201). Consistently, diastereomeric peptides are incapable of
inserting into the lipid bilayer mimicking mammalian cell membranes, whereas peptides
containing only L-amino acids do so readily (118). D-amino acids modulate peptide
cytotoxic activity by changing helicity and hydrophobicity. Furthermore, diastereomers
maintain the antibacterial activity in serum and are resistant to degradation by proteases
(117). Such diastereomers, but not L-amino acid peptides, protect mice against antibiotic-
sensitive as well as -resistant infections, suggesting improved stability of diastereomers in
vivo (14).
Cyclization of certain peptides has been shown to increase the stability of peptides
in vivo (42). Cyclic peptides with alternating D- and L-amino acids are resistant to
proteases and highly stable when administered in vivo (27). Similarly, cyclo CP-11, a
peptide derived from bovine indolicidin, has a prolonged half-life in the presence of
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trypsin as compared to linear CP-11 (130). Cyclization also enhances the antibacterial
activity and reduces the hemolytic activity in several cases. A cyclic peptide with D- and
L-amino acids shows reduced hemolytic activity and broad spectrum antibacterial activity
relative to the linear analog (111). It correlates with an increased ability of the cyclic
peptide to interact with and permeabilize negatively charged membranes and reduced
affinity for zwitterionic membranes. Cyclization also renders peptides resistant to salt.
The most convincing examples of salt-insensitive cyclic peptides are -defensins. These
peptides, as discussed in the previous section, are naturally occurring cyclic defensins of
old world primates. Antibacterial activity of cyclic RTD-1 is insensitive to salt. However,
such an activity is completely lost in the presence of physiological concentrations of salt
when peptide is linearized (156). De novo designed cyclic peptides, resembling -
defensins and porcine protegrins, have also been shown to act in a salt-insensitive manner
(94). Even naturally occurring HDPs can be cyclized to acquire salt-insenstivie
antibacterial activities. For example, end-to-end cyclized rabbit neutrophil peptide-1 (NP-
1) is able to maintain its activity in the presence of salt, whereas wild-type NP-1 is
inactivated (193).
Dimerization of peptides through covalent linkage by disulfide bonds may also
increase antibacterial potency and render peptides salt-insensitive. Evidence for this
argument comes from naturally occurring peptide dimers. Dimerization of cryptdin-
related CRS peptides in mice increases antibacterial potency (54). Dimeric Defr1, a
mouse -defensin-related peptide, retains the antibacterial activity in the presence of
physiological salt concentrations (19). Cathelicidins, PMAP-36 and CAP-11, also exist
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in dimeric forms in neutrophils; however, dimerization does not increase antibacterial
potency (109, 139), although it modulates the kinetics of killing and membrane
permeabilization in the case of PMAP-36 (139). Increasing evidence suggests a positive
association between dimerization and the protease stability of peptides (126). Cross
linking of two tryptophans in indolicidin confers protease resistance without altering the
antibacterial activity (112).
Synthetic combinatorial libraries (SCL) have also been employed to identify small
peptides (hexapeptides) with the antibacterial activity (7). However, constructing such
libraries is cost-prohibitive especially for longer peptides. Another approach to produce a
large number of peptides is high throughput, in situ peptide synthesis on a cellulose
support by pipetting robots (50). Peptides are subsequently cleaved from the support and
the antibacterial activity is studied in a high throughput manner against Peudomonas
aeruginosa expressing a luciferase reporter (50). It is estimated that 100,000 individual
peptides can be produced by this approach using two robots and screened for antibacterial
activities in a year. Using this approach, bovine bactenecin derivatives with increased
antibacterial potency have been obtained (49). A recent report described the rational
design of antimicrobial peptides based on a linguistic model using naturally occurring
HDPs (78). This language is based on grammars that use common sequence patterns
found in natural peptides. Using this strategy, a large number of de novo peptides can be
synthesized and screened for the antibacterial activity.
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Abiotic oligomeric and polymeric compounds are also being synthesized to mimic
the structural properties of HDPs. Such compounds are resistant to proteases. For
example, oligomeric compounds like acrylamide and oligourea and synthetic polymers
like phenylene ethynylene are able to fold into amphipathic structures. These compounds
possess antibacterial activities against a broad range of bacteria including antibiotic-
resistant bacteria (106, 159, 160, 169). Theses abiotic compounds are selectively active
against bacterial membranes. They insert themselves into the bacterial model membranes
and are less selective towards mammalian model membranes (57). Additional
investigations are warranted to study the in vivo toxicity and antibacterial efficacy of
these compounds.
CURRENT THERAPEUTIC APPLICATION AND CLINICAL
DEVELOPMENT
Due to a range of beneficial effects conferred by HDPs including broad-spectrum
antibacterial activity and immunomodulatory effects, efforts are ongoing to develop them
as novel antibiotics to treat infections. The companies involved in their commercial
development are mostly small biotechnology companies. Their efforts have been met
with mixed success. A number of peptides are being developed in various stages of
clinical trials and are yet to be approved by FDA. The diseases against which peptides are
developed include ventilator-associated pneumonia, in-dwelling catheter-associated
infections, oral candidiasis, sepsis, cystic fibrosis, acne, and bacterial meningitis (85,
202).
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The most successful peptide to date is bovine indolicidin-based omiganan
pentahydrochloride 1% gel, also known as MX-226, which has been shown to reduce
catheter-associated infections by 49% in a phase III clinical trial (58, 85). Another
indolicidin-based peptide, MX-594AN, significantly reduced severity of acne lesions in a
phase II trial (58, 85) (www.migenix.com). Pexiganan, a cationic peptide based on frog
magainin, was the first peptide to enter clinical trials for treatment of diabetic foot ulcers.
However, FDA rejected its approval despite its effectiveness, since it did not confer any
additional benefits than treatments currently available to treat diabetic foot ulcers (85).
Iseganan, a peptide based on porcine protegrin, did not provide obvious benefits in
ventilator-associated pneumonia and was withdrawn from clinical trials (85).
Compared to other HDPs, not even a single defensin has reached clinical trials.
The disadvantages associated with defensins are low potency, salt sensitivity, and
significant costs in producing disulfide-containing peptides on a large scale. However,
plectasin, a novel defensin from fungus Pseudoplectania nigrella, can be produced and
purified on an industrial scale using a fungal expression system (97). Plectasin has a half
life of 50 min in serum, presumably due to increased stability towards proteases provided
by disulfide bonds. Furthermore, it protects mice from experimental peritonitis and
pneumonia (97).
Mixed successes are not deterring companies from developing HDPs as
antibacterial therapeutics. However, the trend is to develop smaller versions of peptides,
which are cheaper to synthesize. For example, Helix BioMedix is developing short
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hexapeptides to treat bacterial and fungal infections (202). Also, antibacterial activities of
HDPs can be separated from immunomodulatory activities as discussed in the previous
section. It will not be surprising if companies start utilizing immunomodulatory
fragments, rather than antibacterial fragments for clinical development. Inimex
pharmaceutical has identified a lead compound based on LL-37. This lead peptide lacks
antibacterial activity, but is able to protect against infection in animal models due to its
immunomodulatory activities (11). Helix BioMedix is developing HB107, a peptide
based on cecropin, for wound healing rather than anti-infective purposes (202). Some
companies are even developing peptide mimetics and oligomeric compounds to treat
infections, since such drugs show more stability in serum than HDPs due to their
resistance to proteases (202).
CONCLUSION AND FUTURE PROSPECT
HDPs possess antimicrobial as well as immunomodulatory activities. They have
tremendous potential as novel anti-infective drugs. However, there is a need to address
issues such as antibacterial potency, toxicity, stability, salt sensitivity, and cost of
production. A variety of strategies are emerging to tackle these issues including structure-
based rational design, amidation, cyclization, dimerization, amino acid modification, and
peptide mimetics. Another important issue is the length of peptide as it is directly related
to the production cost. Efforts should be directed to make HDPs as small as possible
without compromising their biological activities. In addition to recombinant production,
making flocks of transgenic animals producing a large amount of peptides is a practical
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approach to produce HDPs. Taken together, identification of novel HDPs, study of their
structure activity relationship, and optimal peptide design will help drive anti-infective
peptides into clinics.
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ABSTRACT
Mammalian -defensins constitute a family of cysteine-rich, cationic antimicrobial
peptides produced by phagocytes and intestinal Paneth cells, playing an important role in
innate host defense. Following comprehensive computational searches, here we report the
discovery of complete repertoires of the -defensin gene family in the human,
chimpanzee, rat, and mouse with new genes identified in each species. The human
genome was found to encode a cluster of 10 distinct -defensin genes and pseudogenes
expanding 132 kb continuously on chromosome 8p23. Such -defensin loci are also
conserved in the syntenic chromosomal regions of chimpanzee, rat, and mouse.
Phylogenetic analyses showed formation of two distinct clusters with primate -defensins
forming one cluster and rodent enteric -defensins forming the other cluster. Species-
specific clustering of genes is evident in non-primate species, but not in the primates.
Phylogenetically distinct subsets of -defensins also exist in each species with most
subsets containing multiple members. In addition, natural selection appears to have acted
to diversify the functionally active mature defensin region but not signal or prosegment
sequences. We concluded that mammalian -defensin genes may have evolved from two
separate ancestors originated from -defensins. The current repertoire of the -defensin
gene family in each species are primarily a result of repeated gene duplication and
positive diversifying selection after divergence of mammalian species from each other,
except for the primate genes, which were evolved prior to the separation of the primate
species. We argue that the presence of multiple, divergent subsets of -defensins in each
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species may help animals to better cope with different microbial challenges in the
ecological niches which they inhabit.
INTRODUCTION
The defensins of vertebrates constitute a large family of cationic antimicrobial
peptides that are characterized by the presence of six cysteine residues at defined
positions. According to the spacing pattern of cysteine residues, these defensins are
further classified into three subfamilies, namely -, - and -defensins with each
consisting of a unique six-cysteine motif and a disulfide bonding pattern (6, 16, 21, 29).
For example, the consensus -defensin motif is C-X1-C-X3-4-C-X9-C-X6-10-C-C, where
C1-C6, C2-C4 and C3-C5 form three intramolecular disulfide bridges. While -defensins
have been found in most vertebrate species with a much wider tissue expression pattern,
-defensins are specific to mammals and are mainly produced by leukocytes of myeloid
origin and Paneth cells of small intestine (6, 16, 21, 29). On the other hand, -defensins
are believed to have evolved from -defensins and have only been discovered in
leukocytes of primates (6, 16, 20).
Defensins possess potent antimicrobial activity against a broad range of bacteria,
fungi, and enveloped viruses (6, 16, 21, 29). In addition, certain defensins are also
capable of inducing maturation of dendritic cells and spermatocytes, inducing secretion
of chloride and proinflammatory cytokines from epithelial cells, and chemoattracting
immune and inflammatory cells (6, 16, 40). The mechanism by which defensins kill
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microbes involves initial electrostatic interactions of cationic peptides with negatively
charged phospholipids on the microbial membranes, followed by permeabilization of
bacterial membrane and cell death (6). In contrast to most conventional antibiotics that
kill microbes by certain biochemical mechanisms, such a physical mechanism of action
confers on defensins a broad-spectrum antimicrobial activity with equal efficacy against
antibiotic-resistant strains and little risk of developing resistance (8, 43). Consequently,
defensins are being explored as a new class of antimicrobials mainly to control antibiotic-
resistant microorganisms.
To date, a number of -defensins have been discovered in human, rhesus
macaque, rabbit, guinea pig, mouse, and rat (6, 16, 21). For example, three myeloid -
defensin genes (DEFA1/2, DEFA3 and DEFA4) and two enteric -defensin genes
(DEFA5/HD5 and DEFA6/HD6) have been found in humans, and a group of 19 highly
homologous enteric -defensins (cryptdins) have also been reported in mice. All -
defensins are synthesized from 80-105 amino acid precursors with each composed of a
short N-terminal signal sequence (~20 amino acids), an anionic prosegment (40-50 amino
acids), and a C-terminal cationic mature peptide (30-35 amino acids) (6, 16, 21). The -
defensins are stored as either inactive proforms or mature active forms in the cytoplasmic
granules of phagocytes and Paneth cells and released (and processed if necessary) in
response to microbial infection or cholinergic stimulation (6, 16, 21). The enzyme
responsible for processing and activation of intestinal -defensins is metalloproteinase
matrilysin (MMP7) in mice (38) and trypsin in humans (7), respectively. The contribution
of -defensins to intestinal mucosal immunity has been best demonstrated by the
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evidence that transgenic mice expressing human DEFA5 or HD5 became fully resistant to
oral lethal infection with Salmonella typhimurium (27) and that MMP7-deficiency
rendered mice more susceptible to S. typhimurium infection (38).
The genomes of several evolutionarily divergent vertebrate species have been
sequenced, including zebrafish, Japanese pufferfish (Fugu rubripes), chicken, dog, rat,
mouse, chimpanzee and human. Availability of such a large amount of sequence
information provides a timely opportunity to search for the possible existence of -
defensins in these species. We hypothesized that identification of the entire repertoire of
-defensin genes across a range of animal species will reveal the origin and evolutionary
relationships of this important gene family. This also serves as a first step to study the
role of -defensins in host immunity and explore their potential as novel antimicrobials.
Following comprehensive genome-wide screening, here we report identification of the
complete repertoires of -defensin genes in the human, chimpanzee, mouse, and rat with
novel sequences being discovered in each species. However, none of -defensins have
been found in any species other than glires (mouse, rat, guinea pig, and rabbit) and
primates (human, chimpanzee, olive baboon, and rhesus macaque). In addition, we
provide strong evidence showing that a rapid duplication and positive diversifying
selection of -defensin genes have occurred following divergence of mammalian species.
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MATERIALS AND METHODS
Computational search for novel -defensins
To identify potential novel sequences in all vertebrate species with whole genome
sequences available, all known -defensin peptide sequences were individually queried
against expressed sequence tags (EST), nonredundant sequences (NR), unfinished high
throughput genomic sequences (HTGS), and whole genome shotgun sequences (WGS) in
the GenBank by using the TBLASTN program (1) with the default settings on the NCBI
web site (http://www.ncbi.nlm.nih.gov/BLAST). The vertebrate species examined
included zebrafish, Japanese pufferfish, chicken, dog, rat, mouse, chimpanzee, and
human. All potential hits were then examined for presence of the characteristic -
defensin motif or highly conserved signal/prosegment sequence. For every novel -
defensin sequence identified, additional iterative BLAST searches were performed as
described above until no more novel sequences can be revealed. Because mammalian
defensins tend to form clusters (17, 30, 31), all genomic sequences containing -
defensins were also retrieved from the GenBank in order to discover potential novel
sequences with distant homology. The nucleotide sequences between two neighboring
defensin genes were translated into six open reading frames and individually compared
with the two defensin peptide sequences for the presence of -defensin motif or
signal/prosegment sequence by using the BLASTP (1) on the NCBI web site
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/) and/or ClustalW program (version 1.82) (35)
on the European Bioinformatics Institute web site (http://www.ebi.ac.uk/clustalw).
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Prediction of full-length coding sequences and genomic structures of -defensins
All known -defensin precursors are encoded in two separate exons separated by
a short intron of less than 2 kb with one exon encoding signal/prosegment sequence and
the other exon encoding the mature peptide containing the six-cysteine -defensin motif
(22). If either the signal/prosegment sequence or -defensin motif of a novel gene was
missing in a genomic sequence within a 2-kb distance, an approximately 5-kb sequence
flanking the -defensin motif or signal/prosegment sequence was retrieved to identify the
full-length coding sequence and to derive the structural organization of that novel -
defensin gene by using a combination of GenomeScan (41), GENSCAN (4) and/or
GeneWise (3). In the case of the rat, all computational predictions of coding sequences,
except for the pseudogenes, have also been confirmed by cloning and sequencing of their
respective RT-PCR products amplified from appropriate tissues.
Identification and characterization of -defensin gene clusters
To determine the relative position and orientation of each defensin in the genome,
individual defensins were searched against the assembled genomes of human (NCBI
Build 35), chimpanzee (NCBI Build 1 Version 1), mouse (NCBI Build 33), and rat (BCM
Version 3.1) released in May 2004, November 2003, May 2004, and June 2003,
respectively. The BLAT program (14) was used for gene mapping through the UCSC
Genome Browser (http://genome.ucsc.edu). The chromosomal locations of the -defensin
gene clusters of human, mouse, and rat were revealed by using the Map Viewer Program
(http://www.ncbi.nlm.nih.gov/mapview).
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Sequence alignment and molecular evolutionary analysis
Multiple sequence alignments were carried out by using the ClustalW program
(version 1.82) (35) (http://www.ebi.ac.uk/clustalw). The neighbor-joining method (26)
was used to construct the phylogenetic tree by calculating the proportion of nucleotide or
amino acid differences (p-distance), and the reliability of each branch was tested by 1000
bootstrap replications. Pairwise comparisons of nucleotide sequences at the codon level
was carried out by using the method of Nei and Gojobori (19) to estimate the number of
nonsynonymous substitutions per nonsynonymous site (dN) and the number of
synonymous substitutions per synonymous site (dS) with the Jukes-Cantor correction for
multiple substitutions. Construction of the phylogenetic tree and pairwise comparison of
nucleotide or amino acid sequences were carried out by using the MEGA software
version 2.1 (15).
RT-PCR analysis of tissue expression patterns of -defensins
A total of 26 different tissue samples were harvested from healthy, 2-month old
Sprague-Dawley rats. Bone marrow progenitor cells were collected from femur, followed
by hypotonic lysis of erythrocytes as described (44, 45). Only lineages of white blood
cells were used for RNA isolation. Total RNA was extracted using Trizol (Invitrogen,
Carlsbad, CA). A panel of 12 human tissue RNA, including bone marrow, small intestine,
kidney, trachea, lung, liver, heart, spleen, skeletal muscle, testis, prostate, and uterus,
were also purchased from BD Biosciences Clontech (Palo Alto, CA) and used for
evaluating the expression pattern of DEFA7. For each human and rat RNA, 4 µg were
reverse transcribed with random hexamers and Superscript II reverse transcriptase by
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using a first-strand cDNA synthesis kit (Invitrogen) according to the instructions. The
subsequent PCR was carried essentially as described (44, 45). Briefly, 1/40 of the first-
strand cDNA from each tissue were used to amplify -defensins and glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) with gene specific primers. Every pair of primers
were designed from less conservative regions located on different exons to aid in specific
amplification of target genes and in distinguishing PCR products amplified from cDNA
versus genomic DNA (Table 1). The PCR program used was: 94oC denaturation for 2
min, followed by different cycles of 94oC denaturation for 20 sec, 55oC annealing for 20
sec, and 72oC extension for 40 sec, followed by a final extension at 72oC for 5 min. The
sequence of primers and number of PCR cycles used are shown in Table 1. The PCR
products were analyzed by electrophoresis on 1.2% agarose gels containing 0.5 µg/ml
ethidium bromide. The specificity of each PCR product was confirmed by cloning of the
PCR product into T/A cloning vector, followed by sequencing of the recombinant
plasmid.
GenBank accession numbers
All cDNA sequences of new - and -defensins described in this manuscript have
been submitted to the GenBank. Accession numbers are as follows: rat, Defa6-
Defa11(AY623750-AY623755), Defa12-ps-Defa14-ps (AY746422-AY746424), Defa-
rs1(AY623756); mouse, Defcr20-Defcr25 (AY746425-AY746430), Defcr26
(AY766470), Defa-ps1 (AY746431), CRS1C-2 (AY761183), CRS1C-3 (AY761184),
CRS4C-6 (AY761185); human, DEFA7P-DEFA11P (AY746432-AY746436);
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chimpanzee, PTAD1-PTAD11-ps (AY746437-AY746445), PTTD1-ps-PTTD2-ps
(AY746446-AY746447); and olive baboon, PAAD1-PAAD3 (AY746448-AY746450).
RESULTS
Genome-wide identification of -defensins in rodents and primates
To identify possible existence of novel -defensin sequences in the vertebrate
species whose genomes have been sequenced, all known -defensin peptide sequences
were individually queried against EST, NR, HTGS, and WGS sequences of zebrafish,
Japanese pufferfish, chicken, dog, rat, mouse, chimpanzee, and human in the GenBank by
using the TBLASTN program (1). For every novel -defensin sequence identified,
additional iterative BLAST searches were performed until no more novel sequences
could be revealed. All genomic sequences containing -defensins were also retrieved
from the GenBank and translated into six open reading frames and curated for the
presence of the -defensin motif or signal/prosegment sequence to reveal potential
sequences with distant homology. Whenever necessary, a combination of gene prediction
programs, including GenomeScan (41), GENSCAN (4) and/or GeneWise (3), were used
to predict full-length coding sequences of novel -defensins from genomic sequences.
As a result, a number of sequences have been discovered in the human,
chimpanzee, rat and mouse. In the case of human, five novel -defensin genes were
found in addition to five previously characterized ones, DEFA1-6 (6, 21). Among new -
defensin genes identified is DEFA7, which consists of a canonical six-cysteine -defensin
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motif and an N-terminal signal/prosegment sequence highly homologous to known
human -defensins (Fig. 1A).
Because DEFA7 lacks the start codon in the consensus position that initiates the
translation of all other -defensins, we sought to confirm if it is a functional gene.
However, RT-PCR analysis revealed no expression of DEFA7 in any of 12 human tissues
examined, including small intestine, bone marrow, and kidney, three of which are the
most dominant sites to produce -defensins in other mammalian species. Although it is
still possible to be transcribed in other places, DEFA7 is most likely to be a pseudogene
and therefore, is designated as DEFA7P. Such results are also consistent with the fact that
there is no single EST sequence for DEFA7P in the GenBank, despite of nearly 5.8
million ESTs being deposited as of September 1, 2004.
In addition to DEFA7P, four -defensin pseudogenes, namely DEFA8P-11P,
have also been discovered in the human (Fig. 1A). Without a premature stop codon, each
pseudogene would otherwise encode a peptide that is highly similar to a typical -
defensin (Fig. 1A). Identification of additional five -defensin genes in the extensively
studied human genome highlighted the power of our computational search strategy.
A total of 11 novel -defensins, including four pseudogenes, have also been
identified in the chimpanzee genome. These genes, which were termed Pan troglodytes
-defensins (PTAD) 1-11, are all human -defensin orthologs (Fig. 1A), and therefore are
expected to show a similar tissue expression pattern to human genes. PTAD1 and PTAD4
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are predicted to be neutrophil-specific, whereas PTAD5 and PTAD6 are expected to be
expressed mainly in Paneth cells of small intestine. Interestingly, PTAD7, the chimpanzee
ortholog of DEFA7P, appears to be a functional gene with the start codon at the
consensus position (Fig. 1A), but its expression site(s) remain(s) to be studied. Four
orthologs of human -defensin pseudogenes are also present in the chimpanzee, namely
PTAD8-ps to PTAD11-ps.
In addition to -defensins, two pseudogenes for -defensin, PTTD1-ps and
PTTD2-ps, have also been found in the chimpanzee (Fig. 1A). Both PTTD1-ps and
PTTD2-ps are highly homologous to each other and to known human -defensin
pseudogene, DEFT1P (6, 16) (Fig. 1A), but they differ with DEFT1P in the locations of
premature stop codons. DEFT1P contains two stop codons at the amino acid positions 17
and 77; however, only the former stop codon is preserved in PTTD1-ps and PTTD2-ps.
Three new -defensins, namely PAAD1-3, were also identified in two bacterial
artificial chromosome (BAC) clones (accession no. AC116558 and AC116559) of olive
baboon (Papio anubis) (Fig. 1A). PAAD1-2 are orthologous to DEFA5, whereas PAAD3
is a DEF7P homolog. However, unlike DEF7P that contains a single nucleotide mutation
at the start codon, PAAD3 is composed of a stretch of completely different nucleotides
around the start codon (See supplementary Fig. 1), and therefore it is also predicted to be
a pseudogene. This prediction is further supported by the fact that, despite of extensive
experimental screening efforts (33, 34), no PAAD3-like sequences have been found to be
produced in either jejunum or leukocytes of rhesus macaque, which is a member of
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cercopithecids (Old World Monkeys) as olive baboon. Presumably, such PAAD3-like
gene(s) are also inactive in rhesus macaque; however, it remains to be experimentally
verified.
In the rat, a total of 14 -defensin genes have been discovered, including four
known ones (RatNP1/2, RatNP3, RatNP4, and RD5) (5, 42). Among ten novel rat -
defensins (Defa), six genes (Defa6-11) encode peptide sequences varying 87-104 amino
acid residues in length with a canonical six-cysteine -defensin motif (Fig. 1B). Also
identified were three -defensin pseudogenes, namely Defa12-ps, Defa13-ps, and
Defa14-ps, with each having a premature stop codon at amino acid positions 34, 29, and
88, respectively (Fig. 1B). In addition, one -defensin related sequence (Defa-rs1) was
also found in the rat. Despite of the conservation in the N-terminal signal/prosegment
sequence, Defa-rs1 has only five cysteine residues at the C-terminus with no
characteristic -defensin motif (Fig. 1B). Similarly, two groups of cryptdin-related
sequences (CRS1C and CRS4C) with the signal/prosegment sequences highly
homologous to -defensins, but with a different number and spacing pattern of cysteines
were reported earlier in mice (13). Such CRS peptides were shown recently to form
covalent homo- or heterodimers and are capable of killing bacteria (9). Therefore, it is
tempting to speculate that Defa-rs1, the only -defensin -related sequence in the rat,
associates with itself by forming homodimers and participates in innate defense in the gut
as other enteric -defensins.
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Among 19 -defensins (cryptdins) reported in mice, 17 belong to the highly
homogeneous cryptdin 1 (Defcr1) subgroup with less than 5 amino acids in difference in
the mature sequence and many are believed to be derived from allelic variants of the
same gene (22). Defcr4 and Defcr5 represent distant cryptdin family members and their
paralogous genes have not been reported in mice. Among eight novel -defensins that we
have identified in the mouse, five sequences (Defcr23-Defcr26 and Defcr-ps1) can be
grouped to the Defcr1 subgroup, whereas the other three (Defcr20-Defcr22) are similar to
Defcr4 (Fig. 1C). In addition, three novel cryptdin-related sequences were also found in
mice (Fig. 1D). Among them, CRS1C-2 and CRS1C-3 are highly homologous to
CRS1C-1, which contains a total of 11 cysteines with eight forming C-X-Y triplet
repeats. On the other hand, CRS4C-6 belongs to a distant member of the CRS4C
subgroup. Instead of consisting seven C-X-Y repeats, CRS4C-6 has an extra cysteine
located close to the N-terminal end of the mature sequence. Unlike other CRS4C peptides
that form intermolecular covalent dimmers (9), CRS4C-6 is likely to function as a
monomer or non-covalently associated dimmers/oligomers. Interestingly, none of -
defensin sequences have been found in the species other than glires and primates. This is
perhaps not surprising, given the fact that no -defensins have been reported in any other
vertebrate species despite of the extensive searching efforts in the past (6, 21).
Tissue expression patterns of rat -defensins
A semi-quantitative RT-PCR was used to analyze tissue expression patterns of rat
-defensins. As shown in Fig. 2, all rat -defensins exhibited two distinct patterns of
expression. One group, which include RatNP1/2, RatNP3, and Defa12-ps, are
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preferentially expressed in bone marrow with or without expression in small intestine
(Fig. 2). Defa7, Defa10, and Defa11 also belong to this group with little but specific
expression in bone marrow (data not shown). In contrast, the other group consisting of
RD5, Defa6, Defa8, Defa9, and Defa-rs1 are specifically expressed in small intestine
(Fig. 2). These genes are highly transcribed in jejunum and ileum with a low level of
expression in duodenum. Interestingly, such a grouping is also consistent with the degree
of conservation in the signal peptide sequences, which are more homologous within each
group (top panel vs. bottom panel, Fig. 1B). It is surprising to see the expression of
RatNP3 and Defa12-ps in both bone marrow and small intestine, given the fact that all
known -defensins are produced either by myeloid or Paneth cells, but not by both cell
lineages (21). The cells that express rat -defensins in the intestinal tract are presumably
Paneth cells, which produce enteric -defensins in humans and mice (21). It is worthy
noting that Defa-rs1 is expressed in the jejunum and ileum at the comparable levels to
most other enteric defensins (Fig. 2), reinforcing the notion that it most likely will
function in vivo.
Molecular evolutionary analyses of mammalian -defensins
To analyze the phylogenetic relationships among all known -defensins in glires
and primates including the newly identified ones, the proportion of amino acid
differences (p-distance) of full-length peptides was calculated by the neighbor-joining
method (26) (See supplementary Fig. 2 for alignment of peptide sequences of 82 -
defensins used). As shown in Fig. 3A, two major clusters are evident with -defensins in
the primates with rabbit and guinea pig forming one cluster supported by a bootstrap
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value of 65%, and mouse and rat enteric -defensins forming the other cluster with a
bootstrap value of 98%. Rat -defensins appear to be unique in that the genes of myeloid
origin formed a separate cluster from the genes of enteric origin. Rat myeloid -defensins
tend to group with primate, rabbit, and guinea pig -defensins.
Perhaps the most striking feature of the phylogenetic tress is that -defensins
formed species-specific clusters in the non-primate species (rat, mouse, guinea pig, and
rabbit), implying that these genes may have undergone repeated duplication after these
species diverged from a common ancestor. In contrast, no species-specific clustering was
demonstrated among four primate species examined (human, chimpanzee, rhesus
macaque, and olive baboon) (Fig. 3A). Instead, several distinct subclusters of -defensins
exist across the primate species. For example, chimpanzee and human are in a complete
analogy with -defensins present in all subclusters. The -defensins of Old World
Monkeys are located in three subclusters with human and chimpanzee DEFA1-3, DEFA5,
and DEFA7P, respectively. These results suggested that many of the primate genes were
likely evolved before the divergence of these species. The primate-specific -defensins,
which exist in both cercopithecids and hominids, are clearly clustered together with the
DEFA10P gene lineage, reinforcing the notion that -defensins were evolved from -
defensins after divergence of the primates from other mammalian species (6, 16, 20, 21).
To minimize possible biases of selection pressure exerted on exon (and therefore
peptide) sequences, the evolutionary relationships of the -defensin genes were further
evaluated by analysis of the intron sequences within the open reading frame. The p-
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distance of the introns of 59 -defensins with known gene sequences was calculated by
the neighbor-joining method (the intron sequences used will be available upon request)
(26). Consistent with the results obtained from the full-length peptide sequences, a
similar two major clusters of genes were obtained, in which mouse and rat enteric -
defensins were separated from others, supported by a bootstrap value of 100%, and hence
were most likely evolved from a different ancestor (Fig. 3B). On the other hand, rat
myeloid gene introns are clearly clustered together with primate -defensins and
therefore were originated from the same ancestral gene. As for rat and mouse enteric
genes, there are two distinct subclusters with each being supported by a bootstrap value
of 100%, implying that mouse cryptdins (Defcr) share the same ancestor with rat RD5,
Def13-ps, and Defa14-ps, whereas mouse cryptdin-related sequences (CRS1C and
CRS4C) were derived from the same primordial gene as rat Defa6, Defa8, and Defa9, and
Defa-rs1 (Fig. 3B). It is obvious that each subcluster has undergone a repeated
duplication and diversification to give rise to multiple members in each species after
these mammalian species diverged from a common ancestor.
Despite of significant sequence conservation in the first exon (Fig. 1C and 1D)
and intron (data not shown), substantial differences exist in the cysteine motif encoded by
the second exon between canonical -defensins and three subgroups of related sequences
in rats and mice, namely Defa-rs1, CRS1C, and CRS4C (Fig. 1C and 1D). To further
address the origin and evolution of the cysteine motif of -defensin-related sequences,
nucleotide sequences of the second exon were compared with rat enteric -defensins
(Defa6, Defa8, and Defa9) in the same subcluster (Fig. 3B). It is evident that Defa-rs1
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shares a high homology with three rat -defensins throughout the entire coding region in
the second exon (Fig. 4), suggesting that, in addition to the first exon and intron, the
second exon of Defa-rs1 was also originated from the same ancestral gene as rat enteric
-defensins. In fact, the change in the number and pattern of cysteines in Defa-rs1 was
mainly because of nucleotide deletions (Fig. 4).
As for mouse CRS1C and CRS4C, both subgroups are highly homologous in the
second exon (Fig. 4), and therefore share the same ancestor. The difference in the
cysteine motif of CRS1C and CRS4C peptides were primarily because of deletions and
insertions rather than nonsynonymous substitutions (Fig. 4). Although CRS peptides
share a less homology with rat enteric -defensins and Defa-rs1, patches of identical
nucleotides are evident among them throughout the entire second exon (Fig. 4), implying
that, similar to Defa-rs1, the changes in the second exon of CRS genes were likely to be a
result of sequence diversification, instead of exon shuffling, which commonly occurred
during the evolution of many gene families (23). Coupled with the fact that both intron
and the first exon are highly conserved among classic -defensins and related sequences,
the full-length CRS genes most likely were derived from the same ancestral genes for rat
enteric -defensins and Defa-rs1. Apparently, CRS genes and Defa-rs1 were
independently evolved from classic -defensins in mice and rats, respectively, following
divergence of these two rodent species from each other.
Collectively, our results suggested that all mammalian -defensins may have
evolved from two ancestral genes with each giving rise to one major cluster of daughter
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genes. The absence of -defensins in non-mammalian species clearly indicated that -
defensins have evolved after the divergence of mammals from other vertebrate species.
Formation of species-specific clusters, particularly in non-primate species, strongly
suggested that many -defensins have evolved independently after these mammalian
species diverged from a common ancestor. It is worthy noting that, because of the lack of
complete repertoires of -defensin genes in the rabbit and guinea pig, the origin of -
defensins in these two species remains inconclusive. Analysis of coding sequences placed
them in the same cluster as primate genes (Fig. 3A). However, comparison of intron
sequences indicated that guinea pig myeloid defensins (GNCP1A, GNCB1B and GNCP2)
and rabbit kidney defensins (RK1 and RK2) may share the same ancestor with rat and
mouse enteric genes, while rabbit myeloid defensins (NP1 and NP2) were likely evolved
from the ancestral genes for primates (Fig. 3B).
To further understand the driving force for sequence divergence of -defensins
during evolution, we tested whether positive Darwinian selection has occurred by
estimating the number of synonymous substitutions per synonymous site (dS) and the
number of nonsynonymous substitutions per nonsynonymous site (dN) substitution for
different regions of mammalian -defensins using the method of Nei and Gojobori (19).
We computed these values for 11 pairs of closely related genes, which were
phylogenetically and thus statistically independent of each other (24). Consistent with
earlier results (10, 12), mean dN was significantly greater than mean dS in the mature
peptide, but there was no significant difference between mean dS and mean dN in the
signal peptide or prosegment (Table 2). These results support the hypothesis that natural
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selection has acted to diversify the functionally active mature defensin region but not
other portions of the molecules (10, 12).
Genomic organization of mammalian -defensin gene clusters
Searching through HTGS and WGS sequences in the GenBank led to
identification of a number of genomic sequences containing -defensin genes in the
human, chimpanzee, rat and mouse genome (data not shown). To determine the relative
position and orientation of each defensin on the chromosome, individual defensins were
searched against the assembled human, chimpanzee, rat and mouse genomes by using the
BLAT program (14) through the UCSC Genome Browser. In the case of human, all 11
known and newly identified - and -defensins genes were found to form a continuous
cluster expanding 132 kb on the chromosome 8p23 (Fig. 5A). All human defensins are
transcribed from the same direction from centromere to telomere with the -defensin
pseudogene (DEFT1P) residing in the center. The chimpanzee genome encodes an -
defensin cluster of 10 distinct genes, which expanded 117 kb in the proximal region of
chromosome 7 (Fig. 5A). The -defensin clusters in the chimpanzee and human are
nearly in perfect synteny. The only difference is the presence of two copies of DEFA1
and DEFT1P in the human rather than a single copy in the chimpanzee. Such syntenic -
defensin loci are also present in rats and mice. In the case of rat, all 14 -defensin genes
are clustered within a 311-kb distance on the chromosome 16q12.4-q12.5 (Fig. 5B),
whereas six mapped mouse -defensin genes are located continuously on chromosome
8A1.3 (Fig. 5C).
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It is noted that all -defensin genes in both rodents and primates reside within a -
defensin cluster (data not shown) and are adjacent to -defensin 1 (Defb1), which is
evolutionarily conserved across the mammalian species (Fig. 5). Therefore, the syntenic
location and physical proximity of -defensins in these species provided additional
evidence to support the conclusion that -defensins have arisen from common ancestor(s)
by gene duplication followed by diversification.
Comparison of the open reading frames with genomic sequences of all known and
newly identified -defensins (including -defensin -related sequences) revealed a highly
conserved gene structure, which is composed of two exons separated by a 500-700 bp
intron, except for DEFA5/PTAD5, DEFA6/PTAD6, RK1, RK2, PAAD1 and PAAD2,
whose introns vary from 848-1646 bp (data available upon request). Consistent with
earlier findings, signal sequence and most of the prosegment of -defensins are encoded
in the first exon, whereas the second exon primarily encodes the mature -defensin
sequences. However, based on -defensin genes studied thus far, it appears that genes of
myeloid origin consist of an additional exon encoding 5’-untranslated region, whereas
enteric genes are composed of only two exons (21). The lack of full-length cDNA
sequences for these newly identified novel sequences prevented us from predicting the
genomic locations of 5’- and 3’-untranslated regions and thus possible existence of
additional introns.
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DISCUSSION
Sequence diversity of mammalian -defensins
Following systemic, genome-wide screenings, the complete repertoires of the -
defensin gene family, including a number of novel genes, have been identified in the
human, chimpanzee, rat, and mouse (Fig. 1). Although it is highly unlikely, we could not
rule out the possibility that additional -defensin genes with distant homology might be
uncovered in these species by different computational methods such as the use of Hidden
Markov models (18, 30, 31). Alignment of all known -defensin peptide sequences
revealed the conservation of signal and negatively charged prosegment sequences as well
as the characteristic six-cysteine-containing -defensin motif, with exception of
pseudogenes and -defensin-related sequences (Fig. 1). Given the significance of six
cysteines in maintaining the spatial structure and biological functions, most pseudogenes
have at least one mutation at the conserved cysteine position (Fig. 1), consistent with
their dysfunctional nature.
Among all newly identified genes in the primates, chimpanzee PTAD7 is unique
in that it represents a distant, putative functional gene. Unlike a typical -defensin that is
positively charged, the putative mature sequence of PTAD7 contains two arginines (R)
and two glutamic acids (E), and therefore is predicted not to have a net positive charge
under physiological conditions. However, its human ortholog, DEFA7P, appears to be a
pseudogene because of an absence of the start codon and hence lack of transcription in a
wide range of tissues. Interestingly, PAAD3, a DEFA7P ortholog in olive baboon, also
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appears to be a pseudogene with no start codon at the canonical position (see
supplementary Fig. 1). The unique sequence and evolutionary dynamics of the PTAD7
gene lineage in different primary species implied that PTAD7 might function differently
in the chimpanzee from other -defensins. Consistent with its novelty, PTAD7 is the only
known putative functional -defensin with a nonsynonymous mutation to serine at the
fourth canonical cysteine position (Fig 1A).
As opposed to many -defensins, most -defensins contain no or only one amino
acid following the last two cysteines (Fig. 1). However, Defa8, Defa9 and Defa11 in the
rat share a unique feature of unusually long C-terminal tail (9-14 amino acids) rich in
charged and polar uncharged amino acids. Such C-terminal tails, which are predicted to
be exposed to the surface to influence the overall charge and amphipathicity, might
confer a different antimicrobial spectrum and/or efficacy on those peptides, as the net
charge and amphipathicity are strongly correlated with antimicrobial activity of defensins
(25, 28, 32). Further studies are warranted to assess the importance of such long C-
terminal tails in antimicrobial activity as well as in other biological functions.
Evolution of mammalian -defensins
All -defensins have been found only in certain mammals, but not in any other
vertebrate species that we examined, suggesting that -defensin genes have appeared
following mammalian divergence. The presence of -defensin loci in syntenic
chromosomal regions of different mammalian species (Fig. 5) is indicative of a common
ancestor. Phylogenetic analyses of both full-length peptide and intron sequences of -
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defensins revealed two distinct clustering (Fig. 3), implying that they may have
independently evolved from two separate ancestral genes. One ancestral gene has
undergone significant duplication and diversification giving rise to enteric-specific -
defensins in the rat and mouse, whereas the other ancestral gene has evolved to the genes
in the primates as well as in rat myeloid cells.
Phylogenetic analysis of primate -defensins revealed an interesting evolutionary
pattern and pointed out possible presence of subgroups of -defensins that are specific in
the hominid lineage. Despite extensive searches for the repertoire of -defensins in both
leukocytes (34) and small intestines (33), neither DEFA4- nor DEFA6-like genes have
been found in rhesus macaques (Fig. 1A and Fig. 3). Such genes are also absent in nearly
1000 olive baboon genomic sequences deposited in the GenBank as of September 1,
2004. Therefore, it is likely that DEFA4/PTAD4 and DEFA6/PTAD6 lineages are
hominid-specific genes. On the other hand, albeit of a single copy of DEFA5/PTAD5
gene encoded in human and chimpanzee genomes, multiple members of the DEFA5-like
genes are present in both rhesus macaque (RED1-6, RMAD4/5, and RMAD6/7) and olive
boboon (PAAD1 and PAAD2) (Fig. 3A). Apparently, the ancestral gene for DEFA5 has
undergone a different evolutionary pattern: It duplicated and expanded in cercopithecids,
but remained a single copy in hominids. In addition, the DEFA5 ancestral gene has
diverged in rhesus macaques to acquire a new ability for certain offspring genes to
express in myeloid cells (e.g., RMAD4/5, and RMAD6/7), in addition to intestinal Paneth
cells (e.g., RED1-RED6) as in humans.
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With regard to the evolution of mammalian -defensins, Bevins et al. proposed a
model, which was based on dot matrix sequence comparisons of introns of a few mouse
and human genes, that -defensins were derived from two ancestral genes for human
enteric DEFA5 and DEFA6, and that a subsequent homologous unequal meiotic
crossover of DEFA5 and DEFA6 generated a hybrid gene that was further evolved to
present day myeloid -defensins (2). Although such a model might be true in primate
species (2), our results clearly argued against its generalization to non-mammalian
species, because the mouse genome apparently encodes neither DEFA5/DEFA6-like
genes nor myeloid -defensins. Therefore, mouse -defensin genes were apparently not
derived from homologous crossover of the primordial genes for DEFA5 or DEFA6.
Furthermore, because of presence of multiple DEFA5 genes expressed in both small
intestine and leukocytes in cercopithecids, but an absence of DEFA6 lineages, the validity
of Bevins’ evolutionary model in primate species remains to be examined with
availability of additional primate genomes.
As for the origin of mammalian -defensins, they were most likely evolved from
-defensins after mammals diverged from other vertebrates, primarily because of the
physical proximity on the chromosome as well as a similarity in spatial structure and
biological activities (6, 39). As suggested by Nguyen et al. (20), appearance and further
diversification of - and -defensins from already a large -defensin gene family is
probably because of the need for antiviral defense in certain mammalian and/or primate
species, as these newly evolved - and -defensins have acquired novel lectin-like
activity and are capable of inhibiting the entry of viruses (such as HIV) to host cells (36,
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37). It is possible that divergence of -defensin-related sequences from canonical -
defensins in rodents could lead to some novel activities beyond antimicrobial. Further
functional characterization of these -defensins will shed light on the significance of their
diversification during evolution and facilitate their development as a new class of
antimicrobial agents.
Our earlier comparative analysis of -defensins in the chicken, rodents, and
human revealed that most gene lineages are conserved across mammalian species and
thus were evolved before the divergence of mammals from each other (39). In contrast,
-defensins tend to form species-specific clusters particularly in non-primate species
(Fig. 3). Distinct subsets of -defensin genes also exist with most subsets containing
multiple members in each species. It is even true with the rat and mouse (Fig. 3), which
only diverged 17-25 million years ago. It is rather unique that most -defensin genes
duplicated very recently in the evolutionary time and have undergone significant, but
independent expansion in different species. Clearly, the -defensin gene family is
evolutionarily older than -defensins. As compared to the former, -defensin genes
duplicated and expanded much more rapidly. Calculation of the rates of synonymous vs.
nonsynonymous substitutions of 11 pairs of representative -defensins revealed that
positive Darwinian selection appears to have acted to diversify -defensins, particularly
in the mature peptide region (Table 2).
Gene duplication followed by positive selection indeed has been observed in
several gene families involved in immune responses (11). Divergence of these immune
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genes often leads to either an additional layer of functional redundancy or acquisition of
functional novelties, both of which conceivably help the hosts cope more effectively with
a broad range of pathogens. In fact, -defensins have been shown to exhibit selectivity
against varied microorganisms, and a modest difference in the primary sequence could
have a significant impact on the antibacterial spectrum and/or potency (22). Therefore, as
different mammals live in quite different ecological niches, the production of species-
specific -defensins would presumably allow them to better respond to the specific
microbial challenges that they face. The presence of -defensin-related sequences in
rodents and functional divergence of -defensins from -defensins in certain primate
species provide additional evidence supporting this notion.
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FIGURE LEGENDS
Fig. 1. Amino acid sequence alignment of novel -defensins and -defensin-related
sequences in the primates (A), rat (B) and mouse (C and D). Panel C shows novel
cryptdins identified in mice, whereas Panel D demonstrates new cryptdin-related
sequences. The dashes are created to optimize the alignment, and canonical cysteines in
the mature defensin regions are shaded. The letter ‘X’ in bold denotes the presence of
premature stop codon in each pseudogene. Note that computational predictions of all
novel rat -defensin peptide sequences, except for the pseudogenes, have been confirmed
by cloning and sequencing of their respective RT-PCR products amplified from
appropriate tissues. Abbreviations: DEFA/Defa, -defensin; DEFT1P, human -defensin
1 pseudogene; PTAD, chimpanzee (Pan troglodytes) -defensin; PTTD, Pan troglodytes
-defensin; RMAD, rhesus macaque myeloid -defensin; RED, rhesus macaque enteric -
defensin; RTD, rhesus macaque -defensin; PAAD, Papio anubis -defensin; RatNP, Rat
neutrophil -defensin; Defa-rs1, rat -defensin-related sequence; RD5, rat -defensin 5;
Defcr, mouse -defensin-related cryptdin; CRS1C, mouse cryptdin-related sequence 1C;
CRS4C, mouse cryptdin-related sequence 4C; P/ps, pseudogene.
Fig. 2. Tissue expression patterns of novel rat -defensins by RT-PCR. See Materials and
Methods for details. The number of PCR cycles was optimized for each gene, and the
specificity of each PCR product was confirmed by sequencing. The house-keeping gene,
GAPDH, was used for normalization of the template input.
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Fig. 3. Phylogenetic tree of mammalian -defensins. The tree was constructed by
calculating the proportion difference (p-distance) of aligned amino acid sites of full-
length peptide sequences (A) or p-distance of aligned nucleotide sites of the entire intron
sequences (B) according to the neighbor-joining method. The reliability of each branch
was tested using 1000 bootstrap replications. Numbers on the branches indicate the
percentage of 1000 bootstrap samples supporting the branch. Only branches supported by
a bootstrap value of at least 40% are shown. Abbreviations: NP/MCP, rabbit neutrophil
-defensin/macrophage cationic peptide; RK, rabbit kidney -defensin; GNCP, guinea
pig neutrophil cationic peptide. See Fig. 1 legend for additional abbreviations.
Fig. 4. Alignment of the second exon sequences of rodent -defensin-related sequences
with three rat enteric -defensins. For clarity, the last ~75 nucleotides of introns were also
aligned and the exon/intron conjunction sites are indicated with a vertical line. Conserved
regions are shaded and the stop codon of each gene boxed. See Fig. 1 legend for
abbreviations.
Fig. 5. Genomic organizations of -defensin clusters in the primates (A), rat (B), and
mouse (C). The position of each gene is represented by a solid vertical bar and the width
of each bar is proportional to the size of each gene. The direction of transcription is
indicated by the triangle. The genes with solid triangles are transcribed in the direction
opposite to the ones with open triangles. The gene clusters were derived from the
assembled genomes of human (NCBI Build 35), chimpanzee (NCBI Build 1 Version 1),
rat (BCM Version 3.1) and mouse (NCBI Build 33). Note that the -defensin cluster is
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located in a syntenic region adjacent to -defensin 1 (DEFB1) in each species. In mice, a
number of additional -defensin genes are encoded in two other large but unmapped
clusters, and are not indicated here for the sake of clarity. Abbreviations: Tel, telomere;
Cen, centromere. See Fig. 1 legend for additional abbreviations.
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Table 1. Primer sequences used for RT-PCR analysis of rat -defensins
Primer Sequence Product Size (bp)Gene
Forward Reverse cDNA Genomic
No. of
Cycles
RatNP1/2 CCATGAGGACGCTCACTCTGCT CAAATGGATTCTTCTTGGTCGG 316 833 35
RatNP3 CAAATGGATTCTTCTTGGTCGG CTTCTTCTTCTTCTTTGTGCTCA 286 793 35
RD5 GAAGACACTTGTCCTCCTTTCTG TGTTGCAGATCCCCATAATGCCT 245 861 35
Defa6 GAAGACACTTGTCCTCCTTTCTG TATTCTTTAGGTCCGCAGTTTGC 228 815 35 
Defa8 GAAGACACTTGTCCTCCTTTCTG AATAGACCTGGACGACAGGACC 258 840 35
Defa9 GAAGACACTTGTCCTCCTTTCTG TCATCCTTGGGGGCCATGTTTCT 305 890 35
Defa10 CAAATGGATTCTTCTTGGTCGG ATCCGGCCATTGATTCGACACA 263 765 40
Defa11 CAAATGGATTCTTCTTGGTCGG TTGTTCATAGTGTTCAGTGGTTG 293 810 40
Defa12-ps CAAATGGATTCTTCTTGGTCGG AGGGGGTAGGTGACGCCACCAG 269 769 40
Defa-rs1 GAAGACACTTGTCCTCCTTTCTG ATGTGGACCTTGATAGCCGATG 261 834 35
GAPDH GTGAAGGTCGGAGTGAACG GAGATGATGACCCTCTTGGC 356 >390 25
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Table 2. Demonstration of positive selection in 11 phylogenetically independent pairs of
mammalian -defensin genes a.
Region dS dN
Signal peptide 0.031 ± 0.014 0.023 ± 0.008
Prosegment 0.066 ± 0.026 0.066 ± 0.022
Mature defensin 0.122 ± 0.041 0.182 ± 0.047b
a Mean (± S.E.) numbers of synonymous substitutions per synonymous site (dS) and of
nonsynonymous substitutions per nonsynonymous site (dN) The following sister pairs of
closely related genes were compared: from Primates, DEFA5 vs. RMAD4/5, DEFA1 vs.
DEFA3, RMAD1/2 vs. RMAD8; from rabbit NP1/MCP1 vs. NP2/MCP2, NP4 vs. NP5;
from rodents, GNCP1A vs. GNCP2, defcr5 vs. defcr6, defcr20 vs. defcr21, RatNP3 vs.
RatNP4, rat defa6 vs. rat defa8, rat defa7 vs. rat defa11.
b Significant difference between dS and dN at P<0.01 level (paired t-test, two-tailed).
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Signal Peptide Prosegment Mature Defensin
Figure 1
A
10 20 30 40 50 60 70 80 90 100 110
DEFA1/2 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIAADIPEVVVSLAWDESLAPKH---PGSR---KNMACYCRIPACIAGERRYGTCIYQG--RLWAFCC--------------
DEFA3 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIAADIPEVVVSLAWDESLAPKH---PGSR---KNMDCYCRIPACIAGERRYGTCIYQG--RLWAFCC--------------
RMAD1/2 MRTLVILAA-ILLVALQAQAEPLQARTDE------ATAAQEQIPTDNPEVVVSLAWDESLAPKDSV-PGLR---KNMACYCRIPACLAGERRYGTCFYLG--RVWAFCC--------------
RMAD3 MRTLVILAA-ILLVALQAQAEPLQARTDE------ATAAQEQIPTDNPEVVVSLAWDESLAPKDSV-PGLR---KNMACYCRIPACLAGERRYGTCFYRR--RVWAFCC--------------
PTAD1 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIPADNPEVVVSLAWDESLAPKH---PGSR---KNVACYCRIPACLAGERRYGTCIYQG--RLWAFCC--------------
DEFA8P -RSLALLAA-ILLVALQARAEPLQAIADE-------ATAQEQPGADDQEVVDSFAWDERAPLQV---SGSR---RGLTCTCRXDSYSPGEHRRGTCSAPG--VRYPYCFS-------------
PTAD8-ps -RSLALLAA-ILLVALQARAEPLQAMTDE-------ATAQEQPGADDQEVVDSFAWDERAALQV---SGSR---RGLTCTCRXDSCSPGEYRRGTCSAPG--VRYPYCFS-------------
DEFA10P MRTLALLTATVLFVALQAQAEPLRARADE-------AAAQEXPGADDQEVSVSFTWDESAALPL--SGESG---RGLRCICRRGICHFFQRRFGSCALPG--RLYRICCC-------------
PTAD10-ps MRTLVLLTATVLFVALQAQAEPLRARADE-------AAAEEQPGADDQEVSVSFTWDESAALPL---SGSG---RGLRCICRXGICHFFQCRFGSCALPG--RLYRICCC-------------
DEFT1P MRTFALLTAMLLLVALXAQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWHESAALPL---SDSA---RGLRCICGRGICRLLXRRFGSCAFRG--TLHRICCR-------------
PTTD1-ps MRTFALLTAMLLLVALXAQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWDESAALPL---SDSA---RGLRCIGGRGICGLLQRRFGSCAFRG--TLHRICCR-------------
PTTD2-ps MTTFALLTAMLLLVALXAQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWDESAALPL---SDSA---RGLRCIGGRGICGLLQRRFGSCAFRG--TLHRICCR-------------
RTD1a MRTFALLTAMLLLVALHAQAEARQARADE-------AAAQQQPGTDDQGMAHSFTWPENAALPL---SESA---KGLRCICTRGFCRLLXCHLGSCAFRG--XLHRICCR-------------
RTD1b MRTFALLTAMLLLVALHAQAEARQARADE-------AAAQQQPGADDQGMAHSFTRPENAALPL---SESA---RGLRCLCRRGVCQLLXRRLGSCAFRG--XLCRICCR-------------
DEFA4 MRIIALLAA-ILLVALQVRAGPLQARGDE-------APGQEQRGPEDQDISISFAWDKSSALQV---SGST---RGMVCSCRLVFCRRTELRVGNCLIGG--VSFTYCCTRVD----------
PTAD4 MRIIAILAA-ILLVALQVRAGPLQARGDE-------APGQEQRGPEDQDISISFAWDKSSALQV---SGST---RGMVCSCRLVFCRRTELRVGNCLIGG--VSFTYCCTRVD----------
DEFA5 MRTIAILAA-ILLVALQAQAESLQERADE-------ATTQKQSGEDNQDLAISFAGNGLSALRT---SGSQ---ARATCYCRTGRCATRESLSGVCEISG--RLYRLCCR-------------
PTAD5 MRTIAILAA-ILLVALQAQAESLQERADE-------ATTQKQSGEDNQDLAISFAGNGLSALRT---SGSQ---ARATCYCRIGHCTILESLSGVCEISG--RLYRLCCR-------------
PAAD1 MRTLAILAA-ILLVALQVQAESLQERADE-------ATTQEQPGEDDQDFAVSFEENGLSTLKA---SGSR---ARIICHCQIGRCSRPESYSRICILHG--QVARLCCRRAS----------
PAAD2 MRTLAILAA-ILLVALQAQAESLQERADE------VAT-QEQPGEDDQDLAVSFEENGLSTLRA---SGSQ---ARRTCYCRTGRCYTPEFHSGKCLFKG--LTYKLCCR-------------
RED1 MRTIAILAA-ILLFALLAQAKSLQETADE-------AATQEQPGEDDQDLAVSFEENGLSTLRD---SGSQ---ARRTCRCRIRRCRGLESSFGNCILHG--QFAKLCCR-------------
RED3 MRTIAILAA-ILLFSLQAQAESLQERADE------VAT-QEQPGEDDQDFAVSFEENGLSTLRA---SGSQ---ARHTCYCRNKRCFTPEFHAGKCKVEG--RTYKLCCR-------------
RED5 MRTLTILAA-ILLVALQAQAESLQERADE-------AATQEQPAEDNQDFAVSFEENGLSTLKA---SGSQ---ARMICLCRIGRCSWREAHFGSCTKMG--QFAKICCRRASR---------
RMAD4/5 MRTIAILAA-ILLFALLAQAKSLQETADD-------AATQEQPGEDDQDLAVSFEENGLSTLRA---SGSQ---ARRTCRCRFGRCFRRESYSGSCNING--RIFSLCCR-------------
DEFA6 MRTLTILTA-VLLVALQAKAEPLQAEDDPLQAKAYEADAQEQRGANDQDFAVSFAEDASSSLRA---LGST---RAFTCHCRRS-CYSTEYSYGTCTVMG--INHRFCCL-------------
PTAD6 MRTLTILTA-VLLVALQAKAEPLQAEDEPLQAKAYEADAQEQRGANDQDFAVSFAEDASSSLRA---LGST---RAFTCHCRRS-CYSTEYSYGTCTVMG--INHRFCCL-------------
DEFA9P MRTLTLLTA-ILLVPLQALSEPLQARADX-------AAAQEQLGADDQDFTISFTGDTSSGFRA---SGPR---TLLRCSCRIRDYHLQERNYGTCTSGE--IHYKFCFL-------------
PTAD9-ps MRTLTLLTA-ILLVPLQALSEPLQARADX-------AAAQEQLGADDQDFAISFTGDTSLGFRA---SGPR---TLLRCSCKIRDYHLQERNYGTCTSGE--IHYKFCFL-------------
DEFA11P MRTLTLLAA-ILLVPLQALSEPLQARADX-------AAAQEQLGADHQDFAISFTGDISSGFRD---SGSA---TGLVCYGRISGCHFSKHRYGTCTNSGIMEHRGKCVHHLL----------
PTAD11-ps MRTLSLLAA-ILLVPLQALSEPLQARADX-------AAAQEQLGADHQDFAISFTGHIRSGFRD---SGST---RGLVCYCRISGCHFSKHHYGTCTNSGIMEHRGKCVHHLL----------
DEFA7P -RTLTLLSA-FLLVALQAWAEPLPARAHE-------MPAQKQPPADDQDVVLYFSGDDSCSLQV---PGST---KGLICHCRVLYCIFGEHLGGTCFILG--ERYPICCY-------------
PTAD7 MRTLTLLSA-FLLVALQAWAEPLQARADE-------MPAQKQPPADDQDVVIYFSGDDSSSLQV---PGST---KGLICHCRVLYCLFGEHLGGTSFIHG--ERYPICCY-------------
PAAD3 -RSLTLLSA-ILLGALQAWTEPLQARADE-------MPAQEQPPANDQDVVIYFSGDDSSSLQV---PGST---KGLSCHCRVLYCLFGEHLGGTSFIHG--ERSPICCY-------------
B
RatNP1/2 MRTLTLLTA-LLLLALHTQAKSPQGTAEE-------APDQEQLVMEDQDISISFGGDKGTALQD---ADVK---AGVTCYCRRTRCGFRERLSGACGYRG--RIYRLCCR-------------
RatNP3 MRTLTLLTT-LLLLALHTQAESPQGSTKE-------APD------EEQDISVFFGGDKGTALQD---AAVK---AGVTCSCRTSSCRFGERLSGACRLNG--RIYRLCC--------------
RatNP4 MRTLTLLIT-LLLLALHTQAESPQERAKA-------APDQD-MVMEDQDIFISFGGYKGTVLQD---AVVK---AGQACYCRIGACVSGERLTGACGLNG--RIYRLCCR-------------
Defa7 MRTLTLLTT-LLLLALHTQAESPQGSRSTEE-----ALDQEQLVMEDQDISISFGGDKGTALQD---ADVK---SGVTCYCRLLSCQFGERLAGSCRSGG--VTYPLCCH-------------
Defa10 MRTLTLLTA-LLLLALHTQAESPQGSPKE-------APDQEQLDMEDQDISVFFGGDKGTALQD---AA--—---GSTCSCRIGTCVSGEWLSWVCRING--RIYRLCCR-------------
Defa11 MGTLTLLTT-LLLLALHTQAESPQGCT-E---------DQKLLIMEDQDISISFTGDKGTALQD---ADVK---SGVICNCRPRGCSFKERVYGECGYNG--HILRLCCQPLNTMNKKSPSVI
Defa12-ps MRTLTLLTA-LLLLALHTQAESPQGRAEE-------APDLEXLVMKDQDISISFGGDKGTALQN---ADVK---SGVTCYCRIS-CQFGERLSGSCRSGG--VTYPLCCR-------------
RD5 MKTLVLLSA-LVLLALQVQAEPTPKTDEG-------TKTDEQPGKEDQVVSVSIEGQGDPAFQD---AVLR----DLKCFCRAKSCNWGEGIMGICNKRY--GSLILCCR-------------
Defa6 MKTLVLLSA-LVLVAYQVQADPIQGAEEE-------TKTEEQPSDEDQDVSVSFEGPEASALQD---FEI—-GRPVRRCRCRAN-CGPKEYATAFCAQGP-FKQFKFCCTA------------
Defa8 MKTLVLLSA-LVLLAFQVQADHIQEAEEE-------TKTEEQPADEDQDMSVSFEGPEASALQN---LEI--GWPLKQCHCRKF-CRPYEKAEGSCRPGL-FIKRKICCIQQWTPGRT-----
Defa9 MKTLVLLSA-LVLLAFQIQADPIQEAEEE-------TKTEEQPADEDQDVSVSFEGPEPSALQN---LEI--RWPWKRCHCRSF-CRPYENATSFCAQGL-FKQHKFCCLETWPPRMK-----
Defa13-ps MKTLLFLSA-LVLLAFQIQADPMQGADEE-------NGVAA---RERSQICLSPLEAQKALLFKMQILFVSSIARNQKCYYRARSCRNREGIIRTCNKRH--ESLILCCR-------------
Defa14-ps MKTLLFLSA-LVLLAFQVQADPTQEADEE-------TKTEKKPGKEDPDVAVSFGGPQGSAFQDADNLFVSLVSRNQKCYYTARSYRNREGIMGTXTKRH--ESLILCCR-------------
Defa-rs1 MKTLILLSA-LVLLALQVQADPIQEAEEE-------TKTEEQPADEDQDVSVSFEGPEASAVQD---LRVR---RTLQCSCRR-VCR----NTCSCIRLS--RSTYAS---------------
C
Defcr1 MKKLVLLFA-LVLLGFQVQADSIQNTDEE-------TKTEEQPGEEDQAVSVSFGDPEGTSLQE---ESLR----DLVCYCRSRGCKGRERMNGTCRKGH--LLYTLCCR-------------
Defcr3 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TKTEEQPGEDDQAVSVSFGDPEGSSLQE---ESLR----DLVCYCRKRGCKRRERMNGTCRKGH--LMYTLCCR-------------
Defcr23 MKTLVLLSA-LILLAFQVQADPIQNTDEE-------TKTEEQPGKEDQAVSVSFGDPEGSSLQE---ESLR----DLVCYCRTRGCKRRERMNGTCRKGH--LIYTLCCR-------------
Defcr24 MKTLILLSA-LVVLAFQVQADPIQNTDEE-------TKTKEQPGEEDQAVSVSFGDPEGASLQE---ESLR----DLVCYCRARGCKGRERMNGTCSKGH--LLYMLCCR-------------
Defcr25 MKTLVLLSA-LALLAFQVQADPIQNRDEE-------SKIDEQPGKEDQAVSVSFGDPEGSSLQE-ECDALR----DLICYCRTRGCKRRERLNGTCRKGH-LMYMLWCC--------------
Defcr26 MKTLVLLSA-LFLLAFQVQADPIQNTDEE-------TNTEVQPQEEDQAVSVSFGNPEGSDLQE---ESLR----DLGCYCRKRGCTRRERINGTCRKGH--LMYTLCCL-------------
Defcr-ps1 MKTLVLLSA-LALLAFQVQADPIQNTDEE-------TNTEEQPGKEDQAVSVSFGDPEGSSLQE---ESLR----DLIXYCRTRGCKRRERLNGTYRKGH--LMYMLCCC-------------
Defcr4 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TKTEEQPGEEDQAVSISFGGQEGSALHE---KSLR----GLLCYCRKGHCKRGERVRGTCG-----IRFLYCCPRR-----------
Defcr20 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TNTEEQAGEEDQAVSVSFGDPEGSALHE---KSSR----DLICYCRKGGCNRGEQVYGTCS-----GRLLFCCRRRHRH--------
Defcr21 MKTLVLLSA-LILLAYQVQTDPIQNTDEE-------TNTEEQPGEDDQAVSVSFGGQEGSALHE---KLSR----DLICLCRNRRCNRGELFYGTCA-----GPFLRCCRRRR----------
Defcr22 MKKLVLLSA-LVLLAYQVQTDPIQNTDEE-------TNTEEQPGEEDQAVSVSFGGQEGSALHE---KLSR----DLICLCRKRRCNRGELFYGTCA-----GPFLRCCRRRR----------
D
CRS1C-1 MKTLVLLSA-LALLALQVQADPIQNTDEE-------TKTQEQPGEEDQAVSVSFGGTEGSALQDV--AQRRFPWCRKCRVCQKCEVCQKCPVCPTCPQCPKQPLCKERQNKTAITTQAPNTHHKGC
CRS1C-2 MKTLVLLSA-LALLAFQVQADPIQNTDEE-------TKTEEQPEEEDQAVSVSFGGTEGSALQDV--AQRRFLWCRKCPVCQKCQVCQKCPVCPTCPQCPKQPLCEERQNKTAITTQAPNTQHKGC
CRS1C-3 MKTLVLLSA-LALLAFQVQADPIKNTDEE-------TKTGEQPEEEDQAVSVSFGGTEGSALQYV--AQRRFPWCRKCPVCQKCQVCQKCPVCPTCPQCPKLPLCKERQNKSAITTQAPNTQHKGC
CRS4C-1 MKKLVLLFA-LVLLAFQVQADSIQNTDEE-------TKTEEQPGEKDQAVSVSFGDPQGSALQD---AALG--WGRRCPQCPRCPSCPSCPRCPRCPRCK----CNPK------------------
CRS4C-2 MKKLVLLFA-LVLLAFQVQADSIQNTDEE-------TKTEEQQGEEDQAVSVSFGDPQGSGLQD--AAALG--WGRRCPRCPPCPRCSWCPRCPTCPRCN----CNPK------------------
CRS4C-4 MKKLVLLSA-FVLLAFQVQADSIQNTDEE-------TKTEEQPGEENQAMSVSFGDPEGSALQD---AAVG--MARPCPPCPSCPSCPWCPMCPRCPSCK----CNPK------------------
CRS4C-5 MKKLVLLSA-FVLLAFQVQADSIQNTDEE-------IKTEEQPGEENQAVSISFGDPEGYALQD--AAAIR--RARRCPPCPSCLSCPWCPRCLRCPMCK----CNPK------------------
CRS4C-6 MKTLVLLSA-LVLLAFYVQADSTQETDEE-------TKTDDQPGEEDQGVSVSFEDPERYVLQV--SGLGKPPQCPKCPVCSKCPQCPQCPQCPGCPRCN----CMTK------------------
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SUPPLEMENTARY MATERIAL
Supplementary Fig. 1. Sequence alignment of the exon encoding the signal peptide and
prosegments of three orthologous genes in the human (DEFA7P), chimpanzee (PTAD7),
and olive baboon (PAAD3). The encoded peptide sequence for each exon is also
indicated. Note that the start codon in PTAD7 is mutated in both DEFA7P and PAAD3 as
highlighted in orange color, and that a string of sequences around the start codon
(underlined) in PAAD3 are completely different from those in DEFA7P and PTAD7.
Abbreviations: DEFA7P, human -defensin 7 pseudogene; PTAD7, Pan troglodytes -
defensin 7; PAAD3, Papio anubis -defensin 3.
Supplementary Fig. 2. Amino acid sequence alignment of a total of 82 known and newly
identified -defensins and -defensin-related sequences in the primates and glires. The
dashes are created to optimize the alignment, and canonical cysteines in the mature
defensin regions are shaded. The premature stop codon in each pseudogene is omitted.
Note that computational predictions of all novel rat -defensin peptide sequences, except
for the pseudogenes, have been confirmed by cloning and sequencing of their respective
RT-PCR products amplified from appropriate tissues. Abbreviations: DEFA/Defa, -
defensin; DEFT1P, human -defensin 1 pseudogene; PTAD, chimpanzee (Pan
troglodytes) -defensin; PTTD, Pan troglodytes -defensin; RMAD, rhesus macaque
myeloid -defensin; RED, rhesus macaque enteric -defensin; RTD, rhesus macaque -
defensin; PAAD, Papio anubis -defensin; RatNP, Rat neutrophil -defensin; Defa-rs1,
rat -defensin-related sequence; RD5, rat -defensin 5; Defcr, mouse -defensin-related
97
cryptdin; CRS1C, mouse cryptdin-related sequence 1C; CRS4C, mouse cryptdin-related
sequence 4C; NP/MCP, rabbit neutrophil -defensin/macrophage cationic peptide; RK,
rabbit kidney -defensin; GNCP, guinea pig neutrophil cationic peptide; P/ps,
pseudogene.
PTAD7 GTGACTACAGTTATGAGGACCCTCACCCTCCTCTCTGCCTTTCTCCTGGTGGCCCTTCAGGCCTGGGCAGAGCCGCTCCAGGCAAGAGCT 90
M R T L T L L S A F L L V A L Q A W A E P L Q A R A
DEFA7P GTGACTACAGTTAGGAGGACCCTCACCCTCCTCTCTGCCTTTCTCCTGGTGGCCCTTCAGGCCTGGGCAGAGCCGCTCCCGGCAAGAGCT 90
R R T L T L L S A F L L V A L Q A W A E P L P A R A
PAAD3 GAGGCTCCTCTCTGCCGTTCCCTCACCCTCCTCTCTGCCATTCTCCTGGGGGCCCTCCAGGCCTGGACAGAGCCGCTCCAGGCAAGAGCT 90
C R S L T L L S A I L L G A L Q A W T E P L Q A R A
PTAD7 GATGAGATGCCAGCCCAGAAGCAGCCTCCAGCAGACGACCAGGATGTGGTCATTTACTTTTCAGGAGATGACAGCTCCTCTCTTCAGGTTCAG 183
D E M P A Q K Q P P A D D Q D V V I Y F S G D D S S S L Q V P
DEFA7P CATGAGATGCCAGCCCAGAAGCAGCCTCCAGCAGATGACCAGGATGTGGTCCTTTACTTTTCAGGAGATGACAGCTGCTCTCTTCAGGTTCAG 183
H E M P A Q K Q P P A D D Q D V V L Y F S G D D S C S L Q V P
PAAD3 GATGAGATGCCAGCCCAGGAGCAGCCTCCAGCAAACGACCAAGATGTGGTCATTTACTTTTCAGGAGATGACAGCTCCTCTCTTCAG--- 177
D E M P A Q E Q P P A N D Q D V V I Y F S G D D S S S L Q
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98
Supplementary Fig. 2
1 15 30 45 60 75 90 105
Defa7 MRTLTLLTT-LLLLALHTQAESPQGSRSTEE-----ALDQEQLVMEDQDISISFGGDKGTALQD---ADVK-----SGVTCYCRLLS-CQFGERLAGSCRSGG---VTYP
RatNP1/2 MRTLTLLTA-LLLLALHTQAKSPQGTAEE-------APDQEQLVMEDQDISISFGGDKGTALQD---ADVK-----AGVTCYCRRTR-CGFRERLSGACGYRG---RIYR
Defa12-ps MRTLTLLTA-LLLLALHTQAESPQGRAEE-------APDLE-LVMKDQDISISFGGDKGTALQN---ADVK-----SGVTCYCRIS--CQFGERLSGSCRSGG---VTYP
Defa11 MGTLTLLTT-LLLLALHTQAESPQGCT-E---------DQKLLIMEDQDISISFTGDKGTALQD---ADVK-----SGVICNCRPRG-CSFKERVYGECGYNG---HILR
RatNP3 MRTLTLLTT-LLLLALHTQAESPQGSTKE-------APD------EEQDISVFFGGDKGTALQD---AAVK-----AGVTCSCRTSS-CRFGERLSGACRLNG---RIYR
Defa10 MRTLTLLTA-LLLLALHTQAESPQGSPKE-------APDQEQLDMEDQDISVFFGGDKGTALQD---AGER-----PGSTCSCRIGT-CVSGEWLSWVCRING---RIYR
RatNP4 MRTLTLLIT-LLLLALHTQAESPQERAKA-------APDQD-MVMEDQDIFISFGGYKGTVLQD---AVVK-----AGQACYCRIGA-CVSGERLTGACGLNG---RIYR
DEFA4 MRIIALLAA-ILLVALQVRAGPLQARGDE-------APGQEQRGPEDQDISISFAWDKSSALQV---SGST-----RGMVCSCRLVF-CRRTELRVGNCLIGG---VSFT
PTAD4 MRIIAILAA-ILLVALQVRAGPLQARGDE-------APGQEQRGPEDQDISISFAWDKSSALQV---SGST-----RGMVCSCRLVF-CRRTELRVGNCLIGG---VSFT
DEFA8P -RSLALLAA-ILLVALQARAEPLQAIADE-------ATAQEQPGADDQEVVDSFAWDERAPLQV---SGSR-----RGLTCTCRD-S-YSPGEHRRGTCSAPG---VRYP
PTAD8-ps -RSLALLAA-ILLVALQARAEPLQAMTDE-------ATAQEQPGADDQEVVDSFAWDERAALQV---SGSR-----RGLTCTCRD-S-CSPGEYRRGTCSAPG---VRYP
DEFA7P -RTLTLLSA-FLLVALQAWAEPLPARAHE-------MPAQKQPPADDQDVVLYFSGDDSCSLQV---PGST-----KGLICHCRVLY-CIFGEHLGGTCFILG---ERYP
PTAD7 MRTLTLLSA-FLLVALQAWAEPLQARADE-------MPAQKQPPADDQDVVIYFSGDDSSSLQV---PGST-----KGLICHCRVLY-CLFGEHLGGTSFIHG---ERYP
PAAD3 -RFATLLAHA-LLSMLQAWTEPLQARADE-------MPAQEQPPANDQDVVIYFSGDDSSSLQV---PGST-----KGLSCHCRVLY-CLFGEHLGGTSFIHG---ERSP
DEFA6* MRTLTILTA-VLLVALQAKAEPLQAEDDPLQAKAYEADAQEQRGANDQDFAVSFAEDASSSLRA---LGST-----RAFTCHCRRS--CYSTEYSYGTCTVMG---INHR
PTAD6 MRTLTILTA-VLLVALQAKAEPLQAEDEPLQAKAYEADAQEQRGANDQDFAVSFAEDASSSLRA---LGST-----RAFTCHCRRS--CYSTEYSYGTCTVMG---INHR
DEFA9P MRTLTLLTA-ILLVPLQALSEPLQARAD--------AAAQEQLGADDQDFTISFTGDTSSGFRA---SGPR-----TLLRCSCRIRD-YHLQERNYGTCT-SG--EIHYK
PTAD9-ps MRTLTLLTA-ILLVPLQALSEPLQARAD--------AAAQEQLGADDQDFAISFTGDTSLGFRA---SGPR-----TLLRCSCKIRD-YHLQERNYGTCT-SG--EIHYK
DEFA11P MRTLTLLAA-ILLVPLQALSEPLQARAD--------AAAQEQLGADHQDFAISFTGDISSGFRD---SGSA-----TGLVCYGRISG-CHFSKHRYGTCTNSGIMEHRGK
PTAD11-ps MRTLSLLAA-ILLVPLQALSEPLQARAD--------AAAQEQLGADHQDFAISFTGHIRSGFRD---SGST-----RGLVCYCRISG-CHFSKHHYGTCTNSGIMEHRGK
DEFA1/2 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIAADIPEVVVSLAWDESLAPKH---PGSR-----KNMACYCRIPA-CIAGERRYGTCIYQG---RLWA
DEFA3 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIAADIPEVVVSLAWDESLAPKH---PGSR-----KNMDCYCRIPA-CIAGERRYGTCIYQG---RLWA
PTAD1 MRTLAILAA-ILLVALQAQAEPLQARADE------VAAAPEQIPADNPEVVVSLAWDESLAPKH---PGSR-----KNVACYCRIPA-CLAGERRYGTCIYQG---RLWA
RMAD3 MRTLVILAA-ILLVALQAQAEPLQARTDE------ATAAQEQIPTDNPEVVVSLAWDESLAPKDS-VPGLR-----KNMACYCRIPA-CLAGERRYGTCFYRR---RVWA
RMAD8 MRTLVILAA-ILLVALQAQAEPLQARTDE------ATAAQEQIPTDNPEVVVSLAWDESLAPKDS-VPGLR-----KNMACYCRIPA-CLAGERRYGTCFYLR---RVWA
RMAD1/2 MRTLVILAA-ILLVALQAQAEPLQARTDE------ATAAQEQIPTDNPEVVVSLAWDESLAPKDS-VPGLR-----KNMACYCRIPA-CLAGERRYGTCFYLG---RVWA
DEFA10P MRTLALLTATVLFVALQAQAEPLRARADE-------AAAQE-PGADDQEVSVSFTWDESAALPL---SGESG----RGLRCICRRGI-CHFFQRRFGSCALPG---RLYR
PTAD10-ps MRTLVLLTATVLFVALQAQAEPLRARADE-------AAAEEQPGADDQEVSVSFTWDESAALPL---SGSG-----RGLRCICR-GI-CHFFQCRFGSCALPG---RLYR
PTTD1-ps MRTFALLTAMLLLVAL-AQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWDESAALPL---SDSA-----RGLRCIGGRGI-CGLLQRRFGSCAFRG---TLHR
PTTD2-ps MTTFALLTAMLLLVAL-AQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWDESAALPL---SDSA-----RGLRCIGGRGI-CGLLQRRFGSCAFRG---TLHR
DEFT1P MRTFALLTAMLLLVAL-AQAEPLQARADE-------AAAQEQPGADDQEMAHAFTWHESAALPL---SDSA-----RGLRCICGRGI-CRLLRR-FGSCAFRG---TLHR
RTD1a MRTFALLTAMLLLVALHAQAEARQARADE-------AAAQQQPGTDDQGMAHSFTWPENAALPL---SESA-----KGLRCICTRGF-CRLL-----------------
RTD1b MRTFALLTAMLLLVALHAQAEARQARADE-------AAAQQQPGADDQGMAHSFTRPENAALPL---SESA-----RGLRCLCRRGV-CQLL-----------------
PAAD2 MRTLAILAA-ILLVALQAQAESLQERADE-------VATQEQPGEDDQDLAVSFEENGLST-LRA--SGSQ-----ARRTCYCRTGR-CYTPEFHSGKCLFKG---LTYK
RED4 MRTLTILAA-ILLFTLQAQAESLQERADE-------VATQEQPGKDDQDLAVSFEENGLSTLRA---SGSQ-----ARRTCYCRTGR-CYTPEFHSGKCVFNG---RTYK
RED3 MRTIAILAA-ILLFSLQAQAESLQERADE-------VATQEQPGEDDQDFAVSFEENGLSTLRA---SGSQ-----ARHTCYCRNKR-CFTPEFHAGKCKVEG---RTYK
RMAD4/5 MRTIAILAA-ILLFALLAQAKSLQETADD-------AATQEQPGEDDQDLAVSFEENGLSTLRA---SGSQ-----ARRTCRCRFGR-CFRRESYSGSCNING---RIFS
RMAD6/7 MRTIAILAA-ILLFALLAQAKSLQETADE-------AATQEQPGEDDQDLAVSFEENGLSTLRA---SGSQ-----ARRTCRCRFGR-CFRRESYSGSCNING---RISS
RED1 MRTIAILAA-ILLFALLAQAKSLQETADE-------AATQEQPGEDDQDLAVSFEENGLSTLRD---SGSQ-----ARRTCRCRIRR-CRGLESSFGNCILHG---QFAK
RED6 MRTLTILAA-ILLFALLAQAKSLQETADD-------AATQEQPGEDDQDLAVSFEENGLSTLRA---SGSQ-----ARRNCHCRIGH-CRRPAAPMGVCIIHG---QFGK
PAAD1 MRTLAILAA-ILLVALQVQAESLQERADE-------ATTQEQPGEDDQDFAVSFEENGLST-LKA--SGSR-----ARIICHCQIGR-CSRPESYSRICILHG---QVAR
RED5 MRTLTILAA-ILLVALQAQAESLQERADE-------AATQEQPAEDNQDFAVSFEENGLSTLKA---SGSQ-----ARMICLCRIGR-CSWREAHFGSCTKMG---QFAK
RED2 MRTLAILAA-ILLVALQAQAESLQERADE-------ATTQEQPGEDDQDLAVSFEENGLSTPRA---SGPQ-----ARFTCHCRIGR-CSWFETRFRSCTLLG---LAAN
DEFA5 MRTIAILAA-ILLVALQAQAESLQERADE-------ATTQKQSGEDNQDLAISFAGNGLSALRT---SGSQ-----ARATCYCRTGR-CATRESLSGVCEISG---RLYR
PTAD5 MRTIAILAA-ILLVALQAQAESLQERADE-------ATTQKQSGEDNQDLAISFAGNGLSALRT---SGSQ-----ARATCYCRIGH-CTILESLSGVCEISG---RLYR
NP1/MCP1 MRTLALLAA-ILLVALQAQAEHVSVSIDE-------VVDQQPPQAEDQDVAIYVKEHESSALEA---LGVK-----AGVVCACRRAL-CLPRERRAGFCRIRG---RIHP
NP2/MCP2 MRTLALLAA-ILLVALQAQAEHISVSIDE-------VVDQQPPQAEDQDVAIYVKEHESSALEA---LGVK-----AGVVCACRRAL-CLPLERRAGFCRIRG---RIHP
NP4 MRTLALLAA-ILLVTLQAQAELHSGMADD-------GVDQQQPRAQDLDVAVYIKQDETSPLEV---LGAK-----AGVSCTCRRFS-CGFGERASGSCTVNG---VRHT
NP5 MRTLALLAA-ILLVTLQAQAELHSGMADD-------GVDQQQPRAQDLDVAVYIKQDETSPLEV---LGAK-----AGVFCTCRGFL-CGSGERASGSCTING---VRHT
GNCP1A MRTVPLFAA-CLLLTLMAQAEPLPRAADH-------SDTKMKGDREDHVAVISFWEEESTSLED---AGAG-----AGRRCICTTRT-CRFPYRRLGTCIFQN---RVYT
GNCP1B MRTVPLFAA-CLLLTLMAQAEPLPRAADH-------SDTKMKGDREDHVAVISFWEEESTSLQD---AGAG-----AGRRCICTTRT-CRFPYRRLGTCIFQN---RVYT
GNCP2 MRTVPLFAA-CLLLTLMAQAEPLPRAADH-------SDTKMKGDREDHVAVISFWEEESTSLQD---AGAG-----AGRRCICTTRT-CRFPYRRLGTCLFQN---RVYT
RK1 MRTFALLTA-IVLVALQAKVEPVPPSDEE-------IPDQEGTDVGGQVMAISFAEDETSALQD---PVSP--LRSQKMPCSCKKY--CDPWEVIDGSCGLFN----SKY
RK2 MRTFTLLTA-IVLVALQAKAKPLSPSDEE-------IPDQEQTDVGEQVMANSCAEDETSALQN---RGCP---QNLKPYCSCKWR--CGIGEEEKGICHKFP---IVTY
Defa9 MKTLVLLSA-LVLLAFQIQADPIQEAEEE-------TKTEEQPADEDQDVSVSFEGPEPSALQN---LEIR----WPWKRCHCRS-F-CRPYENATSFCAQGL--FKQHK
Defa8 MKTLVLLSA-LVLLAFQVQADHIQEAEEE-------TKTEEQPADEDQDMSVSFEGPEASALQN---LEIG----WPLKQCHCRK-F-CRPYEKAEGSCRPGL--FIKRK
Defa6 MKTLVLLSA-LVLVAYQVQADPIQGAEEE-------TKTEEQPSDEDQDVSVSFEGPEASALQD---FEIGR----PVRRCRCRAN--CGPKEYATAFCAQGP--FKQFK
Defa-rs1 MKTLILLSA-LVLLALQVQADPIQEAEEE-------TKTEEQPADEDQDVSVSFEGPEASAVQD---LRVR-----RTLQCSCRR-V-CR----NTCSCIR-LSRSTYAS
CRS1C-2 MKTLVLLSA-LALLAFQVQADPIQNTDEE-------TKTEEQPEEEDQAVSVSFGGTEGSALQDV--AQRRFLWCRKCPVCQ-K-CQVCQKCPV-CPTCPQCPKQP---
CRS1C-3 MKTLVLLSA-LALLAFQVQADPIKNTDEE-------TKTGEQPEEEDQAVSVSFGGTEGSALQYV--AQRRFPWCRKCPVCQ-K-CQVCQKCPV-CPTCPQCPKLP---
CRS1C-1 MKTLVLLSA-LALLALQVQADPIQNTDEE-------TKTQEQPGEEDQAVSVSFGGTEGSALQDV--AQRRFPWCRKCRVCQ-K-CEVCQKCPV-CPTCPQCPKQP---
CRS4C-1 MKKLVLLFA-LVLLAFQVQADSIQNTDEE-------TKTEEQPGEKDQAVSVSFGDPQGSALQD---AALG--WGRRCPQCP-R-CPSCPSCPR-CPRCPRCK------
CRS4C-2 MKKLVLLFA-LVLLAFQVQADSIQNTDEE-------TKTEEQQGEEDQAVSVSFGDPQGSGLQDA--AALG--WGRRCPRCP-P-CPRCSWCPR-CPTCPRCN------
CRS4C-4 MKKLVLLSA-FVLLAFQVQADSIQNTDEE-------TKTEEQPGEENQAMSVSFGDPEGSALQD---AAVG--MARPCPPCP-S-CPSCPWCPM-CPRCPSCK------
CRS4C-5 MKKLVLLSA-FVLLAFQVQADSIQNTDEE-------IKTEEQPGEENQAVSISFGDPEGYALQDA--AAIR--RARRCPPCP-S-CLSCPWCPR-CLRCPMCK------
CRS4C-6 MKTLVLLSA-LVLLAFYVQADSTQETDEE-------TKTDDQPGEEDQGVSVSFEDPERYVLQVS---GLG--KPPQCPKCP-V-CSKCPQCPQ-CPQCPGCPR-----C
Defcr6 MKTLILLSA-LVLLAFQVQADPIQNTDEE-------TKTEEQPGEEDQAVSVSFGDPEGTSLQE---ESLR------DLVCYCRARG-CKGRERMNGTCRKGH---LLYM
Defcr24 MKTLILLSA-LVVLAFQVQADPIQNTDEE-------TKTKEQPGEEDQAVSVSFGDPEGASLQE---ESLR------DLVCYCRARG-CKGRERMNGTCSKGH---LLYM
Defcr1 MKKLVLLFA-LVLLGFQVQADSIQNTDEE-------TKTEEQPGEEDQAVSVSFGDPEGTSLQE---ESLR------DLVCYCRSRG-CKGRERMNGTCRKGH---LLYT
Defcr3 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TKTEEQPGEDDQAVSVSFGDPEGSSLQE---ESLR------DLVCYCRKRG-CKRRERMNGTCRKGH---LMYT
Defcr23 MKTLVLLSA-LILLAFQVQADPIQNTDEE-------TKTEEQPGKEDQAVSVSFGDPEGSSLQE---ESLR------DLVCYCRTRG-CKRRERMNGTCRKGH---LIYT
Defcr26 MKTLVLLSA-LFLLAFQVQADPIQNTDEE-------TNTEVQPQEEDQAVSVSFGNPEGSDLQE---ESLR------DLGCYCRKRG-CTRRERINGTCRKGH---LMYT
Defcr-ps1 MKTLVLLSA-LALLAFQVQADPIQNTDEE-------TNTEEQPGKEDQAVSVSFGDPEGSSLQE---ESLR------DLI-YCRTRG-CKRRERLNGTYRKGH---LMYM
Defcr25 MKTLVLLSA-LALLAFQVQADPIQNRDEE-------SKIDEQPGKEDQAVSVSFGDPEGSSLQE-ECDALR------DLICYCRTRG-CKRRERLNGTCRKGH---LMYM
Defcr20 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TNTEEQAGEEDQAVSVSFGDPEGSALHE---KSSR------DLICYCRKGG-CNRGEQVYGTCS------GRLL
Defcr21 MKTLVLLSA-LILLAYQVQTDPIQNTDEE-------TNTEEQPGEDDQAVSVSFGGQEGSALHE---KLSR------DLICLCRNRR-CNRGELFYGTCA------GPFL
Defcr4 MKTLVLLSA-LVLLAFQVQADPIQNTDEE-------TKTEEQPGEEDQAVSISFGGQEGSALHE---KSLR------GLLCYCRKGH-CKRGERVRGTCG------IRFL
Defcr5 MKTFVLLSA-LVLLAFQVQADPIHKTDEE-------TNTEEQPGEEDQAVSISFGGQEGSALHE---ELSK------KLICYCRIRG-CKRRERVFGTCRNLF---LTFV
Defa13-ps MKTLLFLSA-LVLLAFQIQADPMQGADEE-------NGVAA---RERSQICLSPLEAQKALLFKMQILFVSSIA--RNQKCYYRARS-CRNREGIIRTCNKRH---ESLI
Defa14-ps MKTLLFLSA-LVLLAFQVQADPTQEADEE-------TKTEKKPGKEDPDVAVSFGGPQGSAFQDADNLFVSLVS--RNQKCYYTARS-YRNREGIMGT-TKRH---ESLI
NP3 MRTLILLAA-ILLAALQAQAELFSVNVDE-------VLDQQQP-GSDQDLVIHLTGEESSALQV---PDTK------G-ICACRRRF-CPNSERFSGYCRVNG---ARYV
RD5 MKTLVLLSA-LVLLALQVQAEPTPKTDEG-------TKTDEQPGKEDQVVSVSIEGQGDPAFQDA---VLR------DLKCFCRAKS-CNWGEGIMGICNKRY---GSLI
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ABSTRACT
Mammalian -defensins are an important family of innate host defense peptides with
pleiotropic activities. As a first step to study the evolutionary relationship and biological role of
the -defensin family, we identified their complete repertoires in the human, chimpanzee, mouse,
rat, and dog following systemic, genome-wide computational searches. Although most -
defensins genes are composed of two exons separated by an intron of variable length, some
contain additional one or two exons encoding an internal pro-sequence, a segment of carboxyl
terminal mature sequences or untranslated regions. Alternatively spliced isoforms have also been
found with several -defensins. Furthermore, all -defensin genes are densely clustered in 4-5
syntenic chromosomal regions with each cluster spanning <1.2 Mb across the five species.
Phylogenetic analysis indicated that, although the majority of -defensins are evolutionarily
conserved across species, subgroups of gene lineages exist that are specific in certain species,
implying that some -defensins originated after divergence of these mammals from each other,
while most others arose before the last common ancestor of mammals. Surprisingly, reverse
transcriptase-PCR revealed that all but one rat -defensin transcripts are preferentially expressed
in the male reproductive tract particularly in epididymis and testis, except that Defb4, a human -
defensin-2 ortholog, is more restricted to the respiratory and upper gastrointestinal tracts.
Moreover, most -defensins expressed in the reproductive tract are developmentally regulated
with enhanced expression during sexual maturation. Existence of such a vast array of -defensins
in the male reproductive tract suggests that these genes may play a dual role in both fertility and
host defense.
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INTRODUCTION
Defensins and defensin-like molecules comprise a diverse group of cationic antimicrobial
peptides characterized by the presence of multiple cysteine residues and a highly similar tertiary
structure known as the defensin motif (14, 28, 35, 46, 60). Defensin-like genes have been
discovered in many species including plants, fungi, arthropods, mollusks, reptiles, birds, and
mammals (13, 14, 28, 36, 47, 52, 55, 57). Defensins in vertebrate species are further classified
into three families, namely -, -, and -defensins, based on the spacing pattern of six cysteine
residues (10, 14, 28). Although the evolutionary relationship between vertebrate defensins and
defensins in other species remains unclear, phylogenetic analysis revealed that a primordial -
defensin gene is the common ancestor for all vertebrate defensins (57). -defensins are believed
to evolve before the divergence of mammals from birds (57) and gave rise to -defensins in
glires and primates after they diverged from other mammalian species (36). -defensins further
originated from -defensins following separation of primates from other mammals (33, 36).
In contrast with - and -defensins that are produced primarily in the granules of either
leukocytes or intestinal Paneth cells, -defensins are unique in that they are primarily produced
by nongranular mucosal epithelial cells lining the respiratory, gastrointestinal, and genitourinary
tracts (14, 28, 35, 46, 60). In addition to their broad-spectrum antimicrobial activity against
bacteria, fungi, and certain enveloped viruses, -defensins have been recognized recently to
resemble chemokines both structurally and functionally (14, 28, 46, 60). Recent studies also
revealed that certain -defensins are actively involved in sperm maturation and capacitation (41,
65, 68, 70), physiological properties that are not related to host defense.
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All -defensin genes encode a precursor peptide that consists of a hydrophobic, leucine-
rich signal sequence, a pro-sequence, and a mature six-cysteine defensin motif at the carboxyl
terminus (14, 28). In most cases, -defensin precursors are encoded in two separate exons
separated by an intron of variable length with one exon encoding the signal and pro-sequence
and the other encoding primarily the mature peptide (14, 28). It is generally believed that mature
-defensins need to be cleaved from the pro-sequences by proteolytic enzymes to become
biologically active, although such proteases are yet to be identified.
A number of putative -defensins were reported recently in humans and mice (47);
however, later identification of a novel human sequence implied possible existence of additional
-defensins in those two species (42). In addition, the evolutionary relationships among -
defensin genes across mammalian species are poorly understood, although limited data are
available on -defensin evolution within species or among the primates (9, 22, 32, 48).
Recent availability of complete genome sequences of a number of phylogenetically
distinct mammalian species provides an excellent opportunity to identify the entire -defensin
gene family members in these species. Here, we report the discovery of complete repertoires of
-defensins in the human, chimpanzee, mice, rat, and dog by using a systemic computational
search strategy that we developed recently (36, 57). We showed that -defensin genes form 4-5
syntenic clusters in these mammals. Although the majority of -defensin genes are evolutionarily
conserved across rodents, canines and primates, a few gene lineages exist only in certain species.
We also examined the tissue expression patterns of the entire -defensin gene family in the rat by
reverse transcriptase-PCR. To our surprise, all but one of the -defensins were found to be
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preferentially expressed in the male reproductive system, particularly in testis and different
segments of epididymis. The only exception, Defb4, is more restricted to the respiratory and
upper gastrointestinal tracts with virtually no expression in the male reproductive system.
Furthermore, we provide evidence that many -defensins are developmentally regulated and the
expression levels are elevated with age. These findings argue that the major biological functions
of -defensins may be related to reproduction and fertility, in addition to innate host defense.
MATERIALS AND METHODS
Computational search for novel -defensins
To identify potential novel -defensins in the human, mouse, rat, dog, and chimpanzee,
systemic computational searches were performed essentially as we described (36, 57). In brief,
all known -defensin peptide sequences were individually queried against expressed sequence
tags (EST), nonredundant sequences (NR), unfinished high throughput genomic sequences
(HTGS), and whole genome shotgun sequences (WGS) in GenBank by using the TBLASTN
program (1) with the default settings on the NCBI web site
(http://www.ncbi.nlm.nih.gov/BLAST). We then examined all potential hits for the presence of
the characteristic -defensin motif or conserved signal peptide and prosequence. Additional
iterative BLAST searches were performed for every novel -defensin sequence identified as
described above until no more novel sequences were revealed. Because mammalian defensins
tend to form clusters (47, 48), all genomic sequences containing -defensins were also retrieved
from GenBank to discover potential novel sequences with distant homology. The nucleotide
sequences between two neighboring defensin genes were translated into six open reading frames
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and individually compared with the two defensin peptide sequences for the presence of -
defensin motif or signal peptide/pro-sequence by using the BLASTP program (1) on the NCBI
web site (http://www.ncbi.nlm.nih.gov/blast/bl2seq/) and/or ClustalW program (version 1.82)
(53) on the European Bioinformatics Institute web site (http://www.ebi.ac.uk/clustalw).
Prediction of full-length coding sequences and genomic structures of -defensins
In most cases, signal and pro-sequence of -defensins are encoded in a separated exon
from the mature peptide-encoding exon. If either the signal/pro-sequence or -defensin motif of a
novel gene was missing in a genomic sequence, a 5-15 kb sequence flanking sequence was
retrieved to identify the full-length coding sequence and to derive the structural organization of
that novel -defensin gene by using a combination of GenomeScan (61), GENSCAN (5) and/or
GeneWise2 (4). All cDNA sequences of novel -defensins described in this study have been
submitted to GenBank and the accession numbers are listed in Supplementary Table 1.
Chromosomal mapping of -defensin gene clusters
The BLAT program (25) was used to determine the relative position and orientation of
each defensin in the genome through the UCSC Genome Browser (http://genome.ucsc.edu).
Individual defensins were searched against latest versions of the assembled genomes of human
(NCBI Build 35 Version 1), chimpanzee (NCBI Build 1 Version 1), mouse (NCBI Build 32), rat
(BCM Version 3.1), and dog (NCBI Build 1 Version 1) released in June 2004, November 2003,
September 2004, June 2003, and August 2004, respectively.
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Sequence alignment and phylogenetic analysis of -defensins
Multiple sequence alignments were carried out by using the ClustalW program (version
1.82) (53). The neighbor-joining method (43) was used to construct the phylogenetic tree by
calculating the proportion of amino acid differences (p-distance), and the reliability of each
branch was tested by 1000 bootstrap replications.
Semi-quantitative RT-PCR analysis of tissue and developmental expression patterns of -
defensins
A total of 29 different tissue samples (see Fig. 6B) were harvested from healthy, 2-month
old Sprague-Dawley rats. Total RNA was extracted using Trizol (Invitrogen). For each RNA
sample, 4 µg were reverse transcribed with random hexamers and Superscript II reverse
transcriptase by using a first-strand cDNA synthesis kit (Invitrogen) according to the
instructions. Subsequent PCR was performed with DNA Engine (Model PTC-200, MJ Research)
essentially as described (36, 57, 69). Briefly, 1/40 of the first-strand cDNA from each tissue were
used to amplify -defensins and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) with
gene-specific, exon-spanning primers (Supplementary Table 2). The PCR program used was:
94oC denaturation for 2 min, followed by different cycles of 94oC denaturation for 20 sec, 55oC
annealing for 20 sec, and 72oC extension for 40 sec, followed by a final extension at 72oC for 5
min. The number of PCR cycles was optimized for each gene to ensure linear amplification
(Supplementary Table 2). Specificity of each PCR product was confirmed by cloning the PCR
product into the pGEM-T Easy vector (Promega), followed by sequencing of the recombinant
plasmid.
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To examine developmental expression of the reproductive tract-specific -defensins,
testes were harvested from Sprague-Dawley rats on 1, 15, 30, 60 and 90 days after birth; and
epididymis were collected on 7, 15, 30, 60 and 90 days after birth with 2-4 animals per time
point. RNA isolation and semi-quantitative RT-PCR were performed as described above. Signal
intensity of each gene-specific PCR product was quantified by using Scion Imaging software
(http://www.scioncorp.com), followed by normalization against the GAPDH signal amplified
from the same cDNA sample, and the results were expressed as relative level of expression.
RESULTS
Discovery of mammalian -defensin gene repertoires
Based on the conservation of the characteristic six-cysteine-containing -defensin motif,
an iterative, genome-wide homology search strategy was developed to identify complete
repertories of the -defensin gene family in the human, chimpanzee, mouse, rat, and dog as we
previously described (36, 57). Because such computational searches are biased toward the
defensin motif, the nucleotide sequences identified were primarily composed of the exons
encoding the cysteine-spanning region. To identify the first exon sequences, 5-15 kb of finished
or unfinished genomic sequence containing each putative defensin gene were retrieved from
GenBank and used for computational prediction by using GenomeScan (61), GENSCAN (5),
and/or GeneWise2 (4). As a result, a number of novel, full-length defensin precursor sequences
with conserved six cysteines and signal peptides have been identified in each species and
submitted to the GenBank. All new genes were named by following the recommendations of the
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HUGO and Mouse Gene Nomenclature Committees and kept in consistence with the published
sequences.
In the case of rat, a total of 42 -defensin (Defb) genes and a pseudogene (Defb16-ps)
were discovered, including four known ones (24, 29, 41, 68) (Fig. 1). Among all rat genes, 12 -
defensins, namely Defb1, 4, 14, 22, 24, 27, 29, 33, 36, 39, 51, and 52, were found in the EST
database (data not shown), from which full-length peptide precursor sequences can be deduced
(Fig. 1). All the remaining genes were identified from WGS and HTGS seuqences with first
exons being predicted, except for Defb19. Consistent with earlier observations, the predicted
signal sequences are highly homologous with known -defensin genes in other mammalian
species, rich in leucine and hydrophobic residues (Fig. 1). The accuracy of the exon-intron
boundary predicted for each gene has also been confirmed by direct sequencing of RT-PCR
product with exon-spanning primers (Supplementary Table 2). Inability to identify the signal
sequence for Def19 may be due to mis-annotation of genome sequences or presence of premature
stop codons in its first exon.
It is noted that all rat -defensin genes were named according to their mouse orthologs as
previously described and approved by the Mouse Nomenclature Committee (47). Consequently,
rat -defensin-1 (24), -defensin-2 (24), E-3/2D6 (41, 68), and Bin-1b/EP2e (29) have been
renamed as Defb1, Defb4, Defb22, and Spag11e, respectively. An extra internal exon encoding
an additional segment of pro-sequence has been predicted for Defb12, Defb52, and Spag11c,
which have also been experimentally confirmed by sequencing of RT-PCR products in both
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cases. Presence of an extra exon in Spag11c has also been shown previously in its orthologs
(HE2c/EP2c/SPAG11c) in the human and rhesus monkey (11, 12).
A total of 43 novel -defensins genes and pseudogenes were discovered in the canine
genome (Supplementary Fig. 1). All sequences were named so as to maintain consistency with
the nomenclature of human -defensins. The canine -defensin-1 (CBD1) gene that we identified
earlier was re-named CBD122 (44). Five other CBD genes with no human orthologs were named
CBD138-CBD142. Among all canine sequences identified, eight (CBD1, CBD102, CBD103,
CBD108, CBD122, CBD124, CBD139, and CBD40,) were also supported by at least one EST
sequence (data not shown). First exons of all but two canine -defensins were also predicted.
While most CBD genes consist of two exons separated by an intron, CBD105, CBD118,
CBD122, and CSPAG11c (canine ortholog of human SPAG11c/HE2c) were predicted to have an
extra exon (data not shown).
Although a number of -defensins have been described in humans and mice with the use
of hidden Markov models (HMM) (47), later discovery of another novel sequence in the human
(42) prompted us to re-screen the human and mouse genome sequences for possible presence of
additional new sequences by using the strategy that we described above. Albeit of low
throughput, our method yielded a total of 39 human and 52 mouse -defensin genes and
pseudogenes, including four novel human (DEFB133, 134, 135, and 136) and six new mouse -
defensins (Defb49, 50, 51, 52, 53, and 54-ps). All new -defensin sequences consist of the
characteristic signal sequence and a conserved defensin motif (Fig. 2A). Moreover, most of their
orthologs are present in dogs and/or rodents except for mouse Defb53 and Defb54-ps, which
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appear to be mouse-specific (Fig. 2B). To further support their authenticity, all new genes were
found to locate inside the same genomic clusters as others (Fig. 3).
We also predicted first exons for most human (Supplementary Fig. 2) and mouse genes
(Supplementary Fig. 3), which were lacking in the earlier publication (47). The predicted
sequences and their intron-exon boundaries are consistent with the rat orthologous genes, which
have been confirmed by direct sequencing. Such sequences are also in agreement with a few full-
length human and mouse -defensins as described in the follow-up studies (3, 32, 39, 42, 48, 58,
66).
We also searched the chimpanzee genome and found a repertoire of 37 -defensin genes
that share 91-100% identity to their human orthologs in each case (data not shown), except that
DEFB110 and DEFB128 orthologs were not found the chimpanzee genomic sequences currently
available in GenBank. Because of their conservation in dogs and rodents, there is little reason to
suspect that DEFB110 and DEFB128 are missing in the chimpanzee, but instead it is most likely
due to low coverage (4-fold) of the current genome sequences.
Alignment of all -defensins revealed a high degree of diversity in the primary amino
acid sequence in the mature region despite of the conservation of six cysteine residues, indicative
of their possible nonredundant biological functions. Noticeably, the DEFB126/CBD126/Defb22
lineage (Fig. 1 and Supplementary Figs. 1, 2, and 3) and dog-specific CBD141 (Supplementary
Fig. 1) contain additional four amino acids between the third and fourth cysteine as compared to
most other -defensins. Moreover, three canine- and rodent-specific -defensin lineages, namely
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CBD138/Defb33, CBD139/Defb52, and CBD140/Defb51, consist of 3-4 extra amino acids
between the second and third cysteine but 2-3 fewer amino acids between the third and fourth
cysteine (Fig. 1 and Supplementary Figs. 1 and 3). Conceivably, such variations are expected to
alter their overall tertiary structures and possibly functional properties from conventional -
defensins.
Strikingly, in contrast to most characterized -defensins that contain less than 5 amino
acids following the last cysteine, the majority of the family members in fact have much longer
and mostly linear C-terminal tails. The role of such long tails remains largely a mystery.
However, several -defensins were recently found to be heavily glycosylated in vivo in the tail
region (30, 41, 65, 68). Furthermore, rat Defb22/E-3/2D6 and rhesus DEFB118/ESC42 contain
lectin and trefoil-like motifs, respectively, which potentially facilitate oligomerization and
interactions of proteins with target cell membrane (30, 41).
Chromosomal clustering of -defensins
To identify genomic organization of -defensins, individual -defensin genes were
searched against the most current versions of the assembled human, mouse, rat, chimpanzee, and
dog genomes by using the BLAT program (25) through the UCSC Genome Browser. It is
apparent that -defensin genes in each species are clustered densely in 4-5 different
chromosomal regions with each cluster spanning between 55-1118 kb (Fig. 3). All clusters are
syntenic across species because orthologous genes are extensively conserved with the same order
and orientation for most genes in each cluster (Fig. 3).
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In the rat genome (BCM Version 3.1), all 43 -defensin genes have been mapped and
form four distinct clusters expanding 812 kb, 78 kb, 55 kb, and 193 kb continuously on
chromosomes 16q12.5, 15p12, 9q12-q13, and 3q41, respectively (Fig. 3). Such syntenic clusters
are also conserved in mice (NCBI Build 32) with four clusters spanning 1118 kb, 71 kb, 56 kb,
and 164 kb on chromosomes 8qA1.3-A2, 14qC3, 1qA3, and 2qH1, respectively (Fig. 3).
However, the genomic contig containing mouse Defb33, Defb51, and Defb52 have not been
assigned to a specific region on mouse chromosome 8. The location of mouse Defb48-ps
currently remains unmapped. Mouse Defb32 reported earlier (47) was found on chromosome 6.
However, we suspect that Defb32 is unlikely to be an authentic -defensin gene, because of the
facts that 1) only five instead of six cysteines are present in the putative mature region, 2) such a
cysteine-containing region is negatively instead of positively charged, 3) no characteristic first
exon sequence could be identified within a 15-kb upstream sequence, and 4) no orthologs can be
found in other mammals. It is also noteworthy that we could not find mouse Defb31 and Defb47-
ps (47) in either EST, WGS, HTGS, or assembled genome sequences that are publicly available
in GenBank.
The canine genome (NCBI Build 1 Version 1) also encodes four -defensin clusters
expanding 356 kb, 76 kb, 99 kb, and 373 kb on the syntenic regions on chromosomes 16, 25, 12,
and 24, respectively (Fig. 3). However, human -defensin genes in the most current genome
assembly (NCBI Build 35 Version 1) were annotated in five separate clusters on three different
chromosomes with two on chromosome 8p23.1 (Fig. 3A and 3B), one on 6p12.3 (Fig. 3C), and
two on 20p13 and 20q11.21 (Fig. 3D). Apparently, two human -defensin clusters on the p and
q arms of chromosome 20 share a common ancestor with a continuous synthetic cluster in
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rodents and dogs (Fig. 3D). In contrast, another two human gene clusters on 8p23.1 are only
separated by less than 4 Mb, but their counterparts in rodents and dogs are located on two
different chromosomes (Fig. 3A and 3B). The current chimpanzee genome (NCBI Build 1
Version 1) also encodes five major -defensin clusters in almost perfect synteny with human
genes (Supplementary Fig. 4). It is noteworthy that the -defensin cluster is located within the
largest -defensin cluster in rodents and humans, but is apparently missing in the canine genome
(Fig. 3A), consistent with the fact that -defensins have only been discovered in glires and
primates (36).
Earlier studies indicated that a varied copy number of - and -defensin genes are present
on chromosome 8p23.1 of human individuals (19, 51). Because of such complexity, current
annotation of several human -defensins in this region, such as DEFB107, 108, 109, 130, and
131, shows an obvious discrepancy in the location and order of their orthologous genes with
other species (Fig. 3A and 3B). Thus, the accuracy of the current human genome assembly in
this region remains to be refined and corrected in the future (51).
Nevertheless, our current version of human and mouse -defensin genomic clusters
manifests a significant improvement over an earlier attempt (47). For example, several genes in
human 8p23.1 and their orthologous loci in mice have been re-ordered, which agrees with their
syntenies in other species (Fig. 3A) and are also consistent with more recent studies (48, 51).
Moreover, an ambiguous cluster containing DEFB130 and DEFB131 (47) has been mapped to
human chromosome 8p23.1 with three additional novel genes (DEFB134, 135, and 136) being
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added (Fig. 3B). Another novel human -defensin gene (DEFB133) has also been mapped to
6p12.3 and its orthologs have been found and localized in rodent and canine genomes (Fig. 3C).
Structural organizations and transcriptional flexibility of -defensin genes
A comparison of all available EST with genomic sequences of -defensins across
mammalian species revealed that, similar to enteric -defensins (35), most -defensin genes are
composed of two separate exons with the first exon encoding the signal and pro-sequence and
the second exon encoding primarily the mature sequence containing the defensin motif. The
intron sizes of -defensins vary greatly, spanning 1-10 kb in most cases, in contrast with - and
-defensins consisting of introns of usually <1 kb (36). However, we also found additional five
distinct patterns of the -defensin gene structure (Fig. 4). For example, mouse Defb21 (EST
accession number AK076875), mouse Defb44 (AK079042), rat Defb29 (CK839317), rat Defb51
(BM390654), and canine CBD102 (DN346173), CBD139 (CO687407), and CBD140
(CO692331) have EST sequences showing the presence of additional one or two exons encoding
the 5’-untranslated region (UTR), reminiscent of myeloid -defensin genes (35). On the other
hand, mouse Defb30 (AK078987) contains an additional exon encoding the 3’-UTR. Mouse
Defb28 (AV044615) and canine CBD122 (BM537999) are unique in that they are composed of
three exons with the last exon encoding a segment of the mature sequence downstream of the six
cysteines, while the first two exons encoding the signal, pro- and, majority of mature sequences.
A few genes, such as SPAG11c /CSPAG11c/Spag11c (11, 12) and DEFB105/CBD105/Defb12
(data not shown), exhibit a three-exon structure, containing an extra intron presumably encoding
an additional segment of pro-sequence. Interestingly, rat Defb52 (CR466423) is composed of
four exons with three exons encoding the entire open reading frame and the fourth exon
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encoding a part of 5’-UTR. Additional gene structures are expected to be revealed with
availability of more mRNA and EST sequences for -defensins.
It is well known that the SPAG11 gene is capable of differentially utilizing different
exons to produce multiple isoforms of -defensin-like sequences (11, 12). Such alternative
splicing now does not appear to be unique to the SPAG11 gene. We have found two EST
sequences (AK020304 and BB787829) that consist of the first exon of mouse Defb17 and the
second exon of Defb16, suggesting that these two genes are actually alternatively spliced
isoforms. Such splicing is most likely evolutionarily conserved, because of the absence of signal
sequence for its orthologous gene, DEFB110/CBD110/Defb16 in the human, chimpanzee, dog,
and rat. Therefore, primate DEFB110 and DEFB111, canine CBD110 and CBD111, and rat
Defb16-ps and Defb17 are likely to be two isoforms of the same gene. Similarly, human DEB119
and DEFB120 have been shown recently to share the same first exon encoding the signal
sequence (39). CBD122, on the other hand, has three isoforms sharing identical signal, pro- and
the majority of mature sequences with the only difference in the carboxyl terminal tail after the
last cysteine (44). Collectively, acquirement of additional exons and frequent alternative splicing
add additional layers of complexity in -defensin gene transcription and regulation, which
presumably allow the host to better cope with invading infections.
Phylogenetic analysis of -defensins
To reveal the evolutionary relationships of all known -defensins including newly
identified ones in rodents, dogs, and primates, we sought to construct a phylogenetic tree by
using the neighbor-joining method (43). Interestingly, genes within a genomic cluster tend to
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form a separate clade from the genes in other clusters (data not shown), implying that many of
them most likely evolved by gene duplication events. Indeed, a number of highly similar
paralogous genes are present in each species and physically located adjacent to each other.
Consistent with the genetic mapping data (Fig. 3), many -defensins have obvious orthologs with
minimum sequence variation across four mammalian species and are clustered together (Fig. 5),
meaning that these lineages arose before the last common ancestor of rodents, canines, and
primates. Some even form well-supported clusters with different chicken -defensins, suggesting
their existence prior to the divergence of mammals from birds (57). The conservation of these
genes during evolution may be indicative of their functional significance.
Conversely, subgroups of -defensins also exist that are specific in mice, rats, and dogs,
implying that these genes originated after these species separated and have undergone different
evolutionary patterns. For example, two well-supported clades of rodent-specific genes (Clade I:
Defb2, 9, 10, and 11; and Clade II: Defb37, 38, 39, 40, and 50) exist (Fig. 5). High sequence
similarity within each clade supports the notion that these rodent-specific -defensin genes arose
from gene duplication and positive diversifying selection as previously described (32, 48). In
contrast to the Clade II genes with the orthologs present in both rodent species, many mouse -
defensins in Clade I have no obvious orthologs in rats, implying that many Clade I genes were
likely to have emerged only after the mouse-rat split about 41 million years ago (27), whereas all
Clade II genes apparently appeared prior to the split. Another large cluster of rodent genes,
namely Defb3, 4, 5, 6, 7, and 8, form a common clade with human DEFB4/hBD-2 gene (Fig. 5).
Therefore, it is likely that such a gene lineage duplicated and expanded significantly in rodents,
but remained unchanged in primates and was lost in the canine lineage. Alternatively, multiple
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such ancestral gene lineages were lost in primates and canines, but retained in rodents. However,
significant homology of murine genes in this cluster as well as their physical vicinity (Fig. 3A)
supports the former conclusion.
Multiple gene lineages specific to dogs and primates are also present, including
DEFB104/CBD104, DEFB108/CBD108, DEFB114/CBD114, DEFB120/CBD120,
DEFB121/CBD121, DEFB133/CBD133, and DEFB134/CBD134 (Figs. 3 and 5). Conversely,
CBD138/Defb33, CBD139/Defb52, and CBD140/Defb51 (Fig. 3A) only exist in rodents and
dogs, but are absent in primates (Fig. 5). Dog-specific genes also exist, such as CBD141 and
CBD142 (Fig. 3D). However, no primate-specific -defensins were found, suggesting that gene
duplication did not occur in the primates after their divergence. It is noteworthy that CBD102 is
not the canine ortholog of human DEFB4, murine Defb2 or Defb4, but instead it is specific to the
dog, paralogous to CBD103 (Fig. 5 and Supplementary Fig. 1). Therefore, the CBD102 gene is
most likely to evolve from duplication of the CBD103 gene after separation of canines from
other mammals.
Tissue expression pattern of rat -defensins
We next examined the tissue expression patterns of the entire -defensin gene family in
the rat as a first step toward understanding their in vivo biological functions. Semi-quantitative
RT-PCR was performed with all identified rat -defensin genes by using a panel of 29 different
tissues from healthy, 2 month-old Sprague-Dawley rats. Primers were designed from two
different exons to differentiate between the amplicons from cDNA and those from genomic
DNA and verify predicted exon-intron junctions (Supplementary Table 2). Different numbers of
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PCR cycles were performed for each gene to ensure the linearity of amplification. Specificity of
each amplicon was confirmed by direct sequencing of the RT-PCR product or recombinant
plasmid containing the RT-PCR product.
To our surprise, nearly all -defensins were found to be expressed preferentially in the
male reproductive system particularly in epididymis and testis (Fig. 6A) with no or minimum
expression in most other tissues (data not shown). More strikingly, the reproductive tract-specific
genes are expressed differentially in three different regions of epididymis, namely caput (head),
corpus (body), and cauda (tail) (Fig. 6A). For example, Defb12/35, 15/34, 17, 18, 21, 25, 41,
Spag11c, and Spag11e are more abundantly expressed in the caput of epididymis, whereas
Defb9, 10, 11, 13, and 40 are restricted to the cauda (Fig. 6A). On the other hand, Defb24 and
Defb33 are highly specific to testis (Fig. 6A). Our results are consistent with earlier studies on
the expressions of rat Defb1/RBD-1 (8, 24) and Spag11e/Bin-1b (29) and also largely agree with
the expressions of their human and mouse orthologs (39, 42, 58, 59, 66).
In addition to a canonical Spag11c/EP2c transcript (3, 12, 56), an alternatively spliced
longer transcript was detected in the rat (Fig. 6A) and has been deposited in GenBank under
accession number DQ012093. Such a transcript is unique in that it contains an extra 60 bp at the
3’-end of the first exon, resulting in a longer pro-sequence, which is not found in either human or
rhesus monkey (11, 12). To further illustrate the difference in the SPAG11/HE2/EP2 locus
between primates and rodents, the d isoform, which is composed of the first two exons of the c
form and the last exon of the e form, was not detected in the rat (data not shown), but is readily
detectable in the primates (11, 12).
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Although the majority of genes showed the most abundant expression in testis or
epididymis of healthy adult rats, Defb1 and Defb42 are also expressed at considerable levels in
kidney (Fig. 6A) and Defb24 in spleen and ovary (data not shown). Defb36 was found at a lesser
extent on mucosal surfaces lining the respiratory, gastrointestinal, and reproductive tracts as well
as on skin (Fig. 6B). The only obvious exception is Defb4/RBD-2, which shows virtually no
expression in either testis or epididymis, but instead is more restricted to the respiratory tract,
particularly in lung (Fig. 6B). Defb4 transcript was also found at low levels in the upper
gastrointestinal tract as well as in vagina (Fig. 6B), which is consistent with the previously
published report (24). The biological significance of such concentrated, but apparently
differential production of so many -defensins in testis and different regions of epididymis
remains largely unknown.
It is noted that we failed to detect the expression of Defb3, Defb5, and Defb16-ps
following multiple attempts with different combinations of primer pairs. Although we cannot
rule out possibility of wrong computational prediction of first exons, it is most likely that Defb3
and Defb5 are expressed at extremely low levels in healthy adult rats, but may be inducible in
response to infection and inflammation. Defb16-ps could be a non-expressing pseudogene.
Alternatively, these three genes could be expressed in the tissues other than the ones that we
examined. Because of the inability to identify the first exon of Defb19, we could not detect its
gene expression by RT-PCR either.
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Developmental regulation of rat -defensins
Semi-quantitative RT-PCR was performed to study developmental expression patterns of
a few selected rat genes that are specific to epididymis and/or testis. Rat testes were collected on
1, 15, 30, 60, and 90 days after birth; and epididymis were collected on 7, 15, 30, 60, and 90 days
after birth with 2-4 animals used per time point. As shown in Fig. 7A, expressions of all selected
-defensins (Defb1, 15, 29, 30, 42, and 49) in epididymis are significantly elevated during
development with virtually no expression on day 7 but peaked quickly at one month. Defb42 is
slightly different in that it shows little expression up to one month, but the expression level is
dramatically enhanced at two months of age and increased up to three months after birth. Such a
pattern is reminiscent of rat Spag11e/Bin-1b, whose transcript does not peak in epididymis until
four months and remains elevated in rats of 2 years of age (29).
However, -defensin genes in testis showed a different pattern. Although most
epididymal -defensin genes were not expressed on day 7, many genes in testis display
considerable expression soon after birth, with some (Defb24 and Defb29) expressed
constitutively in rats of all ages studied and some (Defb27 and Defb36) were upregulated and
peaked at one month of age (Fig. 7B). Defb33, on the other hand, behaves similar to epididymal
Defb42 (Fig. 7A) in that it is not detected in testis until one month, but continues to increase for
at least three moths after birth (Fig. 7B). It is interesting to note that Defb29 is developmentally
regulated in the epididymis (Fig. 7A), but exhibits a constitutive pattern in the testis (Fig. 7B),
implying the presence of certain epididymis-specific enhancer(s) or testis-specific inhibitory
factor(s).
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The constitutive expression of several -defensins in testis, but not epididymis, of
newborn animals is presumably required to protect testis and particularly germ cells from
invading infections before the time of sexual maturation. Simultaneous production of such a
large array of defensins in various segments of the male reproductive tract with different
developmental expression patterns implies that these molecules may play a nonredundant role in
the reproductive process.
DISCUSSION
Sequence diversity of mammalian -defensins
Through systemic genome-wide screening, we have discovered a total of 39, 37, 43, 52,
and 43 -defensin genes and pseudogenes in the human, chimpanzee, dog, mouse, and rat,
respectively. Alignment of all -defensins revealed a high degree of conservation in the spacing
pattern of six cysteines with a consensus pattern of C-X5-8-C-X3-7-C-X5-13-C-X4-7-CC. The
invariantly spaced cysteines form a rigid, triple antiparallel -sheet structure and are believed to
be critically important in maintaining the functional activities (14, 28). However, we observed
the absence of a canonical cysteine or presence of an extra cysteine in a few putative functional
defensins. For example, human DEFB107 and mouse Defb8/Defr1 have a nonconservative
mutation in the first cysteine, whereas mouse and rat Defb50 lack the second conserved cysteine
(Supplementary Figs. 2 and 3). DEFB133/Defb49 lineage, on the other hand, contains a mutation
in either the fifth or sixth cysteine in the mouse and human (Supplementary Figs. 2 and 3), but is
fully conserved with six canonical cysteines in the rat (Fig. 1).
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Extra cysteines have also been found within the six-cysteine motif of three peptides,
namely human DEFB119 and DEFB132 and mouse Defb5 (Supplementary Figs. 2 and 3). In
contrast, the instance of cysteines occurring outside the defensin motif appears to be much higher
with multiple members being found in each species. Among 39 human -defensins, seven such
peptides are found (DEFB105, 106, 112, 117, 126, 127, and 133) (Supplementary Fig. 2).
Interestingly, five are conserved across species, including DEFB105/CBD105/Defb12/Defb35,
DEFB106/CBD106/Defb15/Defb34, DEFB112/CBD112, DEFB117/CBD117/Defb19, and
DEFB126/CBD126/Defb22.
It is largely unknown how a missing or an extra cysteine would affect the tertiary
structures and functional properties of -defensins. Obviously, the existence of an odd number of
cysteines will potentially oligomerize through intermolecular disulfide bridging. Indeed, such -
defensins as Defb8/Defr1 (6) and DEFB126/Defb22/ESP13.2/E-3/2D6 (41, 65, 68) have been
shown to form covalently bounded homodimers in vitro and/or in vivo. Such dimerization in fact
leads to enhanced antibacterial activities in the case of Defb8/Defr1 (6). Not surprisingly, a few
-defensins with six cysteines also have a tendency to form dimers or oligomers, which are
believed to facilitate membrane interaction and permeabilization (20, 45).
It is noteworthy that our strategy yielded a total of 10 additional novel -defensins in
humans and mice as compared with the strategy based on the Hidden Markov Model (HMM)
(47). Although we believe that the current list most likely represents the complete repertoires of
-defensins in these species, we could not rule out the possibility that additional -defensin-
related genes with remote similarity might be uncovered in these species. In fact, a group of
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human SPAG11/HE2/EP2 isoforms were recently found to share identical signal and pro-
sequences with similar antimicrobial properties with classic -defensins, but differ significantly
in the number and cysteine spacing pattern in the mature sequence (3, 56, 62, 63). Such -
defensin-related sequences have also been discovered in mice (21, 23) and rats (36).
Nevertheless, the current study represents the most comprehensive attempt to identify
mammalian canonical -defensin gene family members with the characteristic six-cysteine
motif.
Evolutionary relationships of mammalian -defensins
-defensins are the most ancient family of vertebrate defensins as compared to - and -
defensins (57). -defensin-like sequences have been found in the rattlesnake (34), orange-
spotted grouper (GenBank accession number AY129305), and zebrafish (Zhang, G.,
unpublished results), suggesting that the primordial gene for -defensins appeared prior to the
fish-primate split about 450 million years ago (27). In contrast, -defensins were derived from
-defensins after divergence of glires and rodents from other mammals about 91 million years
ago, whereas -defensins did not appear until primates separated from other mammals around 23
million years ago (27, 33, 36).
Our earlier study discovered a single cluster consisting of 13 -defensin genes encoded in
the entire chicken genome (57). Comparative analysis of the chicken and mammalian -defensin
gene clusters revealed that two clusters on human 8p23.1 and their orthologous loci in other
mammalian species (Fig. 3A and 3B) are syntenic with the chicken gene cluster, implying that
the ancestral genes in these two mammalian clusters evolved prior to the bird-mammal
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separation (57). Many genes in these two ancient clusters were demonstrated to have undergone
significant repeated duplication and positive diversification in humans and mice after their
divergence (32, 48), which further gave rise to other -defensin clusters in mammals during
evolution, presumably as a result of chromosomal translocation and expansion of certain gene
lineages.
Consistent with the evolutionarily active nature of the two ancient clusters, subgroups of
genes exist in these two regions that are specific in rodents, dogs and/or primates (Fig. 5). This
notion is further reinforced by the presence of multiple highly homologous - and -defensins
and emergence of - and -defensins in rodents and primates in these regions (Fig. 3A). In
contrast, the remaining genomic clusters are rather static throughout evolution with the presence
of orthologs across mammalian species, except that CBD141 and CBD142 on chromosome 24
are specific to dogs and was likely duplicated and diverged from adjacent genes (Fig. 3D) after
the dog diverged from other mammals.
Collectively, these results suggest that the evolution of mammalian -defensins is an
extremely dynamic and active process. Individual gene lineages were derived at different
evolutionary times. Although some -defensins evolved prior to divergence of mammals from
fish, many appear to be mammal-specific with a few emerging as recently as the rat-mouse split,
which occurred only 41 million years ago (27). However, no gene duplication occurred prior to
the separation of chimpanzee from humans at about 5.5 million years ago (27), because of the
complete orthology of -defensin genes in these two species (Supplementary Fig. 4).
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What is the driving force for the presence of such a large number of divergent -
defensins in mammals? One plausible explanation is that sequence diversification may confer
functional novelties on different -defensins for each species to better cope with a variety of
microbial threats from the environment. Consistent with this hypothesis, different -defensins
(15, 16, 18) and even orthologous genes in different primates (2) have been found to differ quite
dramatically in their antimicrobial potency and spectrum. Furthermore, expression of a large
array of -defensins in the male reproductive tract is presumably to safeguard the reproductive
process, enhance fertility, and sustain species survival, as detailed in the next section.
Dual role of region-specific expression of -defensins in the male reproductive tract
Obviously, optimal reproductive function ensures survival of the species, which needs
full protection of germ cell precursors in testis, sperm in different stages of maturation in
epididymis and after deposition in the female reproductive tract. Infection of testis and
epididymis may result in temporary or permanent loss of fertility by disrupting specialized
environment of these organs conducive for sperm storage and maturation (37). As adaptive
immunity is largely absent in the male reproductive system, the host must evolve alternative and
effective mechanisms of protection of sperm from infectious agents.
Region-specific expression of all but one rat -defensins in the male reproductive system
(Fig. 6) suggests that these molecules may constitute an essential component in maintaining the
normal reproductive process. In line with this, many testis- and epididymis-specific -defensins
were shown to be antimicrobial and capable of protecting sperm from infections (3, 8, 29, 56, 62,
64). In addition to being microbicides, -defensins expressed in different regions of epididymis
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appear to be actively involved in the reproduction. These defensins are mainly produced by
epithelial cells lining the epididymal duct, regulated by androgens, secreted in luminal plasma,
and bind preferentially to the surface of maturing but not immature sperm (29, 30, 41, 65, 68,
70). Rat Spag11e/Bin-1b has been shown to enhance sperm maturation by inducing Ca2+ uptake
and subsequent motility and progressive movement of immature spermatozoa (70). Moreover,
another epididymis-specific -defensin, macaque DEFB126/ESP13.2, coats the entire ejaculated
sperm and masks zona pellucida ligands on the sperm surface, but becomes dissociated when
sperm are fully capacitated, suggesting that DEFB126 may be an important decapacitation factor
on the sperm surface that needs to be removed prior to sperm-zona interaction and fertilization
(54, 65).
Besides -defensins, -defensins have also been reported in the male reproductive tract
(8, 17). Human cathelicidin LL-37/hCAP-18, which belongs to another important family of
vertebrate antimicrobial peptides (40, 67), is expressed by epididymal epithelia and is abundantly
present in the seminal fluid with ability to bind to sperm (31). Furthermore, the female
reproductive tract also produces - and -defensins albeit at low levels (26, 38, 50). Coupled
with the fact that many -defensins in epididymis and testis are developmentally regulated with
elevated expression at the time of puberty and sexual maturation (Fig. 7), these results strongly
favor the argument that -defensins, perhaps together with many other antimicrobial peptides,
have a dual function in both innate host defense and fertility.
Defb4/RBD-2 represents the only -defensin that is expressed most abundantly in lung
with virtually no expression in the reproductive tract (Fig. 6B), and thus it may play an important
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role in airway defense. Its human ortholog, DEFB4/hBD-2 was shown to be the predominant -
defensin in human neonatal lung and developmentally regulated (49) and its concentration is
inversely correlated with the severity of lung disease in cystic fibrosis patients (7). Further
studies are needed to identify the regulatory mechanisms that specify the expression of defensins
in the male reproductive tract vs. respiratory tract. Functional divergence of -defensins
produced in the same and different regions of the reproductive tract also remains to be
investigated and these molecules may have potential as fertility and contraceptive drugs.
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FIGURE LEGENDS
Fig. 1. Amino acid sequence alignment of rat -defensins. Dashes are inserted to optimize the
alignment and conserved residues are shaded. Internal exon sequences of Defb12, Defb52, and
Spag11c have been deleted to maximize the alignment. Long carboxyl terminal tails of several -
defensins as well as an additional segment of amino terminal sequence preceding the canonical
start codon of Defb17 are not shown for the sake of clarity. The letter ‘X’ denotes the presence of
premature stop codon in the pseudogene. All computationally predicted novel rat -defensin
sequences except for Defb3, Defb5, and Defb16p have been confirmed by sequencing of their
respective RT-PCR products amplified from appropriate tissues. The failure to amplify Defb3,
Defb5, and Defb16p is likely due to no or extremely low expression in healthy animals.
Abbreviations: Defb, -defensin; SPAG11, sperm-associated antigen 11; p, pseudogene.
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Fig. 2. Identification of novel -defensins in humans and mice. A, Amino acid sequence
alignment of novel sequences with DEFB1/Defb1. Dashes are inserted to optimize the alignment
and conserved residues are shaded. The letter ‘X’ denotes the presence of premature stop codon
in the pseudogene. B, Phylogenetic tree of novel -defensins in the human and mice
demonstrating their conservation in other mammalian species, except for mouse Defb53 and
Defb54p. The tree was constructed by the neighbor-joining method based on the proportion
difference (p-distance) of aligned amino acid sites of full-length peptide sequences. 1000
bootstrap replicates were used to test the reliability of each branch. Numbers on the branches
indicate the percentage of 1000 bootstrap samples supporting the branch. Only branches
supported by a bootstrap value of at least 50% are shown. Abbreviations: DEFB/Defb, -
defensin; CBD, canine -defensin; mDefb, mouse -defensin; rDefb, rat -defensin; P/p,
pseudogene.
Fig. 3. Genomic organization of syntenic mammalian -defensin gene clusters. Four different -
defensin clusters (A, B, C, and D) are present in the rat, mouse, and dog, whereas five clusters
exist in the human and chimpanzee due to the split of the Cluster D in the rodents and dog into
two separate loci in the primates. The position of each gene is represented by a vertical bar. The
direction of transcription is indicated by the triangle. The orthologous genes are linked across
species and paralogous genes are also connected with dashed lines. However, in panel A, murine
Defb13, Defb15, and Defb35 that are orthologous to DEFB107/CBD107,
DEFB106/CBD106/Defb34, and DEFB105/CBD105/Defb12 gene lineages, respectively, are not
linked for simplicity. Mouse Defb2, 9, 10, and 11 are not orthologs of the rat genes with
corresponding numbers, and therefore they are not linked. The gene mapping was derived from
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the assembled genomes of human (NCBI Build 35 version1), rat (BCM version 3.1), mouse
(NCBI Build 32), and dog (NCBI Build 1 Version 1), respectively. The genomic cluster
containing mouse Defb33, 51, and 52 is not mapped on chromosome 8, and therefore, is placed
within slanted lines based on the locations of their orthologs on rats and dogs. Note that an -
defensin gene cluster is located within a -defensin locus in the human, mouse, and rat, but is
absent in the dog genome (A). Abbreviations: Tel, telomere; Cen, centromere; P/p, pseudogene;
11e/11c, SPAG11e/SPAG11c.
Fig. 4. Structural organizations of mammalian -defensin genes. Although most -defensin genes
are composed of two exons (boxes) separated by an intron (lines) of variable length, certain
genes in mice (Defb21 and Defb44), rats (Defb29 and Defb51), and dogs (CBD102, CBD139,
and CBD140) contain additional one or two exons encoding 5’-untranslated regions. On the other
hand, mouse Defb30 consists of an extra 3’-untranslated region. An extra exon encoding the
carboxyl terminal mature sequence exists in mouse Defb28 and canine CBD122, whereas an
internal extra pro-sequence is present in SPAG11c /CSPAG11c/Spag11c and
DEFB105/CBD105/Defb12 gene lineages. In addition to an extra internal exon, rat Defb52
comprises a fourth exon encoding the 5’-untranslated region. Solid boxes refer to the coding
exons, whereas the open boxes refer to the noncoding exons.
Fig. 5. Phylogenetic tree of mammalian -defensins. Only -defensins in the rat chromosome
16q12.5 and its syntetic loci in the human, dog, and mouse are shown. The tree was constructed
by the neighbor-joining method based on the proportion difference (p-distance) of aligned amino
acid sites of full-length peptide sequences. 1000 bootstrap replicates were used to test the
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reliability of each branch. Numbers on the branches indicate the percentage of 1000 bootstrap
samples supporting the branch. Only branches supported by a bootstrap value of at least 30% are
shown. Abbreviations: DEFB, human -defensin; CBD, canine -defensin; mDefb, mouse -
defensin; rDefb, rat -defensin; SPAG11/spag11, sperm-associated antigen 11; CSPAG11, canine
sperm-associated antigen 11; P/p, pseudogene;
Fig. 6. Tissue expression patterns of rat -defensins by RT-PCR. Lanes: 1, kidney; 2, testis; 3,
caput of epididymis; 4, corpus of epididymis; 5, cauda of epididymis; and 6, vas deferens.
Defb12/35 and Defb15/34 have identical expression patterns and are therefore combined in a
single panel. Notice that most -defensins are expressed preferentially in the male reproductive
system with no or minimum expression in other tissues (A), except that Defb4 and Defb36, which
have more universal distribution patterns (B). See Materials and Methods for details. The number
of PCR cycles was optimized for each gene, and the specificity of each PCR product was
confirmed by sequencing. The house-keeping gene, GAPDH, was used for normalization of the
template input.
Fig. 7. Developmental regulation pattern of rat -defensins in epididymis (A) and testis (B) by
RT-PCR. The signal intensity of each gene-specific PCR product was digitized and quantitated,
followed by normalization against the GAPDH signal amplified from the same cDNA sample.
The results are expressed as means ± SEM of 2-4 animals per data point.
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SUPPLEMENTARY MATERIAL
Supplementary Fig. 1. Amino acid sequence alignment of the canine -defensin gene family.
Dashes are inserted to optimize the alignment and conserved residues are shaded. Internal exon
sequences of CBD105 and CSPAG11c as well as the last several amino acids of the first exon
sequence of CBD112 have been deleted to maximize the alignment. Long carboxyl terminal tails
of several -defensins are not shown for the sake of clarity. The letter ‘X’ denotes the presence
of premature stop codon in the pseudogene. First exons for some -defensins were not identified.
Abbreviations: CBD, canine -defensin; CSPAG11, canine sperm-associated antigen 11; P,
pseudogene.
Supplementary Fig. 2. Amino acid sequence alignment of the human -defensin gene family.
Dashes are inserted to optimize the alignment and conserved residues are shaded. Internal exon
sequences of DEFB105 and SPAG11c as well as the last several amino acids of the first exon
sequence of DEFB112 have been deleted to maximize the alignment. Long carboxyl terminal
tails of several -defensins are not shown for the sake of clarity. The letter ‘X’ denotes the
presence of premature stop codon in the pseudogene. First exons for some -defensins were not
identified. Abbreviations: DEFB, -defensin; SPAG11, sperm-associated antigen 11; P,
pseudogene.
Supplementary Fig. 3. Amino acid sequence alignment of the mouse -defensin gene family.
Dashes are inserted to optimize the alignment and conserved residues are shaded. Internal exon
sequences of Defb12, Defb52, and Spag11c have been deleted to maximize the alignment. Long
147
carboxyl terminal tails of several -defensins are not shown for the sake of clarity. The letter ‘X’
in bold denotes the presence of premature stop codon in the pseudogene. First exons for some -
defensins were not identified. Abbreviations: Defb, -defensin; p, pseudogene.
Supplementary Fig. 4. Genomic organization of five syntenic -defensin gene clusters in the
human and chimpanzee. The position of each gene is represented by a vertical bar. The direction
of transcription is indicated by the triangle. The orthologous genes are linked across species. The
gene mapping was derived from the assembled genomes of human (NCBI Build 35 Version 1)
and chimpanzee (NCBI Build 1 Version 1), respectively. It is noted that chimpanzee DEFB130
and DEFB131 are not conclusively mapped, whereas DEFB110 and DEFB128 are missing in the
current genome assembly. Abbreviations: Tel, telomere; Cen, centromere; P, pseudogene;
11e/11c, SPAG11e/SPAG11c.
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Supplementary Table 1. GenBank accession numbers of mammalian -defensin cDNA sequencesa
Human Chimpanzee Dog Mouse Rat
-defensin Accession No. -defensin Accession No. -defensin Accession No. -defensin Accession No. -defensin Accession No.
DEFB1 NM_005218 DEFB1 NM_001009151 CBD1 DQ011970 Defb1 NM_007843 Defb1 NM_031810
DEFB4 NM_004942 DEFB102 NM_001009076 CBD102 DQ011971 Defb2 NM_010030 Defb2 AY621338
DEFB103 NM_018661 DEFB103 DQ012056 CBD103 DQ011972 Defb3 NM_013756 Defb3 AY621339
DEFB104 NM_080389 DEFB104 DQ012057 CBD104 DQ011973 Defb4 NM_019728 Defb4 AY621374
DEFB105 NM_152250 DEFB105 DQ012058 CBD105 DQ011974 Defb5 NM_030734 Defb5 AY621340
DEFB106 NM_152251 DEFB106 DQ012059 CBD106 DQ011975 Defb6 NM_054074 Defb9 AY621341
DEFB107 DQ119826 DEFB107 DQ012060 CBD107 DQ011976 Defb7 NM_139220 Defb10 AY621342
DEFB108 NM_001002035 DEFB108P DQ012061 CBD108 DQ011977 Defb8 NM_153108 Defb11 AY621343
DEFB109 DQ012013 DEFB109 DQ012062 CBD109 DQ011978 Defb9 NM_139219 Defb12 AY621344
DEFB110 DQ012014 DEFB111 DQ012063 CBD110 DQ011979 Defb10 NM_139225 Defb13 AY621345
DEFB111 DQ012015 DEFB112 DQ012064 CBD111 DQ011980 Defb11 NM_139221 Defb14 AY621346
DEFB112 DQ012016 DEFB113 DQ012065 CBD112 DQ011981 Defb12 NM_152802 Defb15 AY621347
DEFB113 DQ012017 DEFB114 DQ012066 CBD113 DQ011982 Defb13 NM_139223 Defb16-ps DQ012089
DEFB114 DQ012018 DEFB115 DQ012067 CBD114 DQ011983 Defb14 NM_183026 Defb17 AY621348
DEFB115 DQ012019 DEFB116 DQ012068 CBD115P DQ011984 Defb15 NM_139222 Defb18 AY621349
DEFB116 DQ012020 DEFB117 DQ012069 CBD116 DQ011985 Defb16 DQ012027 Defb19 AY621350
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DEFB117 DQ012021 DEFB118 DQ012070 CBD117 DQ011986 Defb17 DQ012028 Defb20 AY621351
DEFB118 NM_054112 DEFB119 DQ012071 CBD118 DQ011987 Defb18 DQ012029 Defb21 AY621352
DEFB119 NM_153289 DEFB120 DQ012072 CBD119 DQ011988 Defb19 DQ012030 Defb22 AY621353
DEFB120 NM_153323 DEFB121 DQ012073 CBD120 DQ011989 Defb20 DQ012031 Defb23 AY621354
DEFB121 NM_001011878 DEFB122P DQ012074 CBD121 DQ011990 Defb21 DQ012032 Defb24 AY621355
DEFB122P AY122474 DEFB123 DQ012075 CBD122 DQ011991 Defb22 DQ012033 Defb25 AY621356
DEFB123 NM_153324 DEFB124 DQ012076 CBD123 DQ011992 Defb23 DQ012034 Defb26 AY621357
DEFB124 DQ119827 DEFB125 DQ012077 CBD124 DQ011993 Defb24 DQ012035 Defb27 AY621358
DEFB125 NM_153325 DEFB126 DQ012078 CBD125 DQ011994 Defb25 DQ012036 Defb28 AY621359
DEFB126 NM_030931 DEFB127 DQ012079 CBD126 DQ011995 Defb26 DQ012037 Defb29 AY621360
DEFB127 NM_139074 DEFB129 DQ012080 CBD127 DQ011996 Defb27 DQ012038 Defb30 AY621361
DEFB128 AF525930 DEFB130 DQ012081 CBD128 DQ011997 Defb28 DQ012039 Defb33 AY621362
DEFB129 NM_080831 DEFB131 DQ012082 CBD129 DQ011998 Defb29 AF515626 Defb36 AY621363
DEFB130 DQ012022 DEFB132 DQ012083 CBD130 DQ011999 Defb30 DQ012040 Defb37 AY621364
DEFB131 AF529414 DEFB133 DQ012084 CBD131 DQ012000 Defb33 DQ012041 Defb38 AY621365
DEFB132 NM_207469 DEFB134 DQ012085 CBD132 DQ012001 Defb34 NM_183035 Defb9 AY621366
DEFB133 DQ012023 DEFB135 DQ012086 CBD133P DQ012002 Defb35 NM_139224 Defb40 AY621367
DEFB134 DQ012024 DEFB136 DQ012087 CBD134 DQ012003 Defb36 DQ012042 Defb41 AY621368
DEFB135 DQ012025 DEFB137P DQ012088 CBD135 DQ012004 Defb37 NM_181683 Defb42 AY621369
DEFB136 DQ012026 SPAG11c AF263553 CBD136 DQ012005 Defb38 NM_183036 Defb43 AY621370
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DEFB137P DQ119828 SPAG11e AF263555 CBD138 DQ012006 Defb39 NM_183038 Defb44 AY621371
SPAG11c NM_058203 CBD139 DQ012007 Defb40 NM_183039 Defb49 AY621372
SPAG11e NM_058207 CBD140 DQ012008 Defb41 DQ012043 Defb50 DQ012090
CBD141 DQ012009 Defb42 DQ012044 Defb51 AY621373
CBD142 DQ012010 Defb43 DQ012045 Defb52 DQ012091
SPAG11c DQ012011 Defb44 DQ012046 Spag11c DQ012092
SPAG11e DQ012012 Defb46-ps DQ012047 Spag11c-1 DQ012093
Defb48-ps DQ012048 Spag11e NM_145087
Defb49 DQ012049
Defb50 DQ012050
Defb51 DQ012051
Defb52 DQ012052
Defb53 DQ012053
Defb54-ps DQ012054
Spag11c DQ012055
Spag11e NM_153115
a The complete repertoires of -defensins identified in the human, chimpanzee, dog, mouse, and rat are shown together
with GenBank accession numbers for their mRNA sequences. Previously identified genes are italicized and listed with
a reference accession number (NM) if available. The remaining genes were discovered in this study. Spag11c-1 is an
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alternatively spliced variant of Spag11c in the rat. Abbreviations: DEFB/Defb, -defensin; SPAG11, sperm-associated
antigen 11; P/ps, pseudogene.
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Supplementary Table 2. Primer sequences used for RT-PCR analysis of rat -defensinsa
Primer Sequence Product Size (bp)Gene
Forward Reverse cDNA Genomic
No. of
Cycles
Defb1 TGGACCCTGACTTCACCGACAT CTTCAAACCACTGTCAACTCCTG 244 15238 32
Defb2 GACTCTCTGCTCTCTGCTGCT CCCACAAACAAGGTAGAACGA 172 13785 40
Defb3 CTCTTCTCATTTCTCCTGGTGCT GTGCCACAACTGCCAATCTCT 150 9905 40
Defb4 CGCATCCATTACCTTCTCTTCTC ATCTCACTCTAGGCAGTCCACAA 173 2943 35
Defb5 CTCTTCTCATTTCTCCTGGTGCT TCTCACTTTACCCAGTCCACAA 164 2125 40
Defb9 GACTCTCTGCTCTCTGCTGCTG CACATGGGAGGTAGGAAAACGAC 163 2731 35
Defb10 GACTCTCTGCTCTCTGCTGCTG GGTGACAGGAACCCACATGCGA 177 10013 35
Defb11 GACTCTCTGCTCTCTGCTGCTG GTAACAGCTACCCAGTCTTCTG 169 6869 35
Defb12/35 AGCAGAGGGACGTTCTATTTTGG CTCCCGACAGCAGAAGAAGTTC 219 2398/2413b 35
Defb13 CGGGCTTGTTCTTCTCATTCAAC GTGTTAAGTCAGCTCGGCAGGT 143 1789 35
Defb14 TCATCTTGTTCTTGGTGCCTG CTGCAGCATTTTTGACCTCTGT 160 814 35
Defb15/34 GACACCGTGCTGACCCTCACA CATCCCCGAGTCCTGTTGTAG 272 2638/2631b 35
Defb16p TGGTCATTGTTTCCCGACTAC GCATACTCATCCACATCACAGAA 216 8567 40
Defb17 TGGTCATTGTTTCCCGACTAC GCATTCTTTCCTCAAGTCCAAG 186 3422 35
Defb18 TTCTCTGTCCTGTGGTCCTTC TATTCTCGCATCACACAGCAAG 173 819 35
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Defb20 TCCTTATTTTGCTGTTTGTGGT TTTCTTGTGCCTTTTGTTCTCC 181 2506 40
Defb21 GCTCTTCCTCTGCTTGCTCTT GTTTGTAGTCGTTGTCGTCCAG 180 1235 40
Defb22 ATGAAGTCCCTATTGTCTGCTC TTTCCCCCTGTTCCCTGTGTT 303 3922 40
Defb23 GCTTCAGTATCAGGTGGAATCA GGTATGTGGGGTATTTCGTGTC 197 3915 35
Defb24 CCTGCTTCTTGCCATATTTGTG TCTGGAAGTCTGTGCATGGCGT 268 6016 32
Defb25 GGCAAAGTGGATTCTGCTCATT ATAGGACAGGCAGCACAGAGA 180 797 40
Defb26 CCTTCATTATCTGTGGGTTGCT CCGAGGTAGGTTTTGGGTGTG 214 3224 35
Defb27 AACACCCTGGATTTCCCGAAGC CTTCGTTTCTGTGGCCTTGGGA 258 4873 40
Defb28 ACATTAAGCTCTGGTTCCTGAC ACTGTATGTGTCCCCGACTTG 285 1890 35
Defb29 TCTGCTGCTGTGATTTCTATCC CTGGCGACATTCAAACCTGAG 359 1336 35/40/30
Defb30 GTTGATCCTTGTGCTCTTTGTC ACGGGCATTTCCTTTCTTTC 221 1764 35
Defb33 GGCTGCTATTTCTTCTCTTTCTCC GGCAGTGTTTGTATCGACTTTTGC 172 2473 35
Defb36 AGGCCCATCATGAAGCTCCTGC TTCCGGCTTCCGGGCAGTTAG 227 13428 35/32
Defb37 TGCTTTCTGCTGCTGGTCCTCT CAGGTGCCGACTACATCACGA 140 20543 40
Defb38 TGCTTTCTGCTGCTGGTCCTCT CGCAGGTGCTAACAGAAATAGAC 145 3181 35
Defb39 TGCTTTCTGCTGCTGGTCCTCT GGCTTTGGAACTCGGATAGACA 205 3712 35
Defb40 TGCTTTCTGCTGCTGGTCCTCT GACTCCACGTAAACCAACGACG 201 2900 35
Defb41 GATCCCACTCCTTCCTGTCTG CCCACCATCTCCTACAACATTTC 197 2471 35
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Defb42 GTATCTGCTCCTCTCTACGCTAC GCAGCATTTCCATCTTCTCC 180 6726 35
Defb43 GAGGCTGCTGCTTTCAATCC CTTGGCTTCTCTCTTCTTCACC 201 5959 35
Defb44 ATGTTTACTGCTCTTCCTGGTG ACACCTTTGGTTTGAGGAAGTG 219 1046 35
Spag11c GACTCCTTCCTTCCTTTGTCAG ATCCCTCATTTTTCTTGCAGTT 246/306 1852 35
Spag11e CATCAGTCACATCTGCTTTCCTG TTCCAGGTCTCTAGCTTCCAAG 315 1675 35
Defb49 CGAAGCTGCCTGTTCTTTTTC ATGGCTCTCATGTCACGCACA 209 4608 35/30
Defb51 ATGAGAATCCACGCTTTCCTG TACAGCAAACAGTGAAGGCTC 177 747 40
Defb52 CCTTCTCATCTCTGTTGTTCTCTT TAATGGTGCCCGTAATCGTTG 147 1829 40
GAPDH GTGAAGGTCGGAGTGAACG GAGATGATGACCCTCTTGGC 356 >390 25
a RT-PCR reactions were performed with DNA Engine (Model PTC-200, MJ Research). Number of PCR cycles used
for evaluating tissue and developmental expression patterns was the same for all relevant genes, except for Defb29,
Defb36, and Defb49. For Defb29 amplification, 35, 40, and 30 cycles were used for gene expression in the tissue panel,
epididymis, and testis, respectively. For Defb36 amplification, 35 cycles were used for the tissue panel with 32 cycles
used for its developmental expression in testis. A total of 35 cycles were performed for tissue expression of Defb49,
whereas 30 cycles were used for developmental expression in epididymis.
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b Because of 100% identity in the coding sequences between Defb12 and Defb35 and between Defb15 and Defb34 in
the rat, the same primers were used for each pair.
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CHAPTER V
RATTUSIN, A NOVEL -DEFENSIN-RELATED PEPTIDE WITH SALT-
INSENSITIVE ANTIBACTERIAL ACTIVITY
161
ABSTRACT
Cationic antimicrobial peptides (CAMPs) are an essential component of the innate
immune system. As a major family of CAMPs, defensins are expressed mainly by
mucosal epithelial cells and neutrophils, which constantly come into direct contact with
microbes. Defensins are capable of killing a broad spectrum of bacteria through physical
disruption of membranes. However, all known defensins show a significantly reduced
antibacterial activity in the presence of salt and/or divalent cations, thereby limiting their
therapeutic potential for the treatment of systemic infections. A genome-wide
computational screen of the entire rat genome led to the identification of a novel -
defensin-related gene, designated rattusin. Rattusin shares a highly conserved pro-
sequence with mammalian -defensins. However, unlike defensins with a canonical six-
cysteine motif, rattusin consists of only five cysteines with a different spacing pattern.
Furthermore, rattusin is preferentially expressed in distal small intestine with potent
activities against a broad range of Gram-negative and Gram-positive bacteria, including
antibiotic-resistant strains. In contrast to classical -defensins, rattusin retains its activity
in the presence of physiological concentrations of salt and divalent cations. To our
knowledge, rattusin is the only defensin-related peptide with salt-insensitive antibacterial
activities, making it an attractive therapeutic candidate for diseases like cystic fibrosis
and Crohn’s disease.
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INTRODUCTION
The emergence of antibiotic-resistant pathogens has become a major health crisis
worldwide (10, 15). Novel antimicrobial drugs against resistant microbes are urgently
needed. Defensins and cathelicidins, an essential component of the vertebrate innate
immune system, are capable of killing a broad spectrum of bacteria with an equal
efficiency against both antibiotic-resistant and -susceptible strains and little chance of
developing resistance (27). Therefore, these CAMPs are being actively explored as
antibacterial drugs. However, the potential of defensins as therapeutics is dampened by a
loss of activity in the presence of physiological concentrations of salt (25, 43). As a
consequence, none of the defensin-based therapeutics except for a fungal defensin,
plectasin, are under clinical development (57).
In vertebrates, there are two major families of antimicrobial peptides, namely
defensins and cathelicidins (12, 25, 55, 56). Unlike cathelicidins that are mostly free of
cysteines, defensins consist of six conserved cysteine residues in the mature region.
Depending upon the disulfide bond connectivity, defensins are further divided into three
classes known as -, -, and -defensins. -defensins are mainly produced by intestinal
Paneth cells and leukocytes, whereas -defensins are mainly produced by skin
keratinocytes as well as mucosal epithelial cells of the gastrointestinal, respiratory and
urogenital tracts (4, 12, 25, 32, 34, 42, 43).
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In humans, there are only two Paneth cell -defensins, namely human -defensin
(HD)-5 and 6, whereas multiple Paneth cell -defensins (known as cryptdins in mice)
have been found in mice and rhesus monkey (4, 32-34). Matrilysin or matrix
metalloproteinase-7 (MMP-7) is responsible for post-translational processing of inactive
cryptdin precursors into antibacterially active peptide (48). Cryptdins are stored as the
mature active form in Paneth cell granules and are released in response to bacterial
products like lipopolysachharide (LPS), lipoteichoic acid, lipid A and muramyl dipeptide
(3). In contrast, HD-5 is stored in Paneth cell granules as the precursor form and is
processed by trypsin during or after secretion into intestinal lumen (13). Recently, a
family of cysteine-rich cryptdin-related sequences (CRS) have been found in mouse
intestine (19). Evidence for the essential role of -defensins in protecting enteric
infections has been demonstrated convincingly. Transgenic mice expressing HD-5 were
resistant to Salmonella typhimurium infection (39). Conversely, mice lacking the
Matrilysin gene were unable to produce mature Paneth cell cryptdins and became highly
susceptible to S. typhimurium infections (48).
Defensins possess pleotropic functions. In addition to broad spectrum
antibacterial, antiviral and antifungal activities, certain defensins are chemotactic for
dendritic cells, mast cells, monocytes, and T cells, and some can also induce maturation
of dendritic cells and sperms. Defensins help in wound healing by inducing
vascularization, promoting proliferation of epithelial and fibroblast cells, and augmenting
wound closure (17, 25, 31, 43). In addition, several human neutrophil -defensins were
shown recently to be capable of neutralizing bacterial toxins (20, 21, 30).
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We identified a -defensin-related gene (Defa-rs1) recently through a
computational screen of the rat genome (36), which we re-named rattusin in this report.
Unlike classical mammlian defensins with a canonical six-cysteine motif, rattusin
consists of five cysteines with a unique cysteine spacing pattern. To test whether rattusin
is a bona fide antimicrobial peptide, we synthesized putatively mature rattusin based on
its C-terminal sequence and compared its activity with mouse cryptdin-4 and human HD-
5, which are the two most potent Paneth cell -defensins that have been reported.
MATERIALS AND METHODS
RT-PCR analysis of gene expression pattern of rattusin
Different segments of the gastrointestinal tract were collected from 2-month-old
Sprague-Dawley rats. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA).
For each RNA sample, 4 µg were reverse transcribed using random hexamers and
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s
instructions. The subsequent PCR was carried out as described (36). Briefly, 1/40 of the
first-strand cDNA was used to amplify rattusin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) with gene-specific primers (36). The PCR product was
analyzed by electrophoresis on 1.2% agarose gel containing 0.5 µg/ml ethidium bromide.
The identity of the rattusin PCR product was confirmed by cloning into T/A cloning
vector and direct DNA sequencing.
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Peptide synthesis and refolding
Since MMP-7 preferentially cleaves the sequence prior to leucine (2, 19, 44, 45),
we rationalized that the mature rattusin is likely to start from the first leucine after pro-
sequence. Therefore, putatively mature rattusin of 31 amino acids (LRVRRTLQCSCRR
VCRNTCSCIRLSRSTYAS) was chemically synthesized in the reduced form using the
standard solid-phase synthesis, purified by reverse phase-high pressure liquid
chromatography (RP-HPLC) to >95% purity (Bio-synthesis, Lewisvile, TX). The mass of
peptide was confirmed by matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometry (MS) using Voyager DE-PRO (Applied Biosystems,
Foster City, CA) housed in the Recombinant DNA/Protein Core Facility at Oklahoma
State University.
To oxidize the reduced rattusin, 0.1 mg/ml of the peptide was exposed to O2 gas
for 5 min in 50 mM Tris, pH 8.0, and stirred gently for 48 h at room temperature with the
cap open as described (19). Following air oxidation, refolded rattusin was purified by RP-
HPLC on a 4.6 × 250 mm Vydac C18 column (Grace Vydac, Hesperia, CA) and
BioLogic DuoFlow Liquid Chromatography System (Bio-Rad, Hercules, CA). Buffer A
consisted of 5% acetonitrile and 0.18% trifluoroacetic acid (TFA). Buffer B consisted of
90% acetonitrile & 0.15% TFA. The gradient used was 0 to 60% buffer B over 90
minutes at a flow rate of 1 ml/min. Eluted peptide was lyophilized and stored at -80oC
until use. The peptide was reconstituted in 0.01% acetic acid and quantified by measuring
UV absorbance at 280 nm based on the extinction coefficients of tyrosine and cysteines
present in rattusin (41). Recombinant cryptdin-4 was produced in bacteria as described
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(41, 44). Plasmid encoding cryptdin-4 was provided by Dr. Andre Ouellette at University
of California, Irvine. Synthetic HD-5 was kindly provided by Dr. Wuyuan Lu at
University of Maryland, Baltimore (49). Cryptdin-4 and HD-5 were used as the reference
peptides.
Recombinant expression and purification of pro-rattusin
Recombinant pro-rattusin was produced as a N-terminal 6X histidine-tagged
fusion protein using the strategy described previously for cryptdin-4 (41, 44). Restriction
sites for HindIII and BamHI were included in forward and reverse primers, respectively,
as underlined in primer sequences. Additional methionine-encoding ATG codon was
introduced in the forward primer prior to the start of pro-rattusin nucleotide sequence to
enable cyanogens bromide cleavage in order to remove tag sequence. Forward primer
was 5’-CGCGGATCCATGGATCCCATTCAAGAGGCAGAGG-3’, and the reverse
primer sequence was 5’-GCCCAAGCTTATCTCATCCTTGGGGTCAT-3’. Pro-rattusin
cDNA was amplified from rat ileum RNA by using random hexamers, SuperScript II
reverse transcriptase, and high-fidelity Platinum Pfx DNA polymerase (Invitrogen). The
resulting PCR product was gel purified, digested with HindIII and BamHI, ligated into
pET28a vector (Novagen, Madison, WI), and transformed into E. coli DH-5. The
presence of the correct insert was confirmed by DNA sequencing.
Recombinant plasmid was then re-transformed into E. coli BL21 (DE3)-Codon
Plus-RIL cells (Stratagene, La Jolla, CA). For large-scale production of recombinant pro-
rattusin, overnight bacteria were subcultured 1:100 in 2 L of LB broth till OD600 reached
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0.4 to 0.6. Recombinant fusion protein was induced by adding isopropyl -D-1-
thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM for 6 h. Bacteria were
pelleted, resuspended in the buffer containing 20 mM sodium phosphate, 0.5 M NaCl, 20
mM imidazole and 6 M guanidine chloride, pH 7.4, and sonicated on ice. The lysate was
further stirred for 1 h at room temperature to ensure complete solubilization of inclusion
bodies.
Follwing centrifugation of the lysate at 30,000 × g for 30 min at 4oC, recombinant
His-tagged pro-rattusin was purified from the supernatant using Ni Sepharose 6 fast flow
resins (GE Healthcare Biosciences, Piscataway, NJ) according to the manufacturer’s
instructions. Fusion protein was then eluted using a buffer contained 20 mM sodium
phosphate, 0.5 M NaCl, 0.5 M imidazole and 6 M guanidine chloride, pH 5.0. Following
dialysis in 0.01% acetic acid using a Slide-A-Lyzer 3.5 MWCO dialysis cassette (Pierce
Biotechnology, Rockford, IL), fusion protein was lyophilized and dissolved in 2.5% TFA
at 2.5 mg/ml and incubated with 25 mg/ml CNBr in dark for 24 h to remove the fusion
tag (50). The cleaved product was lyophilized, dissolved in Buffer A and subjected to
RP-HPLC. Pro-rattusin fraction was then lyophilized, and its molecular weight was
confirmed by MALDI-TOF mass spectrometry. The peptide concentration was quantified
by measuring UV absorbance at 280 nm.
Bacterial culture and antibacterial assays
All bacterial strains including Staphylococcus aureus ATCC 25923, Listeria
monocytogenes ATCC 19115, S. aureus ATCC BAA-39, S. aureus ATCC 43300,
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Escherichia coli O157:H7 ATCC 700728, Salmonella enterica serovar Typhimurium
ATCC 14028, S. enetrica serovar Typhimurium DT104 ATCC 700408, and Klebsiella
pnumoniae ATCC 13883 were purchased from either ATCC (Manassas, VA) or
MicroBiologics (St. Cloud, MN). Bacteria were grown in trypticase soy broth (TSB)
overnight and subcultured for 3-4 h at 37oC in a shaking incubator to the mid-log phase.
To study the antibacterial spectrum, a broth microdilution assay was used as described
(53). Briefly, mid-log phase bacteria were washed with 25 mM sodium phosphate buffer,
pH 7.4, and suspended to 5 × 105 CFU/ml in 25 mM sodium phosphate, pH 7.4,
containing 5% TSB with and without 100 mM NaCl. Bacteria (90 µl) were then
dispensed in a 96-well tissue culture plate, followed by addition in duplicate of serially
diluted rattusin or cryptdin-4 (10 µl). After overnight incubation at 37oC, the minimum
inhibitory concentration (MIC) of each peptide was determined as the lowest
concentration that gave no visible bacterial growth.
To study the kinetics of bacterial killing, a standard colony counting assay was
used as described (53). Rattusin, cryptin-4 and HD-5 were incubated with 90 µl of 5 ×
105 CFU/ml Staphylococcus aureus or E. coli O157:H7 in 25 mM sodium phosphate
buffer, pH 7.4, containing 1% TSB with and without 100 mM NaCl. Following
incubation at 37oC for 10, 30, 60, 120 and 240 min, bacteria were diluted rapidly with
ice-cold PBS and serially plated onto trypticase soy agar (TSA) plates. Viable bacteria
were counted after overnight incubation at 37oC. The effect of Mg2+ on the antibacterial
activity was studied by incubating rattusin and cryptdin-4 for 4 h with 90 µl of S. aureus
(5 × 105 CFU/ml) at the concentration of 2 µM each or with E. coli O157:H7 at the
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concentration of 4 µM each in 1% TSB, 25 mM sodium phosphate buffer, pH 7.4,
containing 0, 1, 2 and 5 mM of MgCl2.
Cytotoxicity Assay
The toxicity of rattusin to human Caucasian colon adenocarcinoma (Caco-2) cells
(ATCC, Manassas, VA) was measured using alamarBlue dye (Biosource, Camarillo, CA)
as described previously (53, 54). Briefly, Caco-2 cells were seeded into a 96 well plate at
5 × 104 cels/ml in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS and
grown overnight in a humidified 5% CO2 incubator. Cells were washed once with
DMEM, followed by addition of fresh DMEM containing 100 µM of rattusin, cryptdin-4
or chicken fowlicidin-1and in the presence and absence of 10% FBS. After 18 h
incubation, 10 µl of alamarBlue dye was added and cells were further incubated for
another 6 h at 37oC. The plate was read with excitation at 545 nm and emission at 590
nm. The percentage of cell death was calculated as [1-(Fpeptide-Fbackground)/ (Facetic acid-
Fbackground)] × 100, where Fpeptide is the fluorescence of cells exposed to 100 µM peptide,
Facetic acid is the fluorescence of cells exposed to 0.01% acetic acid only, and Fbackground is
the background fluorescence of 10% alamarBlue dye in cell culture medium without
cells.
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RESULTS
Rattusin, an -defensin-related peptide with preferential expression in the distal small
intestine
Following a comprehensive screening of the entire rat genome, we identified an
-defensin-related gene (36). Similar to -defensins, this gene is composed of two exons
with the first exon encoding the 5’ untranslated region (UTR) and preprosegment and the
second encoding a putatively mature peptide and 3’ UTR (Fig. 1). The encoded peptide,
named rattusin, shares a high degree of similarity in the signal and pro-sequences with -
defensins (Fig. 2). However, rattusin consists of five cysteines in the C-terminal mature
region, instead of canonical six cysteines in -defensins (36). Futhermore, the cysteine
spacing patterns are quite different between rattusin and classical -defensins (Fig. 2).
We revealed earlier that the rattusin mRNA was transcribed abundantly in the
small intestine of rat (36). To further analyze the detailed expression pattern of rattusin,
RT-PCR was performed using the RNA isolated from different segments of the
gastrointestinal tract of 2-month-old healthy rats. As shown in Fig. 3, rattusin was highly
expressed in distal jejunum and entire ileum, but not in other parts of the gastrointestinal
tract. Cryptdin-4 and HD-5, Paneth cell-specific -defensins, also show a similar
expression pattern in small intestine (9, 35, 47). This suggested that, similar to enteric -
defensins, rattusin is likely to be produced by Paneth cells.
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Antibacterial properties of rattusin
To test whether putatively mature rattusin is functional or not, we synthesized
putatively mature rattusin in the reduced form and further oxidized it. Successful
refolding was confirmed by RP-HPLC, showing a decrease in the retention time due to
the formation of disulfide bonds and a change in the conformation (Fig. 4). Refolded
rattusin was used to study antibacterial activity against several representative Gram-
negative and Gram-positive bacteria by a modified broth microdilution assay with and
without 100 mM NaCl (53). As shown in Table 1, rattusin exhibited antibacterial activity
with the MIC value mostly in the range of 2-4 µM. In most cases, rattusin was as potent
as cryptdin-4, the most efficacious mouse Paneth cell -defensins that has been reported
(32). Importantly, rattusin also displayed a similar antibacterial efficiency against two
strains of methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant
Salmonella typhimurium DT 104 (Table 1). Importantly, the activity of rattusin remained
largely unchanged in the presence of NaCl, in sharp contrast to cryptdin-4, whose activity
was abolished by salt.
To study the kinetics of bacterial killing, each representative strain of Gram-
negative and Gram-positive bacteria was used in a standard colony counting assay.
Rattusin, cryptdin-4 and HD-5 at 4 µM killed E. coli by three logs within 2 h (Fig. 5A).
In the presence of 100 mM of NaCl, killing of bacteria by rattusin was slightly delayed
with a complete killing occurring at 4 h. In contrast, Cryptdin-4 and HD-5 were
completely inactivated in 100 mM NaCl (Fig. 5B). A similar trend also occurred with S.
aureus. All three peptides at 2 µM killed S. aureus by two logs in 4 h (Fig. 6A). Killing
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by rattusin was largely unaffected by 100 mM NaCl. However, cryptdin-4 and HD-5
were significantly inhibited in the presence of salt (Fig. 6B). Collectively, these results
clearly suggested that rattusin with a broad-spectrum, salt-insensitive bactericidal activity
is among the most potent defensins. To further study the effect of salinity, the
antibacterial activity of rattusin was examined in the presence of increasing
concentrations of NaCl. As shown in Fig. 7, rattusin maintained antibacterial activity
against both E. coli and S. aureus in up to 200 mM NaCl.
Divalent cations such as Mg++ are usually present at 1 to 2 mM in most biological
fluids (6, 7). At such low concentrations, divalent cations are known to inhibit
antibacterial activities of cationic peptides (8, 11). To study the effect of Mg++ on the
antibacterial activity, rattusin and cryptdin-4 were incubated with bacteria in the presence
of increasing concentrations of MgCl2. There was a dose-dependent loss of the activity of
cryptdin-4 against E. coli with complete inactivation occurring at 2-5 mM of MgCl2 (Fig.
8A). In contrast, the activity of rattusin was largely unaffected in the presence of MgCl2
(Fig. 8A). Mg++ did not inhibit the activity of either rattusin or cryptdin-4 against S.
aureus (Fig 8B). In the case of cryptdin-4, increased killing observed at 1 mM was not
observed at higher concentrations of MgCl2 (Fig 8B).
Low cytotoxicity of rattusin
The cytotoxic effect of rattusin to intestinal epithelial cells was studied using
human Caco-2 cells. Fowlicidin-1 (100 µM) was used as a positive reference since it
showed significant cytotoxicity towards mammalian cells (53). Following treatment of
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cells for 24 h, rattusin exhibited no cytotoxicity even at 100 µM, similar to cryptdin-4
(Fig. 9).
Inhibition of the antibacterial activity of rattusin by anionic pro-segment
Recombinant pro-rattusin was produced as an N-terminal 6× histidine-tagged
fusion protein followed by removal of the fusion tag by CNBr cleavage. The antibacterial
activity of pro-rattusin was studied by a modified broth microdilution assay against two
representative Gram-positive and Gram-negative bacteria. Pro-rattusin showed a MIC
value of 16 µM against S. aureus, but no inhibition of growth was observed for L.
monocytogenes, E. coli and S. typhimurium even at 32 µM, the highest concentration used
(Table 2). This is reminiscient of cryptdin-4, whose anionic pro-segment also inhibited
the antibacterial activity of C-terminal cationic peptide (44).
DISCUSSION
Rattusin shares a highly conserved signal and pro-sequence with classical
mammalian -defensins, but with a unique C-terminal region (Fig. 2). Our results
demonstrate that this C-terminal peptide possesses potent, broad-spectrum antibacterial
activities. Recently, a number of cysteine-rich cryptdin-related sequences (CRS) in mice
were described, which contain a highly similar prepro-region to mice cryptdins (19).
However, the cysteine-spacing patterns of these CRS peptides are different from rattusin.
Similar to cryptdin-4 and HD-5 (9, 35), rattusin is preferentially expressed in
distal small intestine. It is tempting to speculate that preferential expression of certain
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enteric defensins in the distal small intestine might prevent colonization of microflora
from adjacent colon. Consistently, the number of microbes in small intestine is 104-106
times less than the number of microbes in colon (5). Thus, the number and species of
microorganisms in small intestine might be dictated by Paneth cell defensins.
Desirably, rattusin maintains its antibacterial activity in the presence of
physiological concentrations of NaCl, which is in sharp contrast to cryptdin-4, HD-5, and
other defensins, which show reduced antibacterial activity in the presence of NaCl (12,
25, 38, 43). Maintenance of the antibacterial activity of rattusin in the presence of salt
might be due to its distinct spacial structure conferred by the unique cysteine spacing
pattern. Cryptdin-4 disrupts bilayer head groups through interfacial binding onto lipid
bilayer rather than inserting into the hydrophobic core (40, 41). It interacts favorably with
bacterial phospholipid vesicles containing negatively charged phospholipids than neutral
phospholipids indicating ionic interaction between positive charged peptide and negative
charged lipids (40, 41). Such interaction is more susceptible to inhibition by
physiological concentrations of NaCl, which in rodent ileum is maintained at around 162
mM (29). Since rattusin is relatively resistant to NaCl, its mechanism of action is likely to
be different from cryptdin-4.
Divalent cations such as Mg++ stabilize LPS of Gram-negative bacteria by binding
to negatively charged phosphate and pyrophosphate groups of LPS, thereby preventing
charge-charge repulsion (16, 28). Antimicrobial peptides must displace these divalent
cations in order to interact with the outer membrane (16, 28). A number of defensins and
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cathelicidins are inhibited at physiological concentrations of divalent cations (1, 8, 11, 24,
26). Rattusin kills bacteria in the presence of 2-5 mM Mg++, whereas cryptdin-4 is
inactivated. This suggested that rattusin is able to displace divalent cations.
Divalent cations are not inhibitors of the antibacterial activity of CAMPs against
Gram-positive bacteria since they lack LPS. On the contrary, Mg++ potentiated the
activity of rattusin against S. aureus. However, this finding is not surprising since Mg++
causes transcriptional suppression of dlt operon in S. aureus (22). Genes of dlt operon are
involved in incorporation of D-alanine into lipoteichoic acid and wall teichoic acid,
which introduces positively charged amino group and partially neutralizes negative
charges on teichoic acid, thereby providing resistance to CAMPs (23). Therefore,
suppression of dlt operon by Mg++ increases susceptibility of S. aureus to rattusin and
cryptdin-4.
Similar to pro-cryptdin-4, pro-rattusin generally lacks antibacterial activity (Table
2). Pro-cryptdin-4 does not interact with phospholipid vesicles and lacks a typical -sheet
structure (41). It is likely that such inhibition involves neutralization of positive charges
on the C-terminal peptide by the negative charge on the N-terminal pro-segment. This
mechanism is further supported by evidence that a replacement of aspartate and
glutamate by glycine confers bactericidal and membrane-interacting ability of CAMPs
(46).
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In conclusion, rattusin is unique -defensin-related peptide, which is
preferentially expressed in distal small intestine. It possesses broad-spectrum antibacterial
activity insensitive to salt and divalent cations. The salt-insensitive activity of rattusin
may be further exploited for the treatment of cystic fibrosis and Crohn’s disease.
Increased salt concentrations are believed to be responsible for inactivation of defensins
in the airway of the cystic fibrosis patients (14). In Crohn’s disease, a deficiency of
intestinal Paneth cell defensins is associated with an increase in susceptibility to bacterial
infections (37). Therfore, exogenous delivery of potent, salt-insensitive rattusin
represents a promising therapeutic strategy to treat both topical and systemic antibiotic-
resistant infections.
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FIGURE LEGENDS
Fig.1. Nucleotide sequence of the rattusin gene. Numbering is based upon the
transcription start site, which is numbered +1 with arrow showing the direction of
transcription. Transcribed mRNA sequence is shown in uppercase letters. The open
reading frame coding for the rattusin precursor is indicated below each triplet codon.
TATA and CAAT boxes in the promoter region are underlined. Stop codon is denoted by
an asterisk. The polyadenylation signal is underlined and italicized. The gene structure is
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derived from rat EST sequences available in GenBank (Accession Nos. AI639089.1 and
CR476138.1) and our previous analysis of rattusin gene (36)
Fig. 2. Alignment of rattusin with representative Paneth cell -defensins, namely mouse
cryptdin-4 and human defensin-5 (HD-5). Dashes are created for optimal alignment.
Conserved amino acid residues are shaded. The net positive charge on each mature
peptide, as underlined, is indicated in parenthesis and length of mature peptide is also
indicated. Note that the signal peptide and pro-sequence region of all three peptides are
highly homologous, whereas C-terminal mature peptide region are diversified. A
conserved six-cysteine motif of cryptdin-4 and HD-5 is absent in rattusin.
Fig. 3. Expression pattern of the rattusin gene across gastrointestinal axis. RT-PCR was
used to evaluate the expression of the rattusin transcript. The housekeeping gene,
GAPDH, was used to normalize template input.
Fig. 4. RP-HPLC profile of reduced and oxidized rattusin. Reduced synthetic peptide was
refolded by air oxidation in 50 mM Tris buffer, pH 8.0, for 48 h. Oxidized rattusin was
purified to homogeneity by RP-HPLC. Note that there is a decrease in the retention time
of oxidized rattusin due to refolding.
Fig. 5. Kinetics of killing of E. coli O157:H7 in the absence (A) and presence (B) of 100
mM NaCl by rattusin, cryptdin-4 and HD-5. E. coli O157:H7 ATCC 700728 was
incubated with 4 µM rattusin, cryptdin-4, HD-5, or an equal volume of 0.01% acetic acid
(no peptide) in duplicate in 25 mM sodium phosphate buffer, pH 7.4, 1% TSB with and
without 100 mM NaCl for 10, 30, 60, 120 and 240 min. Surviving bacteria were plated
and counted. Data shown are means ± SEM of two independent experiments.
Fig. 6. Kinetics of killing of S. aureus in the absence (A) and presence (B) of 100 mM
NaCl by rattusin, cryptdin-4 and HD-5 . S. aureus ATCC 25923 was incubated with 2
µM rattusin, cryptdin-4, HD-5, or an equal volume of 0.01% acetic acid (no peptide) in
duplicate in 25 mM sodium phosphate buffer, pH 7.4, 1% TSB with and without 100 mM
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NaCl for 10, 30, 60, 120 and 240 min. Surviving bacteria were plated and counted. Data
shown are means ± SEM of two independent experiments.
Fig. 7. Effect of salinity on the antibacterial activity of rattusin against S. aureus (A) and
E. coli O157:H7 (B). S. aureus and E. coli were incubated with 2 and 4 µM of rattusin, or
an equal volume of 0.01% acetic acid (no peptide) in 25 mM sodium phosphate buffer,
pH 7.4, 1% TSB with increasing concentrations of NaCl, for 4 h. Surviving bacteria were
plated and counted. Data shown are means ± SEM of two independent experiments.
Fig. 8. Effect of Mg++ on the antibacterial activity of rattusin and cryptdin-4 against S.
aureus (A) and E. coli O157:H7 (B). S. aureus or E. coli were incubated with rattusin,
cryptdin-4, or an equal volume of 0.01% acetic acid (no peptide) in 25 mM sodium
phosphate buffer, containing 1% TSB with 0, 1, 2 and 5 mM MgCl2, pH 7.4, for 4 h.
Surviving bacteria were plated and counted. Both peptides were used at identical
concentrations for each bacterial strain (2 and 4 µM against S. aureus and E. coli,
respectively). Data shown are means ± SEM of 2-3 independent experiments.
Fig. 9. Absence of cytotoxicity of rattusin and cryptdin-4 to Caco-2 cells. Cells were
incubated with 100 µM of rattusin, cryptdin-4 or fowlicidin-1 for 24 h in DMEM with
and without 10 % fetal bovine serum for 24 hours. Cell viability was measured with an
alamarBlue dye-based method. Data are representative of two independent experiments
done in duplicate.
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Table 1. Antibacterial spectrum of rattusin and cryptdin 4
MIC (µM)
Bacteria ATCC Rattusin Cryptdin-4
Number 0 mM NaCl 100 mM NaCl 0 mM NaCl 100 mM NaCl
Gram-negative
E. coli O157:H7 700728 2-4 2-4 2 >16
S. typhimurium 14028 4 8 8 >16
S. typhimurium DT104 700408 4 4-8 4-8 >16
K. pneumoniae 13883 2-4 4-8 8 >16
Gram-positive
S. aureus 25923 4 4 1-2 16
L. monocytogenes 19115 4 4 8 >16
S. aureus (MRSA) 43300 4 4 2 8
S. aureus (MRSA) BAA-39 4-8 4-8 1-2 >16
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Table 2. Inhibition of the antibacterial activity of rattusin by the pro-segment
MIC (µM)
Bacteria ATCC Number Pro-rattusin Rattusin
Gram-negative
E. coli O157:H7 700728 >32 2-4
S. typhimurium 14028 >32 4
Gram-positive
S. aureus 25923 16 4
L. monocytogenes 19115 >32 4
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Fig. 1
-154 ggaagccttagggacagaggaacatcaaagggatcctgagggcaacagctgggagcagtt
-94 gccatcaatgagtgccttctctaagtgtggggcatgttctttgccctataaatgcaggct
+1
-34 gcctcctctctctccacacactggtctccagctcACCAATCCTCCAGGTGACTTCCAGCC
27 ATGAAGACTCTTATCCTCCTCTCTGCTCTTGTCCTGCTGGCCTTGCAGGTCCAGGCTGAT
Met Lys Thr Leu Ile Leu Leu Ser Ala Leu Val Leu Leu Ala Leu Gln Val Gln Ala Asp
87 CCCATTCAAGAGGCAGAGGAAGAGACTAAAACTGAGGAGCAGCCAGCAGATGAGGACCAG
Pro Ile Gln Glu Ala Glu Glu Glu Thr Lys Thr Glu Glu Gln Pro Ala Asp Glu Asp Gln
147 GATGTGTCTGTCTCCTTTGAAGGCCCAGAAGCCTCTGCTGTTCAAGATTTACgtgagttc
Asp Val Ser Val Ser Phe Glu Gly Pro Glu Ala Ser Ala Val Gln Asp Leu
207 tggtacacagaatgtttgaggcttggagtctcctgaggcgggaagggttgtagatgagcc
267 ctgtagtcctgtcaggtacagtcttgagagccatcggatcttccctgtctcattcataca
327 agtaacagtgagagtcaagccactgggcttgattttcttccttttaaggtttttgatcca
387 acaatttatctatgaaaaggctttaaaatatagaacatattgattagacattttagatcc
447 gattgataattttgttataggaagagatattcgttctgctttgaaaattagatttgggac
507 ccaaatgccagtgtatgaaggtgttgggtcaggaaaacacaaaaatgctgatagaatgtg
567 gtgtagatgtcaactcctatatgtgattaacacttgttaaacatcttatctccatgtgtt
627 tggggttgaccctggtgctggccatgatgtcacccacacagcaaacctactctctaccat
687 gcacaggatatcttcatagggttgttcactaccacacactgctggcctccttacttcatg
747 cctgatgctttcttctttcctcagGCGTAAGAAGGACCTTGCAGTGCAGTTGCAGAAGAG
Arg Val Arg Arg Thr Leu Gln Cys Ser Cys Arg Arg V
807 TCTGCAGAAATACGTGTAGCTGCATTCGGCTATCAAGGTCCACATATGCATCATAAATTC
al Cys Arg Asn Thr Cys Ser Cys Ile Arg Leu Ser Arg Ser Thr Tyr Ala Ser *
867 TGCTGCAGCTGAACATGGACCCCAAGGATGAGATAACCACATGCCCTGGGGCCTCACAGT
927 CGGTCATTACCCTTGTGCTTGGCCTCGACTGTTTTTCCTTCTCCAATAAACTCCTTGCAG
987 ATAAAGaatctgtgtttttgtttctttgatgctttttctatgtggcttagacgggactct
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CHAPTER VI
SUMMARY AND FUTURE PROSPECT
Using a comprehensive computational search strategy, we identified the complete
repertoire of the -defensin gene family in the human, chimpanzee, rat, and mouse,
including a number of novel genes. -defensin genes were located on syntenic
chromosomes in each species. Phylogenetic analysis revealed that -defensin genes in
rodents have undergone repeated duplication which gave rise to the current repertoire of
genes. We also found that positive selection is acting on the -defensin mature peptide
coding region. Further, gene expression studies with rat -defensin genes revealed that
they are either expressed in bone marrow or small intestine.
We also identified the entire family members of -defensins including a large
number of novel genes in the human, chimpanzee, rat, mouse and dog. Each species
possessed >35 -defensin genes encoded in their genome. Such genes were located on 4-
5 syntenic chromosomes across species. In contrast to most known genes with two-exon
gene structure, several novel -defensin genes had three exons. Phylogenetic analysis
showed that most of the genes are conserved in all species. However, certain gene
lineages were only present in certain species, indicating that these genes appeared by
gene duplication after species separation. Gene expression analysis of rat -defensins
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revealed that all but one are expressed in the male reproductive tract especially in testis
and epididymis. Further, this expression was developmentally regulated with the highest
level occurring at sexual maturity. This indicates that defensins may have a role in both
reproduction and antimicrobial protection.
A novel -defensin-related gene, which we named rattusin, was identified in the
rat and preferentially expressed in small intestine. The encoded peptide displayed an
entirely different cysteine-spacing pattern, suggesting that it might have distinct
antibacterial properties. Putatively mature rattusin possessed a broad-spectrum
antibacterial activity with similar efficiency against both antibiotic-sensitive as well as -
resistant bacteria. Further, this activity of rattusin was salt-insensitive although salt
slightly delayed kinetics of bacterial killing, in contrast with human defensin-5 and
mouse cryptdin-4, both of which are among the most potent defensins identified.
Additionally, rattusin was active in the presence of 2-5 mM of Mg++, whereas cryptdin-4
lost its activity completely. Rattusin also displayed little toxicity towards human colon
epithelial cells.
To our knowledge, rattusin is the only defensin-related peptide with salt-
insensitive antibacterial activities, and therefore, has great potential to become a novel
anti-infective drug. Elucidation of its tertiary structure will help explain the structural-
basis for such an antibacterial property. In addition, this study has also identified a large
number of novel - and -defensins. Their specific functions in reproductive health and
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fertility largely remain unknown. Further studies are needed to explain the biological
significance for such a large number of defensin genes.
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